Analysis, development and management of glucose-insulin regulatory system for out of hospital cardiac arrest (ohca) patients, treated with hypothermia. by Sah Pri, Azurahisham
i 
 
 
ANALYSIS, DEVELOPMENT AND 
MANAGEMENT OF GLUCOSE-INSULIN 
REGULATORY SYSTEM FOR OUT OF 
HOSPITAL CARDIAC ARREST (OHCA) 
PATIENTS, TREATED WITH HYPOTHERMIA 
 
 
 
 
AZURAHISHAM SAH PRI 
  
 
A thesis presented for the degree of  
Doctor of Philosophy in 
Mechanical Engineering 
at the 
University of Canterbury,  
Christchurch, New Zealand.  
 
November 2014 
 
ii 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
iii 
 
 Acknowledgements 
 
 
I would like to thank the following people and groups for their assistance, support and 
friendship during my doctoral study and make this research project possible.  
 
I wish to express my gratitude to my principal supervisor, Distinguished Professor. Dr J. 
Geoffrey Chase for his advice, enthusiasm, encouragement and support during my study. I 
would also like to acknowledge the advice and guidance of my co-supervisors, Dr Thomas 
Desaive and Dr Chris Pretty.   
 
I also wish to express my sincere appreciation to Jennifer Dickson, Liam Fisk and Aaron Le 
Compte for their for their informative discussions and continuous support in this research  
throughout the years. I also would like to convey many thanks to my colleagues, Matt, Azlan, 
Salwa, Musabir, Peng Guo, Shun, Alexander and Ina in the Centre for BioEngineering, for 
your friendship and making the work environment enjoyable and productive.   
  
Finally,   I  wish  to  express  my  love  and  gratitude  to  my  lovely  wife,  Nora Yusni 
Mohamed Yusop  and children – Nurul Zahirah and Muaz, as well as my father and mother 
for   their  endless  love,  resolute  support  and  encouragement  in  my  life. My thanks are 
due to my siblings and family for their loving support. I would also like to extend my deepest 
gratitude to all my friends for their support and made my time here so enjoyable.   
 
I am grateful for the financial support by the “Majlis Amanah Rakyat (MARA)” and 
Universiti Kuala Lumpur (UniKL) through the Academic Staff Training Scheme. 
  
 
 
 
 
 
 
iv 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
v 
 
Table of Contents 
 
Abstract xx 
   
1.0 Introduction  
 1.1   Cardiac Arrest Patients 1 
 1.2   Out of Hospital Cardiac Arrest (OHCA) Patients 2 
 1.3   Aetiology of Hypothermia in OHCA Patients Care 3 
 1.4   Hypothermia and Glucose-Insulin Dynamics System 4 
 1.5   The Problem Statement 7 
 1.6   Significance of the Study 7 
 1.7   Preface 8 
    
2.0 Model Review and Development  
 2.1   Glucose-Insulin Models for Critical Care 13 
 2.2   The Intensive Control Insulin-Nutrition-Glucose 2 (ICING-2 model) 20 
 2.3   Overview of Glycaemic System Model 22 
 2.4   Glycaemic Controller Overview 25 
 2.5   Summary 32 
    
3.0 Patient Demography    
 3.1  Introduction 34 
 3.2  OHCA Patient Demography by Cohort 35 
 3.3  OHCA Patient Demography and Mortality  38 
 3.4  OHCA Patient Demography by Diagnosed Diabetes Status  40 
 3.5  OHCA Patient Demography by Gender 42 
 3.6  OHCA Patient Demography by ROSC 44 
 3.7  Discussion 46 
 3.8  Summary 48 
   
  
 
 
 
vi 
 
4.0 Insulin Sensitivity Level and Variability Analysis  
 4.1    Introduction 50 
 4.2    Subjects and Methods 51 
 4.3    Results 53 
 4.4    Discussion 65 
 4.5    Summary 67 
   
5.0 Blood Glucose Level and Variability Analysis  
 5.1    Introduction 69 
 5.2    Subjects and Methods 69 
 5.3    Results 72 
 5.4    Discussion 82 
 5.5    Summary 85 
   
6.0 Exogenous Insulin and Nutrition Analysis  
 6.1    Introduction 87 
 6.2    Subjects and Methods 87 
 6.3    Results on Exogenous Insulin Infusion 89 
 6.4    Results on Nutrition / Dextrose 95 
 6.5    Discussion 100 
 6.6    Summary 102 
   
7.0 Stochastic Modelling of Insulin Sensitivity Analysis  
 7.1    Introduction 104 
 7.2    Subjects and Methods 105 
 7.3    Stochastic Analysis by Overall Cohort 109 
 7.4    Stochastic Analysis by 12-Hours Block 116 
 7.5    Stochastic Analysis by 6-Hours Block 118 
 7.6    Stochastic Analysis by Sub-Cohort 121 
 7.7    Discussion 124 
 7.8    Summary 125 
   
   
vii 
 
 
8.0 Summary of OHCA Patient Analysis  
 8.1    Overview of OHCA Patient Analysis 127 
 8.2    Analysis Summary by Overall Cohort 130 
 8.3    Analysis Summary by Sub-Cohort 136 
 8.4    Control Design Considerations 138 
 8.5    Control Performance Measures 141 
   
9.0 STAR Control Performance Analysis and Virtual Trials  
 9.1   Introduction 144 
 9.2   Subjects and Methods 146 
 9.3   Virtual Trial Analysis and Discussion 151 
 9.4   Summary 160 
   
10.0 Conclusions    
 10.1   Introduction 162 
 10.2   OHCA Patient Analysis 163 
 10.3   Control Design Requirements and Specifications 164 
 10.4   Virtual Trials Validation 165 
   
11.0 Future Work   
 11.1   Reviewing Endogenous Insulin Secretion (Uen) Parameters for the 
ICING-2 Model during Cool and Warm 
 
167 
 11.2   Clinical Trials for Performance Validation 168 
 11.3   Investigation of Stochastic Control based on Sub-Cohort Models 168 
 11.4   Further Improvement of STAR-OHCA Controller 169 
   
 References 171 
   
 Appendix 1 181 
 Appendix 2 182 
 
 
viii 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
ix 
 
List of Figures 
 
Figure 1.1 Model of Glucose-Insulin Regulatory System. The schematic shows the effect 
of high and low blood glucose levels in the body.  Adapted from website: 
health.howstuffworks.com …………………………………………………….. 
 
 
5 
 
Figure 1.2 Thesis outline. Part I of this thesis introduces relevant background knowledge, 
analyse patients’ data and determine control problem definitions. Part II 
presents the review of glycaemic control, and virtual trials ………………… 
 
 
11 
 
Figure 2.1 Critical care glucose-insulin model …………………………………….......... 16 
Figure 2.2 Intensive Control Insulin-Nutrition-Glucose (ICING) model overview............ 
 
20 
Figure 2.3 Overview of Tight Glycaemic Control block diagram …………………. 24 
Figure 2.4 The SPRINT insulin wheel with dial ………………………………………….. 26 
Figure 2.5 The SPRINT insulin wheel without dial ………………………………………. 26 
Figure 2.6 The SPRINT feed wheel with dial ……………………………………………... 27 
Figure 2.7 The SPRINT feed wheel without dial …………………………………………. 27 
Figure 2.8 The STAR Algorithm (Dickson et al., 2013) ……………………………. 31 
Figure 4.1 Insulin sensitivity level and variability distribution by cohort (left) and per-
patient median (right) during cool and warm after periods for all ICU patients 
53 
Figure 4.2 SI level distribution per-cohort (left) and per-patient median (right) for OHCA 
patients, treated with hypothermia using 12 hour blocks of data. Blue colour 
represent cool period and red colour represent warm period…………………… 
 
54 
Figure 4.3 SI level distribution per-cohort (left) and per-patient median (right) for OHCA 
patients, treated with hypothermia using 6 hour blocks of data.  ………………. 
 
55 
Figure 4.4 Insulin sensitivity level and variability distribution by cohort (left) and per-
patient median (right) during cool and warm after periods for all ICU patients. 
57 
Figure 4.5 SI variability per-cohort (left) and 50% range of SI variability per-patient 
(right) for OHCA patients, treated with hypothermia using 12 hour blocks. 
Blue and red represent cool and warm period respectively. …………………… 
 
58 
Figure 4.6 Insulin sensitivity variability per-cohort (left) and 50% range of SI variability 
CDF per-patient (right) for OHCA patients, treated with hypothermia using 6 
hour blocks of data. ……………………………………………………………. 
 
59 
Figure 5.1 Blood glucose level and variability distribution by cohort (left) and per-patient 
median (right) during cool and warm after periods for all OHCA patients 
72 
Figure 5.2 BG level distribution per-cohort (left) and per-patient median (right) for 
OHCA patients, treated with hypothermia using 12 hour blocks of data. Blue 
colour represent cool period and red colour represent warm   
 
73 
x 
 
Figure 5.3 BG level distribution per-cohort (left) and per-patient median (right) for 
OHCA patients, treated with hypothermia using 6 hour blocks of data.   
 
74 
Figure 5.4 Blood glucose level and variability distribution by cohort (left) and per-patient 
median (right) during cool and warm after periods for all ICU patients 
76 
Figure 5.5 BG variability per-cohort (left) and 50% range of BG variability per-patient 
(right) for OHCA patients, treated with hypothermia using 12 hour blocks of 
data. Blue and red lines represent cool warm period respectively. 
 
77 
Figure 5.6 Blood glucose variability per-cohort (left) and 50% range of BG variability 
CDF per-patient (right) for OHCA patients, treated with hypothermia using 6 
hour blocks of data.   
 
78 
Figure 6.1 Exogenous insulin distribution by cohort (left) and per-patient median (right) 
during cool and warm after periods for all ICU patients 
89 
Figure 6.2 Exogenous Insulin distribution per-cohort (left) and per-patient median (right) 
for OHCA patients, treated with hypothermia using 12 hour blocks of data. 
Blue colour represent cool period and red colour represent warm   
 
90 
Figure 6.3 Exogenous Insulin distribution per-cohort (left) and per-patient median (right) 
for OHCA patients, treated with hypothermia using 6 hour blocks of data.   
 
91 
Figure 6.4 Nutrition/ dextrose level distribution by cohort (left) and per-patient median 
(right) during cool and warm periods for all ICU patients 
95 
Figure 6.5 Nutrition/ dextrose distribution per-cohort (left) and per-patient median (right) 
for OHCA patients, treated with hypothermia using 12 hour blocks of data. 
Blue colour represent cool period and red colour represent warm   
 
96 
Figure 6.6 Nutrition/ dextrose distribution per-cohort (left) and per-patient median (right) 
for OHCA patients, treated with hypothermia using 6 hour blocks of data 
97 
Figure 7.1 Distribution of hourly variation in SI for OHCA patients, treated with 
hypothermia during cool (left) and warm (right) periods as presented in 2-D 
kernel density method. 
 
109 
Figure 7.2 Conditional probability density function SI, n+1 knowing SI, n  for OHCA 
patients, treated with hypothermia during cool (left) and warm (right) periods. 
The structure of the plot is unimodal in the region SI, n < 1.0 x 10
-3
 and SI, n+1 
< 1.0 x 10
-3
, corresponding to the region of dataset density. 
 
110 
Figure 7.3 Probability interval and distribution of hourly variation in SI for OHCA 
patients, treated with hypothermia during cool (left) and warm (right) periods.   
 
110 
Figure 7.4 Probability-bound determination for raw SI data and corresponding BG 
forecasted values based on an equal-tailed 0.90 probability interval of SI 
between 5
th
 -95
th
 at local variance estimator, both cool ( C=1.0) and warm 
(C=3.0) period. The solid lines represent the 5%, 25%, 50%, 75% and 95% 
probability bounds.   
 
114 
xi 
 
Figure 7.5 Simulated trial using model-based control with stochastic model forecasts. The 
top plot shows the comparison between blood glucose concentration under 
simulated control (blue line) and retrospective control (red line). The middle 
plot shows model-fitted SI (green line) and the bottom plot shows 
administration of insulin during simulated control (pink line) compared to 
retrospective control (blue line). The yellow shaded areas in the top and middle 
plots show the 5
th
-95
th
 percentile of forecasted BG and SI respectively. 
 
115 
Figure 8.1 Overview of OHCA patient analysis 129 
Figure 9.1 Virtual trial procedure 147 
Figure 9.2 The STAR-OHCA Controller Algorithm 149 
Figure 9.3 Cumulative distribution functions (CDFs) of hourly BG level for the 
retrospective data and the STAR and STAR-OHCA controller combination, 
both cool (left panel) and warm (right panel) periods. 
151 
Figure 9.4 Cumulative distribution functions (CDFs) of hourly BG variability for 
retrospective data and stochastic based controllers, both cool (left panel) and 
warm (right panel) periods 
153 
Figure 9.5 BG control during virtual trial for OHCA patients. These patients had 
experienced hypoglycemia after simulation with STAR1-OHCA controller 
during warm period.   
 
158 
Figure 9.6 BG control during virtual trial for OHCA patients. These patients had 
experienced hypoglycemia after simulation with STAR1-OHCA controller 
during warm period.   
 
159 
 
 
 
 
 
 
 
 
 
 
 
 
xii 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
xiii 
 
List of Tables 
 
Table 2.1 Parameter values and descriptions for the ICING model …………… 
 
19 
Table 2.2 Exogenous input variables for the ICING model …………………….. 
 
19 
Table 2.3 Parameter values and descriptions for the ICING-2 model ………….. 
 
21 
Table 2.4 Exogenous input variables to the ICING-2 model …………………… 
 
22 
Table 2.5 
 
Summary of STAR protocol 30 
Table 3.1 Demographic data patients those who have met a minimum of 15 hours for 
both the cool and warm after periods.  (All cohort)………………… 
 
35 
Table 3.2 Patients’ demographic data by hospital (Erasme and Lausanne) ………… 
 
36 
Table 3.3 Summary BG statistics of OHCA patients (All cohort)………………… 
 
37 
Table 3.4 Demographic data patients based on mortality …………………………… 
 
38 
Table 3.5 Demographic data patients based on diabetes……………………………… 
 
40 
Table 3.6 Demographic data patients based on gender……………………………… 
 
42 
Table 3.7 Demographic data patients based on return of spontaneous circulation  
 
44 
Table 4.1 Descriptions of 12-hour and 6-hour blocks for data analysis ……………….. 
 
52 
Table 4.2 Summary of SI results for overall OHCA cohort. ………………………… 
 
53 
Table 4.3 Summary of SI results for OHCA cohort based on 12-hours block. …… 54 
 
Table 4.4 Increasing cohort and per patient median SI during cool and warm (12-hour 
blocks of data) ……………………………………………………… 
 
55 
Table 4.5 Summary of SI results for overall OHCA cohort based on 6-hour block. …. 56 
 
Table 4.6 Increasing cohort and per patient median SI during cool and warm as per 6-
hour blocks of data……………………………………………………… 
56 
Table 4.7 Summary of SI variability results for overall OHCA 
cohort……………………………………………………………….. 
 
57 
Table 4.8 Summary of SI variability results for OHCA cohort based on 12-hours 
block.  …………………………………………………………… 
 
58 
Table 4.9 Reductions in the IQR and median SI per patient range of hour-to-hour 
percentage SI change over time during cool and warm after as per 12-hour 
blocks of data ………………………………………… 
 
 
 
58 
xiv 
 
Table 4.10 Summary of SI variability results for overall OHCA cohort based on 6-hour 
block. ……………………………………………………….. 
 
60 
Table 4.11 Reductions in the interquartile range and median SI per patient range of 
hour-to-hour percentage SI change over time during cool and warm after as 
per 6-hour blocks of data …………………………………… 
 
60 
Table 4.12 Summary of SI level results and analysis for OHCA Sub-Cohorts…. 
 
61 
Table 4.13 Summary of increasing cohort and per patient median SI during cool 
and warm as per 12-hour blocks of data for all OHCA sub-cohorts. 
 
62 
Table 4.14 Summary of SI variability results and analysis for OHCA Sub-Cohorts….. 
 
63 
Table 4.15 Summary of reductions in the IQR and median SI per patient range of 
hour-to-hour percentage SI change over time during cool and warm as 
per 12-hour blocks of data for all OHCA sub-cohorts. 
 
64 
Table 5.1 Summary of BG results for overall OHCA cohort.   
 
72 
Table 5.2 Summary of BG results for OHCA cohort based on 12-hours block.   
 
73 
Table 5.3 Decreasing cohort and per patient median BG during cool and warm (12-
hour blocks of data) 
 
74 
Table 5.4 Summary of BG results for overall OHCA cohort based on 6-hour block.   
 
75 
Table 5.5 Decreasing cohort and per patient median BG during cool and warm as per 
6-hour blocks of data. 
 
75 
Table 5.6 Summary of BG variability results for overall OHCA cohort.  
  
76 
Table 5.7 Summary of BG variability results for OHCA cohort based on 12-hours 
block.   
 
77 
Table 5.8 Reductions in the IQR and median BG per patient range of hour-to-hour 
percentage BG change over time during cool and warm after as per 12-hour 
blocks of data 
 
78 
Table 5.9 Summary of BG variability results for overall OHCA cohort based on 6-
hour block.   
 
79 
Table 5.10 Reductions in the interquartile range and median BG per patient range of 
hour-to-hour percentage BG change over time during cool and warm after 
as per 6-hour blocks of data 
 
79 
Table 5.11 Summary of BG level results and analysis for OHCA Sub-Cohorts 
 
80 
Table 5.12 Summary of BG variability results and analysis for OHCA Sub-Cohorts 
 
81 
Table 6.1 Summary of Exogenous Insulin results for overall OHCA cohort.   
 
 
 
89 
xv 
 
Table 6.2 Summary of Exogenous Insulin results for OHCA cohort based on 12-hours 
block.   
 
90 
Table 6.3 Decreasing cohort and per patient median insulin infusion during cool and 
warm (12-hour blocks of data) 
 
91 
Table 6.4 Summary of Exogenous Insulin results for overall OHCA cohort based on 
6-hour block.   
 
92 
Table 6.5 Decreasing cohort and per patient median Exogenous Insulin during cool 
and warm as per 6-hour blocks of data 
 
92 
Table 6.6 Summary of Exogenous Insulin results and analysis for OHCA Sub-Cohorts 
 
94 
Table 6.7 Summary of nutrition results for overall OHCA cohort.   
 
95 
Table 6.8 Summary of nutrition results and analysis for overall OHCA cohort based 
on 12-hours block.   
 
96 
Table 6.9 Decreasing cohort and per patient median nutrition during cool and warm 
(12-hour blocks of data) 
 
97 
Table 6.10 Summary of nutrition/dextrose results and analysis for overall OHCA 
cohort based on 6-hours block.   
 
98 
Table 6.11 Decreasing cohort and per patient median nutrition/dextrose during cool and 
warm as per 6-hour blocks of data 
 
98 
Table 6.12 Summary of nutrition/dextrose results for OHCA Sub-Cohorts. 
 
99 
Table 7.1 Sample results for stochastic model prediction widths at c= 1 
 
111 
Table 7.2 Cross-validation comparison study for 180 patient cohort (Cool) 
 
112 
Table 7.3 Cross-validation comparison study for 180 patient cohort (Warm) 
 
113 
Table 7.4 Comparison of probability bounds for modifications of kernel density 
estimator (σ`x = cσx AND σ`y = cσy) during both cool and warm. 
 
113 
Table 7.5 Stochastic model prediction widths at c= 1 based on 12-block analysis 
 
116 
Table 7.6 Comparison of probability bounds for modifications of kernel density 
estimator (σ`x = cσx AND σ`y = cσy) based on 12-hour block analysis 
 
117 
Table 7.7 Stochastic model prediction widths at c= 1 based on 6-block analysis 
 
118 
Table 7.8 Comparison of probability bounds for modifications of kernel density 
estimator (σ`x = cσx AND σ`y = cσy) based on 6-hour block analysis 
 
120 
Table 7.9 Cross-validation comparison study for OHCA sub-cohorts (Cool 
period) at c=1. 
 
 
122 
xvi 
 
Table 7.10 Cross-validation comparison study for OHCA sub-cohorts (Warm 
period) at c=1. 
 
122 
Table 7.11 Cross-validation comparison study for 180 patient cohort (Warm 
period) 
 
123 
Table 8.1 Summary of SI results for overall OHCA cohort.   
 
132 
Table 8.2 Summary of results for overall OHCA cohort based on 12-hour block 
analysis 
 
134 
Table 8.3 Summary of results for overall OHCA cohort based on 12-hour block 
analysis 
 
135 
Table 8.4 Analysis summary for OHCA patients by sub-cohort 
 
137 
Table 9.1 
 
Summary of BG level results for retrospective data, and STAR and 
STAR-OHCA controller combination   
 
152 
Table 9.2 BG level comparative analysis of stochastic based controllers with 
the retrospective data. 
 
152 
Table 9.3 Summary of BG variability results for retrospective data and 
stochastic based patient-specific controllers 
 
154 
Table 9.4 BG variability comparative analysis of patient-specific controllers 
with the retrospective data. 
 
154 
Table 9.5 Summary of STAR, STAR-OHCA and retrospective controller 
performance analysis during cool period 
 
156 
Table 9.6 Summary of STAR, STAR-OHCA and retrospective controller 
performance analysis during warm period 
 
157 
 
 
 
 
 
 
 
 
 
xvii 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
xviii 
 
Nomenclature 
 
Acronyms and abbreviations 
APACHE  Acute Physiological And Chronic Health Evaluation 
ATP  Adenosine Triphosphate   
BG  Blood Glucose 
CDF  Cumulative Distribution Function 
EGP  Endogenous Glucose Production 
ICING  Intensive Control Insulin-Nutrition-Glucose 
ICU  Intensive Care Unit 
IQR  Interquartile Range 
OHCA  Out of Hospital Cardiac Arrest 
ROSC  Resumption of Spontaneous Circulation 
SI  Insulin sensitivity parameter 
SPRINT  Specialized Relative Insulin and Nutrition Tables 
STAR  Stochastic TARgeted 
T1DM  Type 1 Diabetes Mellitus 
T2DM  Type 2 Diabetes Mellitus 
TGC  Tight Glycaemic Control 
Uen  Endogenous insulin secretion 
   
   
   
   
 
 
 
 
xix 
 
Mathematical variables 
αG  Michaelis-Menten constant for insulin binding saturation parameter 
[L/mU]  
αI  Michaelis-Menten constant for hepatic insulin clearance saturation 
parameter [L/mU] 
c  Variance estimator modification constant 
CNS  Central nervous system glucose uptake [mmol/min] 
D(t)  Oral glucose input rate (enteral nutrition) [mmol/min] 
d1  Glucose transport rate from stomach to gut [1/min] 
d2  Glucose transport rate from gut to plasma [1/min] 
EGP  Endogenous glucose production rate [mmol/min] 
G  Blood glucose concentration [mmol/L] 
I  Blood plasma insulin concentration [mU/L] 
nI  Trans-endothelial diffusion rate [1/min] 
nC  Interstitial insulin degradation rate [1/min] 
nK  Renal insulin clearance rate [1/min] 
nL  Hepatic insulin clearance rate [1/min] 
xL  Fractional first-pass hepatic insulin extraction 
pG  Non-insulin mediated glucose removal [1/min] 
Pmax  Maximum glucose flux from gut to plasma [mmol/min] 
PN(t)  Intravenous glucose input rate (parenteral nutrition) [mmol/min] 
umin  Minimum pancreatic secretion rate [mU/min] 
umax  Maximum pancreatic secretion rate [mU/min] 
uex(t)  Intravenous insulin input rate [mU/min] 
VG  Plasma glucose distribution volume [L] 
VI  Plasma and interstitial insulin distribution volume [L] 
 
 
 
 
xx 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
xxi 
 
Academic Contribution 
 
 
This doctoral thesis was completed by preparing a series of academic papers, with the main 
objective to develop safe and effective stochastic targeted model based glycaemic controller 
for highly intensive care Out of Hospital Cardiac Arrest (OHCA) patients using the existing 
ICING-2 model and STAR framework. The candidate’s academic contributions are 
summarised as follows:   
 
i) Perform evolution and variability analysis of OHCA patients based on metabolic, 
glycaemic and exogenous insulin and nutrition during hypothermia (cool period) and 
normothemia (warm period).  The main findings from this study will be used to define 
control design specifications for the cohort. 
 
ii) Develop new stochastic model, specifically for unique clinical and physiological case 
of the OHCA patients, treated with hypothermia based on clinically validated, model based 
insulin sensitivity during cool and warm period. 
  
iii) Develop adaptive model based STAR-OHCA controller using cohort specific 
stochastic model with some modifications based on the constraints defined by control design 
specifications. 
 
iv) Evaluate controller performance through virtual trial simulations. 
 
 
 
 
 
 
 
 
xxii 
 
The following publications were generated during this study.  
  
1. Peer-Reviewed Journal Articles:   
 
1.1 Sah Pri, A., J. G. Chase, C. G. Pretty, G. M. Shaw, J. C. Preiser, J. L. Vincent, M. 
Oddo, F. S. Taccone, S. Penning and T. Desaive (2014). "Evolution of insulin 
sensitivity and its variability in out of hospital cardiac arrest (OHCA) patients treated 
with hypothermia." Crit Care 18(5): 586. 
  
2. Papers Published in Refereed Conference Proceedings: 
 
2.1 Sah Pri A, Chase J.G, Le Compte A.J, Shaw G.M, Preiser J.C, Taccone F, Penning S, 
Desaive T (2013).  Insulin Sensitivity during Hypothermia in Critically Ill Patients. 
International Journal of Medical Sciences, vol 4 (2): 2013, 41-52 
 
3. Papers Presented in Conference: 
 
3.1 Insulin Sensitivity during Hypothermia in Critically Ill Patients (Paper no: 143) 
This article was presented at the International Conference on Computational 
Bioengineering (ICCB), 11-13 September 2013 at Leuven, Belgium, and accepted for 
publication. 
 
3.2 Insulin Sensitivity Variability during Hypothermia 
This article has been accepted for oral presentation at the 19
th
 (International 
Federation of Automatic Control) IFAC World Congress which will be held in Cape 
Town, South Africa, August 2014. 
 
 
 
 
 
 
 
xxiii 
 
4. Paper Accepted for Poster Presentation in Conference: 
 
4.1 Insulin Sensitivity in Out of Hospital Cardiac Arrest Patients Treated With 
Hypothermia 
This article was accepted for poster presentation at the 26th Annual Congress of the 
European Society of Intensive Care Medicine (ESICM) which was held in Paris, 
France from 5-9 October 2013 
 
5. Papers in Preparation 
 
5.1 Stochastic Modelling of Insulin Sensitivity for Post-Cardiac Arrest Patients during 
hypothermia 
 
5.2 Virtual trial simulation analysis of stochastic-based glycaemic control for OHCA 
patient, treated with hypothermia. 
 
5.3 Blood glucose controller for OHCA patients, treated with hypothermia: Initial 
development and virtual trials 
 
 
 
 
 
 
 
 
 
 
 
 
xxiv 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
xxv 
 
Abstract 
 
 
Hyperglycaemia is  prevalent  in  critical  care  and increases the  risks  of  further  
complications  and  mortality. Glycaemic control has shown benefits in reducing mortality. 
However, due in parts to excessive metabolic variability, many studies have found it difficult 
to reproduce these results. Out-of-Hospital Cardiac Arrest (OHCA) patients have low 
survival rates and often experience hyperglycaemia. However, these patients belongs to one 
group who has shown benefit from accurate glycaemic control (AGC), but can be highly 
insulin resistant and variable, particularly on the first two days of stay. 
 
Hypothermia is often used to treat post-cardiac arrest patients or out of hospital cardiac arrest 
(OHCA) and these same patients often simultaneously receive insulin. In general, it leads to a 
lowering of metabolic rate that induces changes in energy metabolism. However, its impact 
on metabolism and insulin resistance in critical illness is unknown, although one of the 
adverse events associated with hypothermic therapy is a decrease in insulin sensitivity and 
insulin secretion. However, this decrease may not be notable in the cohort that is already 
highly resistant and variable.  Hence, understanding metabolic evolution and variability 
would enable safer and more accurate glycaemic control using insulin in this cohort. 
 
OHCA patients were undergone preliminary analysis during cool and warm, which includes 
insulin sensitivity (SI), blood glucose (BG), and exogenous insulin and dextrose. Patients 
were analysed based on overall cohort, sub-cohorts, and 6 and 12 hour time block. Generally, 
the results show that OHCA patients had very low metabolic activity during cool period but 
significantly increased over time. In contrast, BG is higher during cool period and decreased 
over time. The analysis is equally important as the controller development since it provides 
scientific evidence and understanding of patients’ physiology and metabolic evolution 
especially during cool and warm.   
 
Model-based methods can deliver control that is patient-specific and adaptive to handle 
highly dynamic patients. A physiological ICING-2 model of the glucose-insulin regulatory 
system is presented in this thesis. This model has three compartments for glucose utilisation, 
effective interstitial insulin and its transport, and insulin kinetics in blood plasma, with 
xxvi 
 
emphasis on clinical applicability. The predictive control for the model is driven by the 
patient-specific and time-varying insulin sensitivity parameter. A novel integral-based 
parameter identification enables fast and accurate real-time model adaptation to individual 
patients and patient condition. 
 
Stochastic models and time-series methods for forecasting future insulin sensitivity are 
presented in this thesis. These methods can deliver probability intervals to support clinical 
control interventions. The risk of adverse glycaemic outcomes given observed variability 
from cohort-specific and patient-specific forecasting methods can be quantified to inform 
clinical staff. Hypoglycaemia can thus be further avoided with the probability interval guided 
intervention assessments. 
 
Simulation studies of STAR-OHCA control trials on ‘virtual patients’ derived from 
retrospective clinical data provided a framework to optimise control protocol design in-silico. 
Comparisons with retrospective control showed substantial improvements in glycaemia 
within the target 4 - 7 mmol/L range by optimising the infusions of insulin. The simulation 
environment allowed experimentation with controller parameters to arrive at a protocol that 
operates within the constraints found earlier during patient analysis. 
 
Overall, the research presented takes model-based OHCA glycaemic control from concept to 
proof-of-concept virtual trials. The thesis employs the full range of models, tools and 
methods to optimise the protocol design and problem solution.   
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1 
 
Chapter 1: Introduction 
 
  
Hyperglycemia, or elevated blood glucose level, is a common effect of uncontrolled diabetes 
and is prevalent in critical care patients (Capes et al., 2000, McCowen et al., 2001, Mizock, 
2001, van den Berghe et al., 2001). During recent years, hyperglycemia was associated with 
adverse outcomes in various clinical settings (Rovlias and Kotsou, 2000, Umpierrez et al., 
2002, Krinsley, 2003, Egi et al., 2010). For example, hyperglycemia predicted a higher risk 
after stroke and poor functional recovery in surviving patients. In patients with myocardial 
infarction (heart attack) and coronary artery disease, hyperglycemia was associated with an 
increase of further complications and mortality (Capes et al., 2000, van den Berghe et al., 
2001). 
 
This problem has attracted many researchers to conduct studies on hyperglycaemia in the 
critically ill, and specifically how to perform glycaemic control effectively and safely among 
those patients. Two landmark studies by Van den Berghe (van den Berghe et al., 2001, Van 
den Berghe et al., 2006a) and Krinsley (Krinsley, 2004) showed that tight glycaemic control 
can reduce patient mortality and led to several additional clinical and model-based studies 
(Chase et al., 2008b). However, while some were successful (van den Berghe et al., 2001, 
Krinsley, 2004, Chase et al., 2008b), others failed to repeat the results (Brunkhorst et al., 
2008, Finfer et al., 2009, Preiser et al., 2009). As hyperglycaemia and its complications 
increase risk and costs, it has become a significant research area and was recently reviewed 
by Chase (Chase et al., 2006a, Chase et al., 2007a, Chase et al., 2011b).   
 
1.1   Cardiac Arrest Patients  
 
Cardiac arrest can be described as the cessation of normal circulation of the blood due to 
sudden loss of cardiac function, when the heart abruptly stops beating and pumping blood to 
the brain and other parts of the body (Jameson, 2005). Arrested blood circulation prevents 
delivery of oxygen to the body. Permanent brain damage and death is likely to occur unless 
the flow of blood to the brain is restored (Vespa et al., 2005). Ventricular fibrillation is the 
most common cause of cardiac arrest (Zipes and Wellens, 1998), which occurs due to heart 
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attack (myocardial infarction), respiratory arrest (loss of breathing function), choking, 
trauma, electrocution and drowning (Jameson, 2005).  
 
A person whose heart has stopped will lose consciousness and stop normal breathing, and 
their pulse and blood pressure will be absent.  Cardiac arrest leads to death within a few 
minutes and is obviously a serious emergency unless resuscitative efforts are begun 
immediately (Neumar et al., 2008). Early emergency treatment, such as cardiopulmonary 
resuscitation (CPR) and defibrillation (electrical impulses delivered to the chest to restore 
normal heart rhythm), are primary ways to reverse cardiac arrest and must be implemented 
within a few minutes to increase chances of survival.   
 
1.2   Out of Hospital Cardiac Arrest (OHCA) Patients  
 
Post-Cardiac Arrest or Out-of-Hospital Cardiac Arrest (OHCA) Syndrome is the medical 
emergency that occurs after the immediate resuscitation. It is characterized by resumption of 
spontaneous circulation (ROSC) after prolonged complete whole body ischemia, followed by 
resuscitation (Neumar et al., 2008). Once ROSC is achieved, the patient is technically alive. 
However, rates of early mortality in patients achieving ROSC after cardiac arrest vary 
dramatically among countries, regions and hospitals (Langhelle et al., 2003, Herlitz et al., 
2006). The cause of these differences includes variability of patient populations, reporting 
methods, and, potentially, post-cardiac arrest care.  
 
Approximately 166,200 out-of-hospital cardiac arrests occur annually in the US (Nolan et al., 
2008). On average, approximately 6.4% of out-of-hospital cardiac arrest patients survive to 
hospital discharge. The in-hospital mortality rate of patients who achieve ROSC after cardiac 
arrest has not changed significantly over the past 50 years (Bloom et al., 2007, Ehlenbach et 
al., 2009, Tian et al., 2010). Thus, there may be room for improved treatment after ROSC to 
improve outcomes. 
 
Hyperglycaemia is also common in OHCA patients and is associated with poor neurological 
outcome in survivors (Geocadin et al., 2008, Neumar et al., 2008). Post-cardiac arrest brain 
injury and myocardial dysfunction are common cause of morbidity and mortality which 
contribute to low survival rates after in- and out-of-hospital cardiac arrest (Stub et al., 2011)  .  
However, there is growing evidence that appropriate post-cardiac arrest care, such as tight 
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glycaemic control and therapeutic hypothermia can improve mortality rate and functional 
outcome (Safar et al., 1996, Holzer and Behringer, 2005, Neumar et al., 2008). Hence, these 
findings open further research and development opportunities for improving the existing tight 
glycaemic control system to specifically benefit post-cardiac arrest patients in specific. 
 
1.3   Aetiology of Hypothermia in OHCA Patients Care 
 
Post-Cardiac Arrest or Out-of-Hospital Cardiac Arrest (OHCA) patients are one group who 
have shown benefit from Tight Glycaemic Control (TGC), but can be highly insulin resistant 
and variable, particularly on the first day of stay (Pretty et al., 2012)   . Hypothermia or 
lowering body temperature below 35 degree Celsius is often used to treat out of hospital 
cardiac arrest (OHCA) (Graffagnino et al., 2012, Ornato et al., 2012, Reynolds and Lawner, 
2012, Bucher et al., 2013, Dietrich et al., 2013, Scirica, 2013, Winters et al., 2013, Mearns, 
2014, Picchi et al., 2014, Polderman et al., 2014) and these same patients often 
simultaneously receive insulin (Nolan et al., 2008) . Hypothermia leads to a further lowering 
of the metabolic rate and includes changes in energy metabolism and decreases in adenosine 
triphosphate (ATP) demand during cellular respiration process (Melhuish, 2009). 
 
Symptoms of hypothermia may be vague of difficult to identify, with sympathetic nervous 
system excitation such as shivering, hypertension, tachycardia, tachypnea and 
vasoconstriction (Hanania and Zimmerman, 1999). Other symptoms, such as cold dieresis, 
mental confusion, and hepatic dysfunction, may also present (McCullough and Arora, 2004). 
Most hypothermia-related deaths are preventable but conversely statistical record in year 
2001 have revealed that a total of 646 hypothermia-related deaths were reported in the United 
States, with an annual death rate of 0.2 per 100,000 population (Fallico et al., 2002). These 
statistics data suggest that hypothermia and its complications increase risk even though it is 
increasingly used for treating OHCA patients.   
 
In the event of hypothermia, patients now frequently undergo intensive hypothermic therapy 
(Stub et al., 2011, Graffagnino et al., 2012, Ornato et al., 2012, Dietrich et al., 2013, Scirica, 
2013) as the treatment offers beneficial effects physiologically and clinically (Dietrich et al., 
2009, Marion and Bullock, 2009, Egi et al., 2010). One of the adverse events associated with 
hypothermic therapy is the decrease in insulin sensitivity and insulin secretion (Hayashi, 
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2009). The amount of insulin required to maintain glucose levels within normal range (80 to 
110 mg/dL) is likely to increase during the induction of hypothermia, which can equally lead 
to increased risk of hyperglycaemia and hypoglycaemia. Therefore, these patients require 
additional care in metabolic management. 
 
1.4   Hypothermia and Glucose-Insulin System Dynamics 
 
The metabolic system is one of the important systems in human body. It processes the 
complex carbohydrate and sugar molecules from food and transforms them into glucose for 
storage and metabolism. The system comprises the stomach, pancreas, liver and cells where 
each organ has specific roles in digesting or storing glucose from food. Hormones, such as 
insulin and glucagon, assist the process by providing signals to the cells for releasing stored 
glucose or the liver for storing glucose from bloodstream.   
 
After food is consumed, the body reduces complex carbohydrate and sugar molecules to the 
simple six-carbon sugar known as glucose. Glucose is the body’s fuel, and upon the reduction 
by the body, it is either utilised or stored. Sensing glucose in the bloodstream leads the β-cells 
in the pancreas to produce insulin. The concentration of insulin acts as the body’s signal to 
manage storage and transportation, and thus determines the utilisation or storage rate of 
glucose.   
 
Insulin is a protein that consists of 51 amino acids in two closely connected chains.   Insulin 
molecules and their connecting fragments are then packed together in small granules in the β-
cells, which are secreted on demand through the islets of Langerhans in the pancreas. Along 
with β-cells, the 1 to 2 million islets of Langerhans contain α and δ cells, which secrete 
glucagon and somatostatin, respectively, and act as additional blood glucose regulatory 
hormones. The α, β and δ cells are approximately 25%, 60% and 10% of the total islets and 
are all very closely related (Guyton and Hall, 2000) 
 
The  level  of  insulin  in  the  bloodstream  is  the  signal  that  facilitates  the proper 
metabolic response as shown in Figure 1.1 . A high insulin level promotes storage of glucose, 
and a low insulin and glucose level signals the need for the release of glucose fuels, currently 
in storage, back into the blood stream. A meal results in an increase of insulin concentration 
in the blood, due to the increased secretion of insulin by the β-cells, and signals the liver and 
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muscles to consume the extra fuel (glucose) available.  The liver stores glucose as glycogen 
or fat, and the muscles utilise glucose primarily to repair damaged muscle cells, for energy 
storage as glycogen and lastly storage in fat cells. 
 
 
 
Figure 1.1: Model of Glucose-Insulin Regulatory System. The schematic shows the effect of 
high and low blood glucose levels in the body.  Adapted from health.howstuffworks.com 
 
 
Counter regulatory hormones, such as glucagon and adrenaline, signal the liver to release 
glucose. Too much glucose removal from the blood-stream can result in low blood glucose 
levels. When the glucose available is not sufficient enough to supply the brain’s 
requirements, hypoglycaemic symptoms including hunger, anxiousness, restlessness, 
agitation, perspiration, tachycardia (racing pulse) and palpitation (irregular and/or forced 
heart-beats) occur. These symptoms are partly a result of the release of adrenaline by the 
body as a counter regulatory measure to restore normal blood glucose levels. When the 
amount of insulin released is suddenly reduced, the signal is not available to the body to 
indicate it should remove glucose from the blood stream. The blood glucose level therefore 
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rises until there is hyperglycaemia, requiring further insulin. It is thus a natural feedback 
system using glucose raising / glucagon and adrenaline, and lowering insulin hormones. 
 
Insulin is an anabolic hormone and promotes growth, while lowering glucose levels (Vander, 
2001). Insulin also increases the activity of other enzymes, primarily those involved in 
glycogen, lipid and protein synthesis, and inhibit the activity of those that catalyse glucose 
degradation. However, all these digestive and metabolic activities involving secretion of 
insulin, glycogen and other related hormones and enzymes are optimum only during normal 
body temperature between 36
o
C and 37.5
o
C (Lehninger, 1970, Wilson, 1988). At body 
temperature of higher or lower than normal range, the production of hormones and enzymes 
from the pancreas and other organs shows some decay and can eventually affect the 
metabolic rate and physiological condition of the body (Benz-Woerner et al., 2012). 
 
To date, there is no scientific evidence explaining human glucose-insulin kinetics during 
hypothermia. However, by use of a newly developed technique, substrate profiles and their 
regulation by insulin were examined in hypothermic rats over 24h (Hoo-Paris et al., 1988, 
Cueni-Villoz et al., 2011),  resulting in the following outcomes: 
 
i)   Plasma glucose concentrations increased during cooling and remained high 
thus reducing glucose utilization throughout the period of hypothermia 
(Escolar et al., 1990). 
ii)  Plasma insulin decreased dramatically during cooling and remained very low 
during the whole period of hypothermia, reflecting the suppression of 
endogenous insulin secretion seen in isolated islets at low temperatures 
(Escolar et al., 1987). 
iii)  Resistance to exogenous insulin is increased (Torlinska et al., 2002). 
 
The role of pancreas in producing insulin and glycogen hormones is vital and its ability to 
perform at optimum level is important in regulating blood glucose level at normal glycaemic 
range. However, during hypothermia, the pancreas is unable to function normally, which can 
lead to increased or decreased blood glucose levels (Benz-Woerner et al., 2012). In general, 
hypothermia can be life threatening. However, it also benefits patients with recent heart 
attack. 
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1.5   The Problem Statement 
 
To date, there are no clinically applied glucose-insulin regulatory models developed for 
specific patient cohorts with specific physiological conditions, such as post-cardiac arrest 
patients with hypothermia. The existing glucose-insulin regulatory models (Hann et al., 2005, 
Lin et al., 2011) are suitable when dealing with typical hyperglycaemia cases in critical care 
where all predictable symptoms have taken into account when developing the models, which 
are based on normal or elevated body temperature. However, when induced hypothermia is 
implemented during treatment, the condition is changed from this baseline and the existing 
models may not be able to respond optimally, leading to poor treatment. Thus, highly 
variable blood glucose levels which can adversely affect clinical outcomes and mortality. 
 
Thus, there is a strong need for more rigorous analysis that reviews and improve existing 
model-based glycaemic control methods based on physiological response during 
hypothermia. This goal will lead to a review of the existing glycaemic model and the 
numerical parameters used, improve the insulin sensitivity prediction and blood glucose 
control methods, and improve the overall insulin-nutrition administration system. All of these 
will be specific to these hypothermia treated cohorts. 
 
1.6   Significance of the Study  
 
Rigorous studies in this area will end up developing a model-based glycaemic control 
approach that can deliver computerized glycaemic control adaptable to these specific 
critically ill patients. Additional features like cohort-specific stochastic modelling and 
adaptive control methods can further enhance model-based control with more accurate 
predictive performance and will be equally novel. The new glycaemic control should be able 
to overcome blood glucose variability problems, specific to post-cardiac arrest patients 
undergoing hypothermia, thus potentially improving care and reducing morbidity and 
mortality of ICU patients in this category. 
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1.7   Preface 
 
This thesis is organized in two parts as shown in Figure 1.2. Part I is related to the patient 
analysis and clinical setting of this work. An existing metabolic system model is reviewed, 
considering the physiological conditions due to human body temperature change and 
available data sets are presented. Part II focuses on control system design and virtual trials 
simulation. Detailed overview of all chapters of this thesis is described as follows: 
 
Chapter 2: Model Review and Development 
This chapter reviews the physiology of the glucose-insulin regulatory system and describes 
the fundamental aspects of glycaemic control, which includes an overview of previous 
glycaemic models, metabolic system model (ICING model) used and the more recent ICING-
2 model. This chapter is also reviewing the overall glycaemic control system model and its 
key components, including input, output, actuators, patient and controller in general. Then, 
the discussion is focused on glycaemic control and its development such as SPRINT and 
STAR controller. Finally, performance metrics, suitable for general TGC is also introduced. 
 
Chapter 3:  Patient Demography 
This chapter summarizes the overall OHCA patient background with statistical analysis on 
the cohort by mortality, diabetes, sex and the return of spontaneous circulation (ROSC). This 
set of cohorts is used throughout the thesis. 
 
Chapter 4:  Insulin Sensitivity Level and Variability Analysis  
This chapter explains the physiological and metabolic conditions of OHCA patients treated 
with hypothermia based on insulin sensitivity (SI) level and variability. Analysis and 
comparison is made between cool and warm conditions per-cohort and per-patient, which in 
turn characterize the overall evolution of SI for this cohort. 
 
Chapter 5:  Blood Glucose Level and Variability Analysis  
This chapter explains the physiological and metabolic conditions of OHCA patients, treated 
with hypothermia based on blood glucose (BG) level and variability analysis. Analysis and 
comparison is made between cool and warm conditions per-cohort and per-patient, which in 
turn characterize the overall evolution of BG for this cohort. This topic overlaps Chapter 4, 
but also includes the impact of glycaemic control which differs between cohorts. 
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Chapter 6: Exogenous Insulin and Nutrition Analysis 
This chapter describes a preliminary study of OHCA patients based on exogenous insulin and 
nutrition characteristics during hypothermia (cool period) and normothemia (warm period). It 
analyses the impact of exogenous insulin and nutrition modulation during TH on glycaemic 
outcome. Analysis and comparison is made between cool and warm conditions, which in turn 
characterize the overall insulin and nutrition administration for this cohort.   
 
Chapter 7: Stochastic Modelling of Insulin Sensitivity Analysis 
This chapter develops the method for insulin sensitivity variation forecasting for this specific 
cohort. Stochastic and time-series analysis techniques are used to generate likelihood bands 
for future blood glucose concentration. Observations of differences in stochastic behaviour 
between cool and warm, 12 and 6-hour time block, and patient characteristics such as 
diabetes, mortality, sex and ROSC may further develop protocols for different time blocks 
and groups.   
 
Chapter 8: Summary of OHCA Patient Analysis 
This chapter summarize the overall scenario and define glycaemic control problems based on 
analysis in chapter 4, 5, 6 and 7. It begins with describing overview of OHCA patient 
analysis and its relation with overall research work. Then, patient results from previous 
analysis were tabled based on overall cohort, 6 and 12-hour time block, and patient sub-
cohorts. Patient conditions, problems and treatment observations are identified and discussed 
thoroughly.  
 
Chapter 9: STAR Control Performance Analysis and Virtual Trials 
This chapter presents a comparative study of STAR controller performance over Out-of-
Hospital Cardiac Arrest (OHCA) patients based on general and OHCA-specific stochastic 
models. It analyses the improvement in glycaemic control that can be achieved by these 
stochastic models during treatment, including the evolution of blood glucose and its 
variability. 
 
Chapter 10: Conclusions  
Finally, this chapter summarize the overall research work and its important findings as well 
as proposing the possible future improvements and applications in relation to this studies. 
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Figure 1.2: Thesis outline. Part I of this thesis introduces relevant background knowledge, 
analyse patients’ data and determine control problem definitions. Part II presents the review 
of glycaemic control development and virtual trials. 
PART I: OHCA PATIENT 
ANALYSIS   
PART II: CONTROL DESIGN 
AND VIRTUAL TRIALS 
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Chapter 2: Model Review and Development 
 
 
 
 
The dynamics of the human glucose-insulin regulatory system have been studied extensively. 
A number of researchers have developed models with distinct levels of complexity to suit 
different physiological conditions, clinical or research applications, and targeted clinical 
outcomes. For instance, many models have been designed to provide model-based measures 
to assess metabolic phenomena, with a particular focus on measuring insulin sensitivity 
(Bergman et al., 1979, Bergman et al., 1981, Bergman et al., 1985, Pacini and Bergman, 
1986, Yang et al., 1987, Mari, 1998, Toffolo et al., 1999, Mari et al., 2001, Pacini and Mari, 
2003, Toffolo et al., 2006). These investigations focused on understanding specific metabolic 
phenomena, rather than clinical intervention or control. They thus tended forward more 
minimal models of just glucose, insulin, and insulin sensitivity. Critically, a physiological 
model that captures the basic glucose-insulin dynamics and insulin sensitivity is also the 
starting basis for any glycaemic control problem. 
 
Several researchers have constructed control system models due to a high demand for insulin 
infusion dose advice and control of blood sugar levels (Deutsch et al., 2004, Wong et al., 
2008), model predictive control (MPC) (Hovorka et al., 2004) and automated or semi- 
automated glycaemic control (Parker et al., 1999, Parker et al., 2001, Hovorka et al., 2004, 
Lonergan et al., 2006b, Plank et al., 2006a, Chase et al., 2007b, Wong et al., 2008). These are 
all models for clinical intervention.  
 
More advance biomedical control system models have additions that can capture, predict and 
control patient metabolic behaviour. Such a model offers a safe and fast means for protocol 
development without clinical testing and risk (Chase et al., 2010) . Equally, control system 
models must often work with the available clinical data in real-time, which demand a more 
robust modelling solution compared to models designed to model human physiology in 
research settings (Chase et al., 2006a). 
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This chapter examines several forms of existing metabolic control system models that have 
been used in adult intensive care. A glycaemic control system for OHCA patients, treated 
with hypothermia is developed from this foundation. Since the OHCA cohort patients are 
mainly adult, most of the model parameters during normal body temperature can be adapted. 
However, a clinically validated insulin sensitivity parameter (Chase et al., 2010)  is identified 
in each period to understand the impact of hypothermia or metabolism. 
 
2.1   Glucose-Insulin Models for Critical Care  
 
Intensive care represents a highly controlled environment where most glucose-insulin system 
inputs and outputs can be accounted for and thus modelled. However, the stress of critical 
illness can significantly disturbs the glucose-insulin regulatory system from a healthy 
baseline (Capes et al., 2000, McCowen et al., 2001, Mizock, 2001, van den Berghe et al., 
2001). This situation is exacerbated by the inconsistency and wide range of medications 
administered to the critically ill, many of which exhibit highly patient-specific effects on 
glucose metabolism (Pretty et al., 2011). Such detailed pharmacodynamics information may 
not be measurable in a typical clinical setting. Thus, any control system model must make a 
compromise between physiological validity, clinical applicability and mathematical 
identifiability. 
 
A physiological model that captures glucose-insulin system dynamics and allows accurate 
blood glucose prediction is an acceptable basis for model-based glycaemic control. The vast 
majority of these models have their roots in  basic  compartment  modelling  with  differential  
equations (Carson and Cobelli, 2001). These models and, in particular, those from which the 
model in this thesis is derived, have been extensively reviewed (Le Compte et al., 2009, Lin 
et al., 2011). This section provides a summary of the basic requirements for a compartment 
model that can be used in clinical real-time and introduces the ICING model used throughout 
the rest of this thesis.  
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A compartment model consists of five basic elements:  
 
1.   Compartments in which substances exist at varying concentrations or mass. 
2.   Kinetics describing the transport of substances between compartments such as mass 
or concentration.  
3.   Dynamics that describe the interaction of substances with each other or the 
environment.  
4.   Appearance of substances into the compartment system from the external 
 environment.  
5.   Clearance of substances back to an external environment.  
  
In addition to these five basic elements, a successful model for clinical control should also be 
physiologically valid, clinically applicable and mathematically identifiable (Chase et al., 
2011a). These additional factors ensure that the model output provides useful information 
about patient physiology and status, and can be identified in clinical real-time using the 
limited measurement data available.   
 
2.1.1    Critical care glucose–insulin model (ICU model) 
 
The model from (Chase et al., 2007b) was developed and validated for glycaemic level 
management in the ICU. This model captures the fundamental dynamics seen in critically ill 
patients, yet has a relatively simple mathematical structure enabling rapid identification of 
patient-specific parameters (Hann et al., 2005). This model only blood glucose (BG) 
measurements, so it can be used at the bedside for clinical real-time identification and control. 
This structure has been widely used in clinical TGC studies and other analyses (Lin et al., 
2008, Wong et al., 2008, Le Compte et al., 2009). 
 
Equations (2.1) – (2.5) present this ICU model as used for glycaemic control in intensive 
care: 
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where G(t) [mmol/L] denotes the total blood glucose, I(t) [mU/L] is the plasma insulin, Q(t) 
[mU/L] is the effect of previously infused insulin being utilized over time, with k [1/min] 
accounting for the effective life of insulin in the system. Endogenous glucose removal and 
insulin sensitivity are denoted pG [1/min] and SI [L/mU/min], respectively. VI [L] is the 
insulin distribution volume and n [1/min] is the constant first order decay rate for insulin 
from plasma. Basal endogenous glucose production unsuppressed by glucose and insulin 
concentration is denoted by EGPb [mmol/min] and VG [L] represents the glucose distribution 
volume. CNS [mmol/min] represents non-insulin mediated glucose uptake by the central 
nervous system. Michaelis-Menten functions are used to model saturation, with αI [L/mU] 
used for the saturation of plasma insulin disappearance, and αG [L/mU] for the saturation of 
insulin-dependent glucose clearance. P1 [mmol] represents the glucose in the stomach and P2 
[mmol] represents glucose in the gut. The rate of transfer between the stomach and gut is 
represented by d1 [1/min], and the rate of transfer from the gut to the bloodstream is d2 
[1/min].  Pmax represents the maximum disposal rate from the gut. Exogenous inputs are 
glucose appearance P(t) [mmol/min] and intravenous insulin u(t). A schematic of the model 
is shown in Figure 2.1. 
 
This model was developed and validated in critical care glycaemic control studies (Wong et 
al., 2006b, Chase et al., 2007b). Insulin sensitivity SI is identified hourly from patient data, 
producing a step-wise hourly varying profile that effectively describes the patients’ 
physiological behaviour under various metabolic conditions (Hann et al., 2005).  The validity 
and independence of this patient-specific parameter have been validated using data from 
clinically matched cohorts (Chase et al., 2010) and in gold-standard insulin sensitivity tests 
(McAuley et al., 2011). 
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Figure 2.1:  Critical care glucose-insulin model 
 
 
2.1.2    Glucose–insulin model for insulin sensitivity test (SI Test or DISST Model) 
 
The second model from (Lotz et al., 2008) was developed for diagnosis of insulin resistance. 
The modelled insulin sensitivity has high correlation to the euglycaemic hyperinsulinemic 
clamp (EIC) and high repeatability (Lotz et al., 2006, Lotz et al., 2008). This model has more 
patient specific parameters, but is not suitable for real- time patient-specific parameter 
identification because it also requires non-real-time plasma insulin and C-peptide assays 
(Lotz et al., 2009). Hence, it is suitable for SI screening and research tests. Recent work has 
sought to eliminate this issue in healthy subjects, but at a loss of a small amount of precision 
(Docherty et al., 2009). 
 
Equations (2.6) – (2.8) presents this model: 
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The nomenclature for this model is largely the same as that for the ICU model in Section 
2.1.1. This model has more parameters and more extensive insulin kinetics. The model also 
includes the endogenous glucose production rate EGP (mmol/L/min), as well as the 
endogenous insulin production uen (mU/min). The endogenous insulin production can be 
calculated from C-peptide measurements using well validated insulin –C-peptide kinetics 
model (Van Cauter et al., 1992). Endogenous insulin goes through first pass hepatic 
extraction, where XL is the fraction of extraction. This model also has more explicitly defined 
physiologically specific insulin transport parameters compared to the ICU model, where nK is 
the kidney clearance rate of insulin from plasma [1/min], nL is the liver clearance rate of 
insulin from plasma [1/min], nI is the diffusion constant of insulin between compartments 
(L/min), and nC is the cellular insulin clearance rate from interstitium [1/min]. Finally, it also 
uses different volumes for each compartment, where VP (L) is the plasma and test exchanging 
tissues volume and VQ (L) is the interstitial fluid volume.  
 
In (Lotz et al., 2008, Lotz et al., 2009), measurements from insulin and C-peptide are used to 
identify nL and XL for each person.  SI and VG are then calculated for each person using BG 
measurements. All other parameters are treated as population constants. The insulin 
sensitivity SI identified using this model correlates highly (r > 0.97) to EIC results when both 
tests are modelled together (Lotz et al., 2006, Lotz et al., 2008). Therefore, this model is 
effective as a diagnostic tool for insulin resistance. However because plasma insulin and C-
peptide measurements cannot be obtained in real time, this model cannot be readily adapted 
for TGC for ICU patients. 
 
2.1.3    Intensive Control Insulin-Nutrition-Glucose model (ICING model) 
 
The new and more physiologically comprehensive model ICING, addressing several implicit 
physiological aspects from prior models by (Chase et al., 2007b) and (Lotz et al., 2008) is 
presented in Equations (2.9) – (2.15): 
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Where G(t) [mmol/L] denotes the absolute total blood glucose, I(t) [mU/L] is the plasma 
insulin, and u(t) [mU/min] represents exogenous insulin input. Q(t) [mU/L] is the effect of 
previously infused insulin being utilized over time, with nI [1/min] accounting for the rate of 
transport between plasma and interstitial insulin compartments. Endogenous insulin 
production is model estimated with uen [mU/min] based on clinical data and a validated 
insulin C-peptide kinetics model (Van Cauter et al., 1992), with first pass hepatic insulin 
clearance is represented by xL. Patient endogenous glucose removal and insulin sensitivity are 
denoted pG [1/min] and SI [L/mU/min], respectively. The parameter VI [L] is the insulin 
distribution volume and nK [1/min] and nL [1/min] the clearance rate of insulin from plasma 
via renal and hepatic routes respectively. Basal endogenous glucose production, unsuppressed 
by glucose and insulin concentration, is denoted by EGPb [mmol/min], and VG [L] represents 
the glucose distribution volume. Finally, CNS [mmol/min] represents non-insulin mediated 
glucose uptake by the central nervous system.  
 
Michaelis-Menten functions are used to model effect saturation, with αI [L/mU] used for the 
saturation of plasma insulin disappearance, and αG [L/mU] for the saturation of insulin-
dependent glucose clearance. P1 [mmol] represents the glucose in the stomach and P2 [mmol] 
represents glucose in the gut. The rate of transfer between the stomach and gut is represented 
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by d1 [1/min], and the rate of transfer from the gut to the bloodstream is d2 [1/min]. Amount 
of dextrose from enteral feeding is D(t) [mmol/min]. Pmax represents the maximum disposal 
rate from the gut. Exogenous inputs are glucose appearance P(t) [mmol/min] from enteral 
food intake, flux out of the gut P2 and intravenous insulin u(t). Any additional parenteral 
dextrose is represented by PN(t). Summary of parameter values and descriptions, and 
exogenous input variables for the ICING model are listed in Table 2.1 and 2.2 respectively. A 
schematic of the model is shown in Figure 2.2. 
 
Table 2.1: Parameter values and descriptions for the ICING model 
Parameter Value Unit Description 
pG 0.006 1/min Non-insulin mediated glucose removal 
EGP 1.16 mmol/min Endogenous glucose production rate 
CNS 0.3 mmol/min Central nervous system glucose uptake 
VG 13.3 L Plasma glucose distribution volume 
VI 3.15 L Plasma and interstitial insulin distribution volume 
αG 0.0154 L/mU Insulin binding saturation parameter 
αI 0.0017 L/mU Hepatic insulin clearance saturation parameter 
nI 0.003 1/min Trans-endothelial diffusion rate 
nC 0.003 1/min Interstitial insulin degradation rate 
nK 0.0542 1/min Renal insulin clearance rate 
nL 0.1578 1/min Hepatic insulin clearance rate 
xL 0.67  Fractional first-pass hepatic insulin extraction 
d1 0.0347 1/min Glucose transport rate from stomach to gut 
d2 0.0069 1/min Glucose transport rate from gut to plasma 
Pmax 6.11 mmol/min Maximum glucose flux from gut to plasma 
k1 45.7 mU/min Maximum endogenous insulin secretion rate 
k2 1.5  Insulin secretion suppression factor 1 
k3 1000  Insulin secretion suppression factor 2 
 
Table 2.2: Exogenous input variables for the ICING model 
Variable Unit Description 
PN(t) mmol/min Intravenous glucose input rate (parenteral nutrition) 
D(t) mmol/min Oral glucose input rate (enteral nutrition) 
uex(t) mU/min Intravenous insulin input rate 
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Figure 2.2: Intensive Control Insulin-Nutrition-Glucose (ICING) model overview 
 
 
2.2   The Intensive Control Insulin-Nutrition-Glucose 2 model (ICING-2 model) 
 
The ICING-2 model (Pretty, 2012) is the modified version of the ICING model (Lin et al., 
2011) which proposed the following changes from its original: 
i)  New endogenous insulin secretion model as a function of blood glucose 
concentration. 
ii)  Improved insulin kinetics. 
 
The model is presented in Equations (2.16) – (2.22) and the associated parameter values and 
descriptions are listed in Table 2.3, while Table 2.4 shows the exogenous input variables to 
the model. The model is defined: 
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Table 2.3: Parameter values and descriptions for the ICING-2 model  
Parameter Value Unit Description 
pG 0.006 1/min Non-insulin mediated glucose removal 
EGP 1.16 mmol/min Endogenous glucose production rate 
CNS 0.3 mmol/min Central nervous system glucose uptake 
VG 13.3 L Plasma glucose distribution volume 
VI 4.0 L Plasma and interstitial insulin distribution 
volume 
αG 0.0154 L/mU Insulin binding saturation parameter 
αI 0.0017 L/mU Hepatic insulin clearance saturation 
parameter 
nI 0.006 1/min Trans-endothelial diffusion rate 
nC 0.006 1/min Interstitial insulin degradation rate 
nK 0.0542 1/min Renal insulin clearance rate 
nL 0.1578 1/min Hepatic insulin clearance rate 
xL 0.67  Fractional first-pass hepatic insulin 
extraction 
d1 0.0347 1/min Glucose transport rate from stomach to gut 
d2 0.0069 1/min Glucose transport rate from gut to plasma 
Pmax 6.11 mmol/min Maximum glucose flux from gut to plasma 
umin 16.7 mU/min Minimum pancreatic secretion rate 
umax 266.7 mU/min Maximum pancreatic secretion rate 
k1 ND 14.9 mU.L/mmol.
min 
Pancreatic insulin secretion glucose-
sensitivity T2DM 4.9 
T1DM 0.0 
k2 ND -49.9 mU/min Pancreatic insulin secretion offset 
T2DM -27.4 
T1DM 16.7 
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Table 2.4: Exogenous input variables to the ICING-2 model  
Variable Unit Description 
PN(t) mmol/min Intravenous glucose input rate (parenteral nutrition) 
D(t) mmol/min Oral glucose input rate (enteral nutrition) 
uex(t) mU/min Intravenous insulin input rate 
 
2.3   Overview of Glycaemic System Model 
 
The overview of Glycaemic System Model block diagram is shown in Figure 2.3. In general, 
this block diagram describes the overall glycaemic system model, and how they are related 
between each other. Besides, it also indicates the interaction between system model with 
actuators and patients. The Glycaemic System Model consists of inputs, outputs and control 
system as per explained below: 
  
i)  Inputs 
 
There are two types of inputs which are internal and external. Internal inputs are any 
parameters generated from internal human body system for metabolic activities and will be 
used by the controller or metabolic system model (ICING) such as endogenous glucose 
production [EGP] and endogenous insulin production [Uen]. Unlike internal inputs, external 
inputs are any nutrients uptake by human from outside   for metabolic activities such as 
nutrition [P] and exogenous insulin [Uex]. At the moment, internal inputs are set based on 
population constant, whereas external inputs are determined by the controller. 
 
ii)  Control System 
 
a) Metabolic system model 
 
Model-based insulin sensitivity (SI), generated from the ICING model will be able to describe 
metabolic system behaviour of OHCA patient. Thus, the analysis will provide scientific 
information about patient metabolic level and evolution over time, from cool to warm 
conditions. The understanding of SI evolution is vital for design and implementation 
glycaemic control. In addition to that, model-based SI can be exploited to create its stochastic 
model, which describes the metabolic variability conditions of the patient. Analysis of SI 
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stochastic model is important for improving stochastic control, particularly in reducing 
metabolic and glycaemic variability. 
 
b) Controller 
 
Controller is a major part of the system where the decision is being made to determine how 
much insulin and nutrition should be given to the patients. It will developed based on various 
needs and problems, and use current BG, predicted BG, model-based SI and current inputs to 
calculate the predicted insulin and nutrition. To date, there are various glycaemic controllers 
that are already developed such as SPRINT and STAR controllers. However, none of them 
cater for OHCA patients. Thus, rigorous analysis of OHCA patients conducted (Chapter 4-7) 
in this thesis will be used to develop new OHCA controller which consider the problems 
highlighted. In addition, the new model-based STAR_OHCA controller will be developed 
using single or multiple stochastic model OHCA. 
 
iii)  Output 
 
The outcome of the system after undergo real or model process is called an output. In this 
system, blood glucose and plasma insulin have been chosen as output. However, BG is 
widely used as it become subject of reference whether the glycaemic control is successful or 
not.  
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Fig 2.3:  Overview of Tight Glycaemic Control block diagram 
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2.4   Glycaemic Controller Overview 
 
2.4.1 The SPRINT Controller 
 
Specialized Relative Insulin Nutrition Titration (SPRINT) is a model-derived protocol 
(Lonergan et al., 2006a, Wong et al., 2006b, Chase et al., 2007b, Chase et al., 2008b)  that 
controls both insulin and (carbohydrate) nutrition inputs. It was implemented at the 
Christchurch Hospital Department of Intensive Care on August 2005 (Chase et al., 2008b) 
and has now been used on over 1,000 patients. In SPRINT, the interventions consider current 
and previous blood glucose measurements, current nutrition rate relative to a patient specific 
goal rate, and the prior hourly insulin dose to determine a new nutrition and insulin 
intervention for the coming 1-2 hour measurement interval defined in the protocol (Chase et 
al., 2008b) 
 
The SPRINT protocol consists of two wheels dedicated to insulin bolus administration and 
enteral nutrition optimization, as shown in Figures 2.4 - 2.7. In SPRINT, blood glucose 
measurements are taken 1-2 hourly at bedside based on the protocol. The approach is patient-
specific in nutrition rate and its titration of inputs in response to the patient-specific metabolic 
condition. 
 
More specifically, SPRINT titrates its insulin and nutrition inputs to achieve a target range of 
4-6 mmol/L based on the patient’s current insulin sensitivity, which is effectively determined 
by the response to the insulin and nutrition interventions. More resistant patients receive more 
insulin and less nutrition (relative to their 100% goal feed rate). Stability and stopping criteria 
were also based on patient-specific insulin sensitivity. Hence, the protocol explicitly 
considers glycaemic response in the context of both insulin and carbohydrate intake and is 
thus not blind to carbohydrate intake, which is unique (Chase et al., 2011b). Virtually all 
other studies leave nutritional intake to local clinical standards and are thus blind to this 
critical parameter that directly affects glycaemic levels. 
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Fig 2.4: The SPRINT insulin wheel with dial (Lonergan et al., 2006a) 
 
 
 
 
Fig 2.5: The SPRINT insulin wheel without dial (Lonergan et al., 2006a) 
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Fig 2.6: The SPRINT feed wheel with dial (Lonergan et al., 2006a) 
 
 
 
Fig 2.7: The SPRINT feed wheel without dial (Lonergan et al., 2006a) 
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A low carbohydrate enteral nutrition formula was also specified for all SPRINT patients, 
reducing the percentage of carbohydrate calories as a percentage of the total caloric intake. 
Minimum and maximum nutrition rates are 7.5 and 25 kcal/kg/day respectively, with 2.7 to 9 
kcal/kg/day (35-40%) from carbohydrates, which matches ACCP guidelines at the maximum 
level (Cerra et al., 1997). 
 
Finally, SPRINT uses insulin boluses, limited to 6U per hour to minimize insulin saturation 
(Prigeon et al., 1996, Natali et al., 2000, Chase et al., 2005). Boluses also avoid high rates of 
insulin infusion being left running when clinical staff are occupied, increasing potential 
safety, which is an important aspect in situations where high insulin infusion rates combined 
with infrequent measurement can lead to significantly increased hypoglycaemic events and 
variability resulting from acute changes in patient condition and metabolic response. This 
latter point is critical because, like hyperglycaemia, low BG or hypoglycaemia is also linked 
to increased mortality (Griesdale et al., 2009). 
 
Overall, SPRINT is a unique TGC protocol among all those published. It was the only TGC 
protocol to reduce both mortality and hypoglycaemia, where many attempts fail at both (Van 
den Berghe et al., 2006b, Preiser and Devos, 2007, Brunkhorst et al., 2008, De La Rosa Gdel 
et al., 2008). Its uniqueness stems from its direct management of insulin and nutrition based 
on patient-specific, time varying insulin sensitivity. It thus manage inter- and intra-patient 
variability, and thus glycaemia and hypoglycaemia risk, better than others (Griesdale et al., 
2009). 
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2.4.2 The STAR Controller 
 
The Stochastic TARgeted (STAR) protocol is a unique, model-based TGC protocol (Chase et 
al., 2011b, Evans et al., 2011, Evans et al., 2012, Fisk et al., 2012) for insulin therapy that 
uses clinically validated metabolic and stochastic models (Lin et al., 2006, Lin et al., 2008) to 
optimize treatment in the context of possible future patient variation.  Probabilistic 
forecasting enables more adaptive, optimized patient-specific care with clinically specified 
maximum risk(s) of hyper- and hypoglycaemia.  This protocol implements insulin and 
nutrition interventions based on the current patient-specific insulin sensitivity (SI(t)). Insulin 
sensitivity is identified hourly for each patient using recent BG measurements and a 
computerized metabolic system model. With this value, the predicted blood glucose response 
to a particular intervention can be calculated.  The algorithm for STAR is illustrated in the 
Figure 2.10. 
 
The stochastic forecasting is unique and enables a maximum likelihood approach to targeting 
a desired glycaemic range while enabling the clinical risk of hypo- or hyperglycaemia to be 
directly managed. It also enables patients with very different metabolic (intra- and inter- 
patient) variability to be directly managed and controlled within a single (STAR) model-
based framework. Summary of protocol is shown at the Table 2.6. 
 
The STAR protocol has the ability to specify risk of hypoglycemia below a clinically set 
threshold, and the ability to enable multiple hourly measurements based on clinically set 
glycemic thresholds. Within that framework, clinical or site-specific constraints may be 
added for how control is provided, which is via insulin and nutrition control. This approach 
can provide quality control performance that is tighter across patients and thus more patient-
specific reduced light hypoglycaemia using a clinically specified maximum risk with 
stochastic forecasting of metabolic variation. However, there is no guarantee that all ICU 
patients would have similar metabolic variability (Le Compte et al., 2010, Penning et al., 
2012). 
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Table 2.5: Summary of STAR protocol 
 Target Particular STAR protocol 
i) Blood Glucose Range within 4 – 6.5 mmol/L as specified in 5-95th percentiles 
range. 
ii) Clinical risk of hypo- or 
hyperglycemia 
Maximum 5% risk of BG < 4.0  
iii) Measurement interval a) 1 - 3 hours when BG levels are within 4 – 7.5 mmol/L. 
b) Every hour when BG levels are outside range. 
iv) Control intervention Intervention of insulin and nutrition are based on the current 
patient-specific insulin sensitivity (SI(t)) to maximize the 
likelihood of BG in a clinically specific range and maximum 
acceptable risk of hypoglycaemia. 
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Fig 2.8: The STAR Algorithm (Dickson et al., 2013) 
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2.5    Summary 
 
This chapter discusses the basis and background of the glucose-insulin system models dealing 
to the model used in this thesis, and reviews several other models that have been developed 
and used for glycaemic understanding, control and management. These models have been 
used clinically for various studies for understanding or intervention. The use for 
understanding versus intervention requires differences in model capability and complexity 
that may not translate directly from one use to another. However, not all of these models were 
physiologically complete and some failed to capture inter- and intra- patient variability. The 
ICING-2 model presented in this chapter provides an overall measure of a patient’s insulin 
sensitivity, particularly to exogenous insulin and nutrition inputs that guide and determine the 
metabolic balance in ICU patients. It is also already proven to be suitable for clinical control, 
while accurately accounting for all relevant and observed physiological behaviour.   
 
The overall glycaemic control system model and its key components, including input, output, 
actuators, patient and controller is also introduced to indicate the relation between glucose-
insulin model and glycaemic control system model. The existing controllers such as SPRINT 
and STAR are explained since these controllers will be used during virtual trials.  Control 
performance measures are defined to standardize the criteria assessment of the various 
controllers used in these studies. 
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Chapter 3: Patient Demography 
 
 
 
This chapter presents the OHCA patient data used in this thesis. Patient data is analysed 
statistically to summarize the demography by whole cohort and by hospital. Additionally, the 
cohort is sub-divided and analysed by gender, diabetes status, mortality, and return of 
spontaneous circulation (ROSC).  This data and analysis will be used in Chapter 4 – 7. 
 
3.1   Introduction 
 
A retrospective analysis of glycaemic control data from 180 OHCA patients (7812 hours) 
treated with hypothermia, shortly after admission to the Intensive Care Units (ICUs) of 
Erasme Hospital, Belgium and Lausanne Hospital, Switzerland. All patients were on local 
glycaemic protocols. Therapeutic Hypothermia (TH) was applied following a standardized 
written protocol.  
 
All patients were treated with mild TH to 33 ± 1
o
C for 24 hours, irrespective of age, initial 
arrest rhythm and other physiological conditions. TH was started immediately after admission 
and was induced with ice-cold packs and intravenous ice-cold fluids. Body temperature was 
maintained at hypothermia using a surface cooling device with a computerized adjustment of 
patient temperature target. During this time, some short-acting drugs, such as midazolam 
(0.1mg/kg.hr), fentanyl (1.5µg/kg/hr) and vecuronium (0.1mg/kg boluses), were used to 
administer sedation, analgesia and control shivering. Rewarming was achieved passively, and 
sedation-analgesia was stopped when patient temperature was greater than 35
o
C. 
 
Blood glucose (BG) and temperature readings were taken 1-2 hourly. Data were divided into 
three periods: 1) cool (T<=35
o
C); 2) idle period of 2 hours as hypothermia was removed; and 
3) warm (T>35
o
C). A maximum of 24 and a minimum of 15 hours for the cool and warm 
periods were considered, ensuring a balance of contiguous data across the periods and 
transition. The idle period is not considered in the analysis. 
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3.2   OHCA Patient Demography by Cohort 
 
Overall patient demography provides the cohort information such as level and range of inter-
patient variations, or similarity in the different areas of data, as shown in Table 3.1. 
Additionally, per-hospital demographics as shown in Table 3.2 illustrate the variations 
between units due to differences in clinical practices and patient demography. 
 
Table 3.1:  Demographic data patients those who have met a minimum of 15 hours for both 
the cool and warm after periods.  (All cohort) 
 
Variables 
Value 
Cool Warm 
Total patients, number (n) 180 
Median age, years [IQR] 61 [51, 72] 
Female gender, number (%) 37 (20.6%) 
ICU mortality, number (%) 82 (45.6%) 
Diabetes, number (%) 23 (12.8%) 
ROSC < 15 min, number (%) 63 (35%) 
15 < ROSC < 30 min, number (%) 89 (49.4%) 
ROSC > 30 min, number (%) 28 (15.6%) 
Total treatment, hours (h) 3873 3939 
Blood Glucose, median  (mmol/L) [IQR] 7.6 [6.3, 9.7] 6.8 [5.9, 8.0] 
Insulin Rate, median rate (U/hr) [IQR] 3.0 [1.3, 6.0] 2.5 [1.6, 5.0] 
Glucose Rate, median rate (g/hr) [IQR] 2.7 [1.0, 5.3] 5.4 [2.7, 8.1] 
Per-patient median BG, (mmol/L) [IQR] 7.5 [6.8, 8.6] 6.8 [6. 1, 7.5] 
Per-patient median Insulin Rate, (U/hr) [IQR] 1.8 [1.0, 3.3] 1.6 [0.9, 3.7] 
Per-patient median Glucose Rate, (g/hr) [IQR] 2.5 [0.8, 3.5] 3.2 [1.6, 5.3] 
       Data are presented as median [interquartile range] where appropriate. 
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Table 3.2:  Patients’ demographic data by hospital (Erasme, Lausanne) 
Variables Erasme Hospital Lausanne Hospital 
p-value 
Cool Warm Cool Warm 
Total patients, (n) 122 98  
Median age, years [IQR] 61.5 [50 , 75] 60 [52 , 69]  
Female gender, (%) 18 (18.2%) 19 (23.5%) 0.3 
ICU mortality, (%) 45 (45.5%) 37 (45.7%) 0.5 
Diabetes, (%) 19 (19.2%) 4 (4.9%) < 0.05 
ROSC < 15 min, (%) 45 (45.5%) 18 (22.2%) < 0.05 
15 <ROSC< 30 min, (%) 44 (44.4%) 45 (55.6%) 0.2 
ROSC > 30 min, (%) 10 (10.1%) 18 (22.2%) < 0.05 
Total treatment, hrs (h) 2714 2737 1927 1941  
E
x
te
rn
a
l 
In
p
u
ts
 Insulin 
Insulin rate 
(U/hr) 
Median [IQR] 
2.5     
[1.2,6.4] 
1.7    
[1.0,4.0] 
3.3    
[1.3,8.0] 
3.9    
[1.7,7.8] 
 
Nutrition 
Glucose rate 
(g/hr) Median 
[IQR] 
6.9  
[4.2,9.4] 
5.5 
 [2.8,8.2] 
2.0 
[0.8,4.1] 
5.4 
[2.7,8.1] 
 
G
ly
ca
em
ic
 
O
u
tp
u
ts
 
BG Level 
Blood Glucose 
(mmol/L)      
Median [IQR] 
7.9 
[6.4,10.4] 
6.7    
[5.7,7.9] 
7.1       
[6.3,8.6] 
6.7    
[6.0,7.7] 
 
BG Variability 
Hourly %ΔBG 
Median [IQR] 
-0.6  
[-1.1,-0.2] 
-0.2  
[-0.6,0.3] 
-1.1 
[-1.9,-0.5] 
-0.6  
[-1.4,0.2] 
 
P-values are calculated using Fisher’s Exact Probability Test 2x2. Data are presented as median [interquartile 
range] where appropriate.   
 
In addition to the above, summary of blood glucose (BG) statistics of OHCA patients for the 
whole cohort is also presented in table 3.3, which describe the overall local protocol 
performance implemented at those hospitals. This summary provides a more detail analysis 
of BG in various conditions which gives general idea of the patients’ characteristics per 
cohort that we are dealing with throughout the research studies.  
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Table 3.3:  Summary BG statistics of OHCA patients (All cohort) 
 
Summary of BG Statistics 
OHCA patients  (All cohort) 
Value 
p-value 
Cool Warm 
Whole cohort statistics:    
Total patients, number (n) 180 180  
Total treatment, hours (h) 3873 3939  
Blood Glucose, median  (mmol/L) [IQR]-  7.6 [6.3, 9.7] 6.8 [5.9, 8.0]  
BG Mean (geometric) (mmol/L) 7.7 6.8  
BG Std.Dev (geometric) (mmol/L) 1.5 1.4  
% BG > 10.0 mmol/L  22.0 7.9 < 0.05 
% BG within 8.0 – 10.0 mmol/L  21.5 17.4 0.3 
% BG within 4.4 – 8.0 mmol/L 55.9 73.1 < 0.05 
% BG within 4.4 – 7.0 mmol/L 38.3 53.3 < 0.05 
% BG within 4.4 – 6.5 mmol/L 26.7 40.7 < 0.05 
% BG < 4.4 mmol/L 1.4 2.4 0.8 
% BG < 4.0 mmol/L 0.6 0.8 1.0 
% BG < 2.22 mmol/L 0 0 1.0 
Per-patient statistics with hourly 
resampled data 
 
 
 
Per-patient BG Median [IQR] (mmol/L) 
(resampled) 
7.5 [6.4, 9.2] 
6.7 [5.9 ,7.8] 
 
Per-patient % resampled BG > 10.0 mmol/L 18.4 5.8 < 0.05 
Per-patient % resampled BG within 8.0 - 
10.0 mmol/L 
22.1 
16.0 
0.6 
Per-patient % resampled BG within 4.4 - 8.0 
mmol/L 
59.2 
77.1 
< 0.05 
Per-patient % BG resampled within 4.4 - 7.0 
mmol/L 
39.1 
56.0 
< 0.05 
Per-patient % resampled BG within 4.4 - 6.5 
mmol/L 
26.8 
40.6 
< 0.05 
Per-patient % resampled BG < 4.4 mmol/L 1.1 1.9 0.8 
Per-patient % resampled BG < 4.0 mmol/L 0.4 0.7 1.0 
Per-patient % resampled BG < 2.22 mmol/L 0 0 1.0 
No of patients < 2.22 mmol/L (resampled) 0 0 1.0 
P-values are calculated using Fisher’s Exact Probability Test 2x2. Data are presented as median 
[interquartile range] where appropriate. 
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3.3   OHCA Patient Demography and Mortality 
 
Table 3.4 presents OHCA patient demography by mortality comparing survivors and non-
survivors data based on gender, diagnosed diabetes status and ROSC  
 
Table 3.4:  Demographic data patients based on mortality 
Variables  Survivors Non-Survivors 
p-values 
Cool Warm Cool Warm 
Total patients, (n) 
 
98 82  
Median age, years [IQR] 
 
61 [51, 72] 61 [50.5, 72]  
Female gender, (%) 
 
17 (17.3%) 20 (24.4%) 0.2 
Diabetes, (%) 
 
13 (13.3%) 10 (12.2%) 0.6 
ROSC < 15 min, (%) 
 
47 (48.0%) 16 (19.5%) < 0.05 
15 < ROSC< 30 min, (%) 
 
40 (40.8%) 49 (59.8%) < 0.05 
ROSC > 30 min, (%) 
 
11 (11.2%) 17 (20.7%) 0.1 
Total treatment, hours (h) 2123 2214 1750 1725  
Blood Glucose, median  
(mmol/L) [IQR] 
7.5  
[6.4, 9.4] 
6.7  
[5.8, 7.8] 
7.7  
[6.3, 10.2]  
7.0  
[6.0, 8.3] 
 
BG Mean (geometric) 
(mmol/L) 
7.6 6.7 7.8 6.9  
BG Std.Dev (geometric) 
(mmol/L) 
1.2 1.2 1.3 1.2  
% BG > 10.0 mmol/L  19.0 4.9 25.7 11.7  
% BG within 8.0 – 10.0 
mmol/L  
22.4 16.2 20.5 19.0  
% BG within 4.4 – 8.0 
mmol/L 
59.2 77.5 51.9 67.4  
% BG within 4.4 – 7.0 
mmol/L 
40.6 57.5 35.4 47.8  
% BG within 4.4 – 6.5 
mmol/L 
27.3 44.0 26.0 36.4  
% BG < 4.4 mmol/L 0.5 2.1 2.6 2.9  
% BG < 4.0 mmol/L 0.1 0.6 1.1 1.0  
% BG < 2.22 mmol/L 0 0 0 0  
Per-patient statistics with 
hourly resampled data 
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Per-patient BG Median 
[IQR] (mmol/L) 
(resampled) 
7.4       
[6.4 – 8.9] 
6.7       
[5.8 – 7.7] 
7.5       
[6.3 – 9.6] 
6.8       
[6.0 – 8.1] 
 
Per-patient % resampled 
BG > 10.0 mmol/L 
15.6 3.5 21.8 8.9  
Per-patient % resampled 
BG within 8.0 - 10.0 
mmol/L 
22.7 14.3 21.4 18.0  
Per-patient % resampled 
BG within 4.4 - 8.0 
mmol/L 
62.1 81.4 55.6 71.5  
Per-patient % BG 
resampled within 4.4 - 7.0 
mmol/L 
40.4 59.1 37.6 51.8  
Per-patient % resampled 
BG within 4.4 - 6.5 
mmol/L 
26.6 42.4 26.9 38.3  
Per-patient % resampled 
BG < 4.4 mmol/L 
0.4 1.3 1.9 2.5  
Per-patient % resampled 
BG < 4.0 mmol/L 
0.1 0.4 0.8 1.1  
Per-patient % resampled 
BG < 2.22 mmol/L 
0.0 0.0 0.0 0.0  
No of patients < 2.22 
mmol/L (resampled) 
0 0 0 0  
P-values are calculated using Fisher’s Exact Probability Test 2x2. Data are presented as median [interquartile 
range] where appropriate. 
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3.4   OHCA Patient Demography by Diagnosed Diabetes Status 
 
The OHCA patient demography by diabetes (Table 3.5) compares the retrospective data 
between diabetes and non-diabetes patients based on gender, mortality and ROSC, and 
provides a more detail BG analysis which define patients’ characteristics by these cohorts. 
 
Table 3.5:  Demographic data patients based on diagnosed diabetes status 
Variables  Diabetes Non-Diabetes 
p-value 
Cool Warm Cool Warm 
Total patients, (n) 
 
23 157  
Median age, years [IQR] 
 
61 [51, 73] 61 [51, 72]  
Female gender, (%) 
 
3 (13.0%) 34 (21.7%) 0.4 
ICU mortality, (%) 
 
10 (43.5%) 72 (45.9%) 0.5 
ROSC < 15 min, (%) 
 
13 (56.5%) 50 (31.8%) < 0.05 
15< ROSC < 30 min, (%) 
 
9 (39.1%) 80 (51.0%) 0.4 
ROSC > 30 min, (%) 
 
1 (4.3%) 27 (17.2%) 0.1 
Total treatment, (h) 508 513 3365 3426  
Blood Glucose, median  
(mmol/L) [IQR] 
8.5 
[6.9, 10.9] 
7.8 
[6.2, 9.0] 
7.4 
[6.3, 9.5] 
6.7 
[5.8, 7.8] 
 
BG Mean (geometric) 
(mmol/L) 
8.3 7.6 7.6 6.7  
BG Std.Dev (geometric) 
(mmol/L) 
1.1 1.1 1.5 1.4  
% BG > 10.0 mmol/L  30.1 19.6 20.6 5.6  
% BG within 8.0 – 10.0 
mmol/L  
26.6 22.8 20.6 16.4  
% BG within 4.4 – 8.0 
mmol/L 
43.1 57.8 58.2 76.1  
% BG within 4.4 – 7.0 
mmol/L 
25.4 36.0 40.6 56.6  
% BG within 4.4 – 6.5 
mmol/L 
18.9 28.8 28.1 43.0  
% BG < 4.4 mmol/L 1.2 0.5 1.5 2.8  
% BG < 4.0 mmol/L 0.5 0.3 0.6 0.9  
% BG < 2.22 mmol/L 0 0 0 0  
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Per-patient statistics with 
hourly resampled data 
     
Per-patient BG Median 
[IQR] (mmol/L) 
(resampled) 
8.3        
[6.9 –10.7] 
7.7         
[6.2-9.0] 
7.4   
[6.3-9.0] 
6.7   
[5.9-7.6] 
 
Per-patient % resampled BG 
> 10.0 mmol/L 
28.9 18.5 16.8 3.9  
Per-patient % resampled BG 
within 8.0 - 10.0 mmol/L 
25.3 22.8 21.7 14.9  
Per-patient % resampled BG 
within 4.4 - 8.0 mmol/L 
45.7 59.0 61.2 79.8  
Per-patient % BG resampled 
within 4.4 - 7.0 mmol/L 
27.4 39.0 40.9 58.4  
Per-patient % resampled BG 
within 4.4 - 6.5 mmol/L 
20.2 30.6 27.7 42.1  
Per-patient % resampled BG 
< 4.4 mmol/L 
0.9 0.6 1.1 2.0  
Per-patient % resampled BG 
< 4.0 mmol/L 
0.4 0.2 0.4 0.7  
Per-patient % resampled BG 
< 2.22 mmol/L 
0.0 0.0 0.0 0.0  
No of patients < 2.22 
mmol/L (resampled) 
0 0 0 0  
P-values are calculated using Fisher’s Exact Probability Test 2x2. Data are presented as median [interquartile 
range] where appropriate. 
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3.5   OHCA Patient Demography by Gender 
 
The OHCA patient demography by gender (Table 3.6) compares the retrospective data 
between male and female patients based on diabetes, mortality and ROSC, and provides a 
more detail BG analysis which define patients’ characteristics by these cohorts. 
 
Table 3.6:  Demographic data patients based on gender 
Variables  Male Female 
p-value 
Cool Warm Cool Warm 
Total patients, (n) 143 37  
Median age, years [IQR] 61 [51, 72] 61 [51, 73]  
Diabetes, (%) 20 (14.0%) 3 (8.1%) 0.4 
ICU mortality, (%) 62 (43.3%) 19 (51.3%) 0.5 
ROSC < 15 min, (%) 53 (37.0%) 9 (24.3%) 0.2 
15 < ROSC < 30 min, (%) 71 (49.7%) 15 (40.5%) 0.3 
ROSC > 30 min, (%) 13 (9.1%) 6 (16.2%) 0.2 
Total treatment,  (h) 3094 3129 779 810  
Blood Glucose, median  
(mmol/L) [IQR] 
7.6 
[6.4, 9.6] 
6.7 
[5.9, 8.0] 
7.4 
[6.2, 10.1] 
6.8 
[5.8, 7.9] 
 
BG Mean (geometric) 
(mmol/L) 
7.7 6.8 7.7 6.7  
BG Std.Dev (geometric) 
(mmol/L) 
1.5 1.4 1.2 1.2  
% BG > 10.0 mmol/L  21.3 8.0 25.3 7.2  
% BG within 8.0 – 10.0 
mmol/L  
22.8 17.7 16.2 16.3  
% BG within 4.4 – 8.0 
mmol/L 
55.5 73.0 57.8 73.4  
% BG within 4.4 – 7.0 
mmol/L 
37.3 53.6 42.4 52.1  
% BG within 4.4 – 6.5 
mmol/L 
25.7 41.0 31.2 39.1  
% BG < 4.4 mmol/L 1.4 2.2 1.7 3.5  
% BG < 4.0 mmol/L 0.6 0.7 0.4 0.9  
% BG < 2.22 mmol/L 0 0 0 0  
Per-patient statistics with 
hourly resampled data 
     
Per-patient BG Median 
[IQR] (mmol/L) 
(resampled) 
7.5       
[6.4 – 9.1] 
6.7       
[5.9 – 7.8] 
7.5         
[6.4 – 9.6] 
6.8       
[5.9 – 7.7] 
 
Per-patient % resampled 
BG > 10.0 mmol/L 
17.5 6.0 21.9 5.3  
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Per-patient % resampled 
BG within 8.0 - 10.0 
mmol/L 
23.1 16.3 18.5 14,4  
Per-patient % resampled 
BG within 4.4 - 8.0 
mmol/L 
59.1 76.7 59.4 78.6  
Per-patient % BG 
resampled within 4.4 - 7.0 
mmol/L 
39.1 56.1 39.1 55.2  
Per-patient % resampled 
BG within 4.4 - 6.5 
mmol/L 
26.5 41.2 27.9 38.4  
Per-patient % resampled 
BG < 4.4 mmol/L 
1.1 1.8 1.1 2.1  
Per-patient % resampled 
BG < 4.0 mmol/L 
0.4 0.7 0.3 0.5  
Per-patient % resampled 
BG < 2.22 mmol/L 
0.0 0.0 0.0 0.0  
No of patients < 2.22 
mmol/L (resampled) 
0 0 0 0  
P-values are calculated using Fisher’s Exact Probability Test 2x2. Data are presented as median [interquartile 
range] where appropriate. 
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3.6   OHCA Patient Demography by ROSC 
 
The OHCA patient demography by ROSC (Table 3.7) compares the retrospective data 
between ROSC<15 min, ROSC<30 min and ROSC>30 min patients based on gender, 
diabetes and mortality, and provides a more detail BG analysis which define patients’ 
characteristics by these cohort categories. 
 
Table 3.7:  Demographic data patients based on return of spontaneous circulation (ROSC) 
Variables  ROSC < 15 min 15 < ROSC < 30 
min 
ROSC > 30 min p-
values 
Cool Warm Cool Warm Cool Warm 
Total patients (n) 63 89 28  
Median age [IQR] 61 [51, 73] 61 [51, 72] 61 [51, 72]  
Gender, female (%) 10 (15.9%) 18 (20.2%) 9 (32.1%) 0.2 
Diabetes, (%) 13 (20.6%) 9 (10.1%) 1 (3.6%) < 0.05 
Mortality, (%) 16 (25.4%) 49 (55.1%) 17 (60.7%) < 0.05 
Total hours (h) 
1407 1404 1872 1925 594 610  
BG median  (mmol/L) 
[IQR] 
7.8 
[6.4, 9.6] 
6.8 
[5.8, 8.0] 
7.4 
[6.3, 9.7] 
6.7 
[6.0, 8.1] 
7.4 
[6.4,10.3] 
6.7 
[5.7, 7.8] 
 
BG Mean (geometric) 
(mmol/L) 
7.8 6.9 7.7 6.7 7.6 6.7  
BG Std.Dev 
(geometric) (mmol/L) 
1.4 1.2 1.5 1.4 1.2 1.2  
% BG > 10.0 mmol/L  
20.0 8.0 22.5 8.3 26.4 6.0  
% BG within 8.0 – 
10.0 mmol/L  
26.2 18.0 19.3 17.9 15.7 14.2  
% BG within 4.4 – 8.0 
mmol/L 
53.7 72.4 57.4 72.7 57.3 77.0  
% BG within 4.4 – 7.0 
mmol/L 
36.8 51.2 38.8 54.3 40.6 56.6  
% BG within 4.4 – 6.5 
mmol/L 
26.7 40.3 27.2 40.2 25.4 43.7  
% BG < 4.4 mmol/L 
0.6 2.9 2.1 1.8 1.3 3.5  
% BG < 4.0 mmol/L 
0.3 0.9 0.8 0.5 0.8 1.3  
% BG < 2.22 mmol/L 
0 0 0 0 0 0  
Per-patient statistics 
with hourly 
resampled data 
       
Per-patient BG Median 
[IQR] (mmol/L) 
(resampled) 
7.6       
[6.4 – 9.1] 
6.9        
[5.9 – 8.0] 
7.4        
[6.4 – 9.2] 
6.7        
[5.9 – 7.8] 
7.3        
[6.5 – 9.2] 
6.7       
[6.0 – 7.6] 
 
Per-patient % 
resampled BG > 10.0 
mmol/L 
17.1 6.8 18.8 5.9 20.3 3.6  
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Per-patient % 
resampled BG within 
8.0 - 10.0 mmol/L 
25.0 18.3 21.2 15.2 18.2 13.0  
Per-patient % 
resampled BG within 
4.4 - 8.0 mmol/L 
57.7 73.2 59.6 78.3 61.4 81.8  
Per-patient % BG 
resampled within 4.4 - 
7.0 mmol/L 
38.6 50.0 38.7 59.5 41.8 58.0  
Per-patient % 
resampled BG within 
4.4 - 6.5 mmol/L 
27.1 37.8 26.9 42.8 25.6 40.1  
Per-patient % 
resampled BG < 4.4 
mmol/L 
0.6 2.7 1.5 1.2 0.8 1.9  
Per-patient % 
resampled BG < 4.0 
mmol/L 
0.2 1.1 0.5 0.4 0.5 0.6  
Per-patient % 
resampled BG < 2.22 
mmol/L 
0.0 0.0 0.0 0.0 0.0 0.0  
No of patients < 2.22 
mmol/L (resampled) 
0 0 0 0 0 0  
P-values are calculated using Fisher’s Exact Probability Test 2x3. Data are presented as median [interquartile 
range] where appropriate. 
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3.7   Discussion 
 
The overall patient demography presented in this chapter summarize the cohort information 
statistically based on retrospective data (Table 3.1). In general, majority of the patients in this 
cohort are male (79.4%), non-diabetic (87.2%) and ROSC below 30 minutes (84.4%). In 
terms of mortality, the percentage are not much significant between survive (54.4%) and non-
survive (45.6%) patients. The overall summary of BG statistics (Table 3.1), summary by 
hospital (Table 3.2) and summary of BG statistics (Table 3.3) show that BG level is lower 
from cool to warm, where the percentage of BG within 4.4 – 8.0 mmol/L is increased from 
56% to 73% , which observe the improvement made by local glycaemic protocol at the 
respective hospitals. Conversely, the percentage of BG below 4.4 mmol/L is also increased 
from 1.4% to 2.4% which indicate a major setback to the therapies conducted on this cohort 
even though the number of patients whose BG < 2.22 mmol/L is zero.   
 
Apart from overall cohort demography, this chapter is also analysed the cohort background in 
more details based on the following categories; 
 
i) Mortality 
 
The purpose of analysing the cohort by mortality is to describe the patient demography and 
its glycaemic characteristics based on survive and non-survive and to observe any parameters 
and variables that might be significant between these two treatment outcomes. According to 
the table 3.4, it is obvious that variables such as gender and diabetes are similar between 
survive and non-survive. Percentage of BG in the analysis are similar and doesn’t show any 
significant difference, even though the improvement shown by survived patients from cool to 
warm are much better than the non-survived patients. However, the ROSC shows some 
uniqueness in the results where the number of survived patients is higher (48%) compare to 
non-survive (19.5%) for ROSC lower than15 minutes. In contrast, the number of survived 
patients is lower (52%) compared to non-survive (80.5%) for ROSC greater than 15 minutes.   
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ii) Diabetes 
 
Besides mortality, the cohort is analysed by diabetes which is aimed to describe the patient 
demography and its glycaemic characteristics based on healthy metabolic conditions and 
unhealthy metabolic conditions, and to observe any parameters and variables that might be 
significant to differentiate between these two physiological conditions. According to the table 
3.5, it is obvious that variables such as gender, mortality and ROSCs are similar between 
diabetes and non-diabetes patients. However, the majority of percentages of BGs in the 
analysis are higher for diabetic patients despite improvement shown from cool to warm 
periods. Thus, none of these variables or parameters give significant results, suggesting that 
analysing or even developing control based on diabetes will not provide any significant 
impact on the treatment positive outcome. However, further research and analysis is required 
such as insulin sensitivity before making such conclusion 
  
iii) Gender (Sex) 
 
 The patient demography is also being analysed by gender or sex based on male and female 
which is aimed to determine its glycaemic characteristics, and to observe any parameters and 
variables that might be significant to differentiate between these two physiological 
conditions. According to the table 3.6, it is obvious that variables such as diabetes, mortality 
and ROSCs are similar between male and female patients. In addition, percentages of BG in 
the analysis are similar and don’t show any significant difference. Thus, none of these 
variables or parameters gives significant results, suggesting that analysing or even developing 
control based on gender will not provide any significant impact on the treatment positive 
outcome. However, further research and analysis is required such as insulin sensitivity before 
making such conclusion. 
 
iv)      Return of Spontaneous Circulation (ROSC) 
 
 Finally, the patient demography is being analysed by the return of spontaneous circulation 
(ROSC) which is aimed to determine its glycaemic characteristics and to observe any 
parameters and variables that might be significant to differentiate between these 
physiological conditions. According to the table 3.7, it is obvious that variables such as 
gender and diabetes are not much different between ROSCs. Percentages of BG in the 
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analysis are also similar and match with the improvement shown from cool to warm periods. 
However, it is evidence that the analysis based on mortality shows some uniqueness in the 
results where the number of non-survived patients is lower (25.4%) for ROSC lower than 15 
minutes, compared to ROSC higher than 15 minutes but lower than 30 minutes (55.1%) as 
well as ROSC greater than 30 minutes (60.7%).   
 
3.8   Summary 
 
The results presented in these analyses indicate that all patients in this cohort had appropriate 
local protocol treatment at the respective hospitals and had shown some various physiological 
response individually which have resulted in the decreased of BG percentage above 8.0 
mmol/L, the increased of BG percentage within 4.4 – 8.0 mmol/L and the increased in BG 
percentage below 4.4 mmol/L from cool to warm periods. While these trends for BG 
percentage above 8.0 mmol/L and BG percentage within 4.4 – 8.0 mmol/L looks improving, 
the increased of BG percentage below 4.4 mmol/L shows poor treatment conducted which 
shows that the glycaemic outcome for this cohort is vulnerable. 
 
The analyses of cohort demography based on mortality, diabetes, sex and ROSC has revealed 
that the ROSC is most likely the variable or parameter that might be significant to 
differentiate between these mortality outcomes for OHCA patient, treated with hypothermia. 
However, further research and analysis is required such as insulin sensitivity and stochastic 
modelling before suggesting this parameter for control development.    
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Chapter 4: Insulin Sensitivity Level and Variability Analysis                                                                                                                       
 
 
 
This chapter describes a preliminary study of Out-of-Hospital Cardiac Arrest (OHCA) 
patients based on metabolic characteristics during hypothermia (cool period) and 
normothemia (warm period). It analyses the impact of therapeutic hypothermia (TH) on 
metabolism, including the evolution of insulin sensitivity (SI) and its variability. Patient data 
are analysed based for cohort and sub-cohort groups as defined in Chapter 3. 
  
4.1   Introduction 
 
Hypothermia is often used to treat OHCA patients (Andres, 2011, Brown and Bourdeaux, 
2011, Karanjia and Geocadin, 2011, Kirkham, 2011, Kory et al., 2011, Stub et al., 2011, 
Graffagnino et al., 2012, Ornato et al., 2012, Reynolds and Lawner, 2012, Bucher et al., 
2013, Dietrich et al., 2013, Scirica, 2013, Mangla et al., 2014, Mearns, 2014, Picchi et al., 
2014, Polderman et al., 2014). In general, it leads to a lowering of metabolic rate that induces 
changes in energy metabolism. However, its impact on metabolism and insulin resistance in 
critical illness is unknown, although one of the adverse events associated with hypothermic 
therapy is a decrease in insulin sensitivity and insulin secretion (Hayashi, 2009).  However, 
this decrease may not be notable in the cohort that is already highly resistant and variable 
(Pretty et al., 2012). Hence, understanding metabolic evolution and variability would enable 
safer and more accurate glycaemic control. 
 
This study analyses the evolution of a clinically validated model-based insulin sensitivity (SI) 
metric (Chase et al., 2010, McAuley et al., 2011) in OHCA patients to assess the impact of 
hypothermia. The analysis is performed at both a cohort and patient-specific level to better 
understand patient condition and physiology. The results should provide new insight to 
enable safer metabolic management. 
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4.2   Subjects and Methods 
 
4.2.1 Patients and Data  
 
This analysis was performed on a cohort of 180 OHCA patients (7812 hours) treated with 
hypothermia, shortly after admission in Intensive Care Units (ICUs) of Erasme Hospital, 
Belgium and Lausanne Hospital, Switzerland. These patients were on local AGC protocols. 
Data collections were carried out as per described in sub-chapter 3.1. Additional information 
for each patient such as mortality, diabetes history, gender and return of spontaneous 
circulation (ROSC) were recorded. These inputs will be taken into consideration for separate 
sub-analysis studies from full cohort. Details of the cohort demography, including sub-
cohorts are presented in Table 3.1.   
 
4.2.2 Analyses and Metrics  
 
SI level during the cool (T<35
o
C) and warm (T>37
o
C) periods were identified hourly using 
the ICING model (Lin et al., 2011) for each patient. SI Variability was calculated as the hour-
to-hour percentage change in SI or %ΔSI, defined:  
   
%∆𝑆𝐼 =  
( 𝑆𝐼𝑛+1 −  𝑆𝐼𝑛)
𝑆𝐼𝑛
 𝑥 100 
 
(4.1) 
 
The use of percentage change, rather than absolute change, normalises the metric so patients 
with differing SI levels can be compared fairly.  
 
SI  level  and  variability  were  analysed  during both cool and warm periods on  overall  
cohort  and  per-patient  bases as follows: 
i)  Overall cohort patient. 
ii)  Analysis of patient by 12-hour block. 
iii)  Analysis of patient by 6-hour block.  
  
Cohort analysis assessed every hour of SI level and variability for the entire cohort, and 
shows trend based on the overall group behaviour. In contrast, per-patient analysis examined 
the SI level by median values within each timeframe. To quantify per-patient variability, the 
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interquartile range (IQR: 25
th
 -75
th
 percentile) of %ΔSI is calculated. This metric captures the 
width of the hour-to-hour variability distributions for each patient.  
 
Table 4.1: Descriptions of 12-hour and 6-hour blocks for data analysis   
Day 
12-hour blocks 6-hour blocks 
Block Hours Range Period Block Hours Range Period 
1 
1 0 – 12 hours Cool 
1 0 – 6 hours Cool 
2 6 – 12 hours Cool 
2 12 – 24 hours Cool 
3 12 – 18 hours Cool 
4 18 – 24 hours Cool 
2 
3 24 – 36 hours Warm 
5 24 – 30 hours Warm 
6 30 – 36 hours Warm 
4 36 – 48 hours Warm 
7 36 – 42 hours Warm 
8 42 – 48 hours Warm 
 
 
The SI analysis of patients’ uses 12-hour and 6-hour blocks is described in Table 4.1. It is 
aimed to capture SI evolution over time with different resolution. For the cohort analysis, SI 
and ∆%SI data from all patients was grouped into each appropriate time-block. Median values 
for each time-block were calculated for comparison to the previous block, thus capturing 
overall cohort changes over time in level and hour-to-hour variability. For the per-patient 
analysis, the median value of SI and the interquartile range (IQR) of ∆%SI were calculated for 
each patient, for each time-block. The IQR captures the width of degree of variability for a 
given patient within each hour block. Thus, a reduction in the IQR of ∆%SI over time would 
indicate a reduction in hour-to-hour variability for a given patient. 
 
SI level and variability are non-Gaussian and thus were compared using non-parametric 
cumulative distribution functions (CDFs). All distributed data were compared using a 
Wilcoxon rank-sum test (Mann-Whitney U-test), except for SI variability results. SI 
variability was compared using the Kolmogorov-Smirnov (KS) test as it has greater power to 
detect differences in the shape of distributions when median values are similar. In all cases, p 
< 0.05 is considered statistically significant.  
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4.3   Results 
 
4.3.1 Results by Overall Cohort 
 
4.3.1.1   SI Level Analysis 
 
Figure 4.1 presents the cumulative distribution functions (CDFs) of hourly SI level and its 
variability for both cool and warm after periods by cohort (left panel) and median hourly SI 
per-patient (right panel) for all cohort patients. Table 4.2 summarizes SI level results and 
analysis for overall OHCA cohort.  
 
Per-Cohort Analysis 
 
Per-Patient Analysis 
 
  
Fig. 4.1:  Insulin sensitivity level and variability distribution by cohort (left) and per-patient median 
(right) during cool and warm after periods for all ICU patients 
 
Table 4.2:  Summary of SI results for overall OHCA cohort.   
 
 
Day 
 
Period Hours Range 
Per-Cohort 
Median SI [IQR]  
[L/mU/min] 
Per-Patient 
Median SI [IQR] 
[L/mU/min] 
1 Cool 
 
0 – 24 hours 2.4 x10-4  [1.1, 4.4] x 10-4 2.4 x10-4  [1.1, 3.5] x 10-4 
2 Warm 
 
24 – 48 hours 5.4 x10-4  [2.8, 9.7] x 10-4 5.2 x10-4  [2.8, 8.3] x 10-4 
 
 
 
p-value p < 0.05 p < 0.05 
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F
(x
)
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-5 -4 -3 -2 -1 0 1 2 3 4 5
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-3
0
0.1
0.2
0.3
0.4
0.5
0.6
0.7
0.8
0.9
1
Insulin Sensitivity (SI)
Per-Patient SI Level Analysis
 
 
Cool
Warm
Cool-Warm
P < 0.05 
P < 0.05 
80% of all OHCA 
patients had higher 
SI during warm  
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The results show that insulin sensitivity levels are initially low during the cool period and 
significantly increase (p<0.05) over time for the first 2 days of ICU stay, with consistent 
trends between per-cohort and per-patient median values. However, there are around 20% (36 
patients) of all patients that have contrasting results, where SI level is higher during the cool 
period, counter to the overall trend. 
 
Figure 4.2 presents the 12-hour block SI level by cohort (left panel) and median SI per-patient 
(right panel). Table 4.3 presents the summary of SI results based on 12-hour block and Table 
4.4 presents the increase in median SI between successive blocks.   
 
 Per-Cohort  
 
Per-Patient 
 
Fig. 4.2:  SI level distribution per-cohort (left) and per-patient median (right) for OHCA patients, treated with 
hypothermia using 12 hour blocks of data. Blue colour represent cool period and red colour represent warm 
period. 
 
Table 4.3:  Summary of SI results for OHCA cohort based on 12-hours block.   
 
 
Day Block Hours Range 
Per-Cohort 
Median SI [IQR]  
[L/mU/min] 
Per-Patient 
Median SI [IQR] 
[L/mU/min] 
1 1 
0 – 12 hours 
2.0 x10
-4   
[1.0, 3.6] x 10
-4
 
1.9 x10
-4   
[1.0, 3.0] x 10
-4
 
2 
12 – 24 hours 
3.0 x10
-4   
[1.3, 5.1] x 10
-4
 
2.7 x10
-4   
[1.2, 4.5] x 10
-4
 
2 3 
24 – 36 hours 
5.3 x10
-4   
[2.6, 9.8] x 10
-4
 
4.8 x10
-4   
[2.5, 8.3] x 10
-4
 
4 
36 – 48 hours 
5.6 x10
-4   
[3.0, 9.5] x 10
-4
 
5.2 x10
-4   
[3.0, 8.5] x 10
-4
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Table 4.4:   Increasing cohort and per patient median SI during cool and warm (12-hour 
blocks of data) 
 
SI Level 
analysis 
Cohort analysis Per-patient analysis 
 [12-hr blocks] 
% Increase at 
median 
p-value 
% Increase at 
median 
p-value 
Block 1-2 (C)            
  (0 - 12 vs. 12 - 24 hr) 
50.0 <0.05 42.1 <0.05 
Block 2-3 (C-W)    
  (12 - 24 vs. 24 - 36 hr) 
76.7 <0.05 77.8 <0.05 
Block 3-4 (W)        
(24 - 36 vs. 36 - 48 hr) 
5.7 0.1 8.3 0.4 
 P-values calculated using Wilcoxon rank-sum test   
  
The results suggest that SI increases for the cohort and per-patient are statistically significant 
for the first 36 hours (p<0.05) in both cases. Similarly, the percentage increase at median is 
also very high within these period. However, the percentage of SI increase is smaller after the 
subsequent hours.   
 
Figure 4.3 presents the 6-hour block SI level by cohort (left panel) and median SI per-patient 
(right panel). Table 4.5 presents the summary of SI results based on 6-hour block and Table 
4.6 presents the increase in median SI between successive blocks.   
 
Per-Cohort  
 
Per-Patient 
 
Fig. 4.3:  SI level distribution per-cohort (left) and per-patient median (right) for OHCA patients, treated with 
hypothermia using 6 hour blocks of data.   
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Table 4.5:  Summary of SI results for overall OHCA cohort based on 6-hour block.   
 
 
Day Block Hours Range 
Per-Cohort 
Median SI [IQR]  
[L/mU/min] 
Per-Patient 
Median SI [IQR] 
[L/mU/min] 
1 
1 0 – 6 hours 
1.8 x10
-4   
[0.9, 3.3] x 10
-4
 
1.5 x10
-4   
[0.6, 2.6] x 10
-4
 
2 6 – 12 hours 
2.3 x10
-4   
[1.0, 4.0] x 10
-4
 
1.9 x10
-4   
[0.9, 3.2] x 10
-4
 
3 12 – 18 hours 
2.6 x10
-4   
[1.2, 4.5] x 10
-4
 
2.1 x10
-4   
[1.0, 4.0] x 10
-4
 
4 18 – 24 hours 
3.4 x10
-4   
[1.4, 5.9] x 10
-4
 
3.0 x10
-4   
[1.2, 5.1] x 10
-4
 
2 
5 24 – 30 hours 
5.3 x10
-4   
[2.7, 9.8] x 10
-4
 
4.5 x10
-4   
[2.2, 8.3] x 10
-4
 
6 30 – 36 hours 
5.2 x10
-4   
[2.3, 9.7] x 10
-4
 
4.4 x10
-4   
[1.7, 8.7] x 10
-4
 
7 36 – 42 hours 
5.4 x10
-4   
[2.9, 9.3] x 10
-4
 
4.8 x10
-4   
[2.6, 7.7] x 10
-4
 
8 42 – 48 hours 
5.6 x10
-4   
[3.0, 9.6] x 10
-4
 
5.0 x10
-4   
[2.7, 8.5] x 10
-4
 
 
 
Table 4.6:   Increasing cohort and per patient median SI during cool and warm as per 6-hour 
blocks of data 
 
SI Level 
analysis 
Cohort analysis Per-patient analysis 
 [6-hr blocks] 
% Increase at 
median 
p-value 
% Increase at 
median 
p-value 
Block 1-2 (C)            
  (0 - 6 vs. 6 - 12 hr) 
27.8 < 0.05 30.4 < 0.05 
Block 2-3 (C)            
  (6 - 12 vs. 12 - 18 hr) 
13.0 < 0.05 8.8 < 0.05 
Block 3-4 (C)            
  (12 - 18 vs. 18 - 24 hr) 
30.8 < 0.05 42.6 < 0.05 
Block 4-5 (C-W)    
  (18 - 24 vs. 24 - 30 hr) 
55.9 < 0.05 52.1 < 0.05 
Block 5-6 (W)    
  (24 - 30 vs. 30 - 36 hr) 
-1.9 0.2 -2.2 0.6 
Block 6-7 (W)    
  (30 - 36 vs. 36 - 42 hr) 
3.8 0.2 9.3 0.3 
Block 7-8 (W)    
  (36 - 42 vs. 42 - 48 hr) 
3.7 0.3 5.3 0.6 
 P-values calculated using Wilcoxon rank-sum test   
 
The results suggest that SI levels are initially low during the cool period and increase over 
time for the first 36-42 hours of ICU stay, matching the 12-hour block analyses. It is evident 
that the increase in SI between each time block is significantly larger (p < 0.05) for the first 
36 hours of treatment than after 36 hours which are not significantly different. 
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4.3.1.2   SI Variability Analysis 
  
Figure 4.4 presents the cumulative distribution functions (CDFs) of hourly SI level and its 
variability for both cool and warm after periods by cohort (left panel) and median hourly SI 
per-patient (right panel) for all cohort patients. Table 4.7 presents summary of SI variability 
results for overall OHCA cohort.    
 
Per-Cohort Analysis 
 
Per-Patient Analysis 
 
 
 
Fig. 4.4:  Insulin sensitivity level and variability distribution by cohort (left) and per-patient median 
(right) during cool and warm after periods for all ICU patients 
 
Table 4.7:  Summary of SI variability results for overall OHCA cohort.   
 
 
Day 
 
Period Hours Range 
Per-Cohort 
Median DeltaSI  
[IQR] [%] 
Per-Patient 
Median DeltaSI 
[IQR] [%] 
1 Cool 
 
0 – 24 hours 1.1 [-1.8, 4.4] 2.3 [-0.8, 8.9] 
2 Warm 
 
24 – 48 hours 0.2 [-2.2, 2.2] 0.4 [-2.5, 3.4] 
 
 
 
p-value 0.3 0.08 
 
The results in show that SI is more variable during cool than warm and significantly decrease 
(p<0.05) over time for the first 2 days of ICU stay. However, there are around 40% (72 
patients) of all patients that have contrasting results, where SI variability is higher during the 
warm period, in contrast to the overall trend. The results also show that 60% of %ΔSI are 
positive bias both cool and warm periods, indicating more rising SI as seen in Figure 4.4. 
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Figure 4.5 presents 12-hourly blocks of %∆SI (left panel) and 50% range of SI variability per-
patient (right panel). Table 4.8 presents the summary of SI variability results based on 12-
hour block and Table 4.9 presents the reductions between successive blocks.   
 
Per-Cohort  
 
Per-Patient 
 
Fig. 4.5:  SI variability per-cohort (left) and 50% range of SI variability per-patient (right) for OHCA patients, 
treated with hypothermia using 12 hour blocks. Blue and red represent cool and warm period respectively. 
 
Table 4.8:  Summary of SI variability results for OHCA cohort based on 12-hours block.   
 
 
Day Block Hours Range 
Per-Cohort 
Median DeltaSI  
[IQR] [%] 
Per-Patient 
Median DeltaSI 
[IQR] [%] 
1 1 
0 – 12 hours 1.1 [-2.2, 5.3] 9.0 [5.1, 17.0] 
2 12 – 24 hours 1.2 [-1.5, 3.7] 5.8 [2.8, 10.3] 
2 3 24 – 36 hours 0.07 [-2.5, 2.0] 4.8 [2.8, 9.5] 
4 36 – 48 hours 0.3 [-1.7, 2.3] 4.8 [2.7, 9.2] 
 
Table 4.9:   Reductions in the IQR and median SI per patient range of hour-to-hour 
percentage SI change over time during cool and warm after as per 12-hour blocks of data 
 
SI Variability 
analysis 
Cohort analysis Per-patient analysis 
 [12-hr blocks] 
%  Reduction 
of IQR 
p-value 
% Decrease at 
median 
p-value 
Block 1-2 (C)            
  (0 - 12 vs. 12 - 24 hr) 
31.1 < 0.05 35.6 < 0.05 
Block 2-3 (C-W)    
  (12 - 24 vs. 24 - 36 hr) 
12.4 0.9 17.2 0.2 
Block 3-4 (W)        
(24 - 36 vs. 36 - 48 hr) 
12.2 0.2 0.0 0.4 
P-values are calculated using Kolmogorov-Smirnov test   
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The results and analyses from both per-cohort and per-patient suggest that insulin sensitivity 
is more variable during the cool period and significantly decreases over time for the first 12 
hours of treatment. However, small decrease is observed between block 2 (12-24 hrs) and 
block 3 (24-36 hrs), but rise again for the next consequent block. The decrease between block 
1-2 (cooling) and block 3-4 (warming) is statistically significant for both per-cohort and per-
patient analyses, but the change is much less between block 2-3 (cooling-warming) and may 
not be significant. 
 
Figure 4.6 presents 6-hourly blocks of %∆SI (left panel) and 50% range of SI variability per-
patient (right panel). Table 4.10 presents the summary of SI results based on 6-hour block and 
Table 4.11 presents the reductions between successive blocks. 
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Fig. 4.6:  Insulin sensitivity variability per-cohort (left) and 50% range of SI variability CDF per-patient (right) 
for OHCA patients, treated with hypothermia using 6 hour blocks of data.   
 
Cohort and per-patent variability decreases over time for the first 48 hours of ICU stay. 
However, it increases across the cool to warm transition, indicating some potential stress 
across the cool-warm transition with negative reductions. The decreasing trend returns for all 
subsequent blocks. The results suggest that %∆SI decreases per-cohort and per-patient are 
statistically significant (p<0.05) for the first 36 hours in both cases. 
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Table 4.10:  Summary of SI variability results for overall OHCA cohort based on 6-hour 
block.   
 
 
Day Block Hours Range 
Per-Cohort 
Median DeltaSI  
[IQR] [%] 
Per-Patient 
Median DeltaSI 
[IQR] [%] 
1 
1 0 – 6 hours 
1.4 [-2.5, 6.2] 
10.7 [4.7, 25.6] 
2 6 – 12 hours 0.9 [-2.0, 4.7] 6.8 [3.4, 14.4] 
3 12 – 18 hours 1.2 [-1.7, 3.9] 5.8 [2.9, 10.9] 
4 18 – 24 hours 1.1 [-1.4, 3.6] 4.3 [2.0, 8.6] 
2 
5 24 – 30 hours -0.4 [-2.8, 1.7] 4.0 [2.4, 8.8] 
6 30 – 36 hours 0.5 [-2.3, 2.6] 4.5 [2.1, 9.0] 
7 36 – 42 hours 0.6 [-1.7, 2.5] 4.3 [2.1, 7.1] 
8 42 – 48 hours 0.2 [-1.7, 2.0] 4.2 [1.5, 6.3] 
 
 
Table 4.11:   Reductions in the interquartile range and median SI per patient range of hour-
to-hour percentage SI change over time during cool and warm after as per 6-hour blocks of 
data 
 
SI Variability 
analysis 
Cohort analysis Per-patient analysis 
 [6-hr blocks] 
%  Reduction 
of IQR 
p-value 
% Decrease at 
median 
p-value 
Block 1-2 (C)            
  (0 - 6 vs. 6 - 12 hr) 
23.4 < 0.05 36.4 < 0.05 
Block 2-3 (C)            
  (6 - 12 vs. 12 - 18 hr) 
15.8 < 0.05 14.7 < 0.05 
Block 3-4 (C)            
  (12 - 18 vs. 18 - 24 hr) 
11.7 < 0.05 25.9 < 0.05 
Block 4-5 (C-W)    
  (18 - 24 vs. 24 - 30 hr) 
9.4 0.6 9.3 0.8 
Block 5-6 (W)    
  (24 - 30 vs. 30 - 36 hr) 
-8.5 0.5 -15.4 0.8 
Block 6-7 (W)    
  (30 - 36 vs. 36 - 42 hr) 
13.7 0.4 4.4 0.6 
Block 7-8 (W)    
  (36 - 42 vs. 42 - 48 hr) 
10.7 0.08 2.3 0.06 
P-values calculated using Kolmogorov-Smirnov test   
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4.3.2 Results by Sub-Cohort 
 
4.3.2.1   SI Level Analysis 
 
Table 4.12 presents the summary of SI level results and analysis for OHCA Sub-Cohorts. The 
summary shows that SI levels are low during the cool period and significantly increase 
(p<0.05) over time for the first 2 days of ICU stay, with consistent trends among all OHCA 
sub-cohorts. However, there are around 20% of each sub-cohort patients that have contrasting 
results against the overall trend. 
 
Table 4.12:  Summary of SI level results and analysis for OHCA Sub-Cohorts 
OHCA Sub-Cohort 
No of 
Patients 
Median SI [IQR] 
at cool period 
[L/mU.min] 
Median SI [IQR]  
at warm period 
[L/mU.min] 
% patients had 
higher SI at 
warm period  
[Diff(Cool-warm)] 
p-value 
Overall OHCA cohort 180 2.5 x 10
-4 
[1.1, 4.4] x10
-4
 
 5.4 x 10
-4 
[2.8, 9.7] x10
-4
 
80% p < 0.05 
Survived Patients 98 2.5 x 10
-4 
[1.2, 4.5] x10
-4
 
 5.8 x 10
-4 
[2.9, 10.6] x10
-4
 
80% p < 0.05 
Non-Survived Patients 82 2.2 x 10
-4 
[1.1, 4.2] x10
-4
 
 5.1 x 10
-4 
[2.6, 8.4] x10
-4
 
80% p < 0.05 
Diabetes Patients 23 2.3 x 10
-4 
[1.1, 3.9] x10
-4
 
 4.1 x 10
-4 
[2.5, 6.2] x10
-4
 
80% p < 0.05 
Non-Diabetes Patients 157 2.4 x 10
-4 
[1.1, 4.4] x10
-4
 
 5.7 x 10
-4 
[2.8, 10.1] x10
-4
 
80% p < 0.05 
Male Patients 143 2.5 x 10
-4 
[1.2, 4.4] x10
-4
 
 5.6 x 10
-4 
[2.9, 10.2] x10
-4
 
80% p < 0.05 
Female Patients 37 2.0 x 10
-4 
[0.9, 4.0] x10
-4
 
 4.8 x 10
-4 
[2.5, 8.0] x10
-4
 
80% p < 0.05 
ROSC < 15 mins 63 2.7 x 10
-4 
[1.4, 4.5] x10
-4
 
 5.7 x 10
-4 
[3.1, 9.7] x10
-4
 
80% p < 0.05 
ROSC < 30 mins 89 2.3 x 10
-4 
[1.0, 4.3] x10
-4
 
 5.3 x 10
-4 
[2.8, 9.6] x10
-4
 
80% p < 0.05 
ROSC > 30 mins 28 2.0 x 10
-4 
[0.9, 3.9] x10
-4
 
 5.3 x 10
-4 
[1.8, 9.8] x10
-4
 
80% p < 0.05  
 
 
Table 4.13 presents the summary of increasing cohort and per patient median SI during cool 
and warm as per 12-hour blocks of data for all OHCA sub-cohorts. The results suggest that SI 
increases for the cohort and per-patient are statistically significant for the first 36 hours 
(p<0.05), with consistent trends among all OHCA sub-cohorts. 
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Table 4.13:   Summary of increasing cohort and per patient median SI during cool and warm 
as per 12-hour blocks of data for all OHCA sub-cohorts. 
 
SI Level 
analysis 
 [12-hr 
blocks] 
No of 
Patients 
Block 1-2 (C) 
(0 - 12 vs. 12 - 24 hr) 
Block 2-3 (C-W) 
(12 - 24 vs. 24 - 36 hr) 
Block 3-4 (W) 
(24 - 36 vs. 36 - 48 hr) 
Cohort analysis Per-patient 
analysis 
Cohort analysis Per-patient 
analysis 
Cohort analysis Per-patient 
analysis 
% Increase 
at median 
p-value % Increase 
at median 
p-value % Increase 
at median 
p-value % Increase 
at median 
p-value % Increase 
at median 
p-value % Increase 
at median 
p-value 
All OHCA 
patients 
 
180 47.3 <0.01 45.6 <0.01 77.5 <0.01 77.8 <0.01 6.2 0.10 8.3 0.40 
Survived 
Patients 
 
98 52.6 <0.01 57.3 <0.01 66.3 <0.01 58.7 <0.01 9.1 0.12 15.1 0.50 
Non-
Survived 
Patients 
82 42.7 <0.01 46.3 0.02 94.7 <0.01 96.5 <0.01 0.5 0.6 4.3 0.80 
Diabetes 
Patients 
 
23 40.2 <0.01 31.3 0.25 44.4 <0.01 22.2 <0.01 5.5 0.5 26.3 0.54 
Non-
Diabetes 
Patients 
157 48.2 <0.01 48.9 <0.01 81.6 <0.01 84.3 <0.01 7.5 0.09 10.0 0.46 
Male 
Patients 
 
143 40.0 <0.01 44.3 <0.01 77.8 <0.01 66.6 <0.01 7.8 0.04 12.2 0.32 
Female 
Patients 
 
37 72.3  <0.01 77.3 <0.01 84.0 <0.01 94.8 <0.01 -3.8 0.9 -1.4 0.9 
ROSC < 15 
mins 
 
63 55.5  <0.01 64.5 <0.01 60.0 <0.01 49.3 <0.01 0.6 0.4 0.4 0.9 
ROSC < 30 
mins 
 
89 48.7  <0.01 38.5 0.03 77.7 <0.01 79.2 <0.01 10.1 0.2 11.7 0.3 
ROSC > 30 
mins 
 
28 62.0  <0.01 60.5 0.11 88.8 <0.01 100.1 <0.01 19.5 0.4 11.7 0.9 
P-values are calculated using Wilcoxon rank-sum test   
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4.3.2.2   SI Variability Analysis 
 
Table 4.14 presents the summary of SI variability results and analysis for OHCA Sub-
Cohorts. The results show that SI is more variable during cool than warm and significantly 
decrease (p<0.01) over time for the first 2 days of ICU stay, with consistent trends among all 
OHCA sub-cohorts. However, there are around 30% - 40% patients for each sub-cohort that 
have contrasting results, where SI variability is higher during the warm period, in contrast to 
the overall trend.   
 
Table 4.14:   Summary of SI variability results and analysis for OHCA Sub-Cohorts 
OHCA Sub-Cohorts 
No of 
Patients 
Median SI 
variability 
[IQR] at cool 
period 
[%∆SI] 
Median SI 
variability 
[IQR]  at 
warm period 
[%∆SI] 
% patients 
had higher SI 
variability 
during cool   
[Diff(Cool-
warm)] 
% patients 
had 
contrasting 
SI variability 
against 
overall trend 
 
p-value 
Overall OHCA cohort 180  1.2 [-1.8, 4.4]  0.2 [-2.2, 2.2] 60% 40% 0.08 
Survived Patients 98 1.0 [-1.8, 4.1]  0.3 [-2.0, 2.2] 60% 40% 0.1 
Non-Survived Patients 82 1.4 [-1.9, 4.8] 0.07[-2.4, 2.1] 60% 40% 0.2 
Diabetes Patients 23 1.0 [-1.3, 3.7] 0.04[-2.4, 2.2] 60% 40% 0.3 
Non-Diabetes Patients 157 1.2 [-1.9, 4.6]  0.3 [-2.2, 2.2] 60% 40% 0.06 
Male Patients 143 1.0 [-1.8, 4.4]  0.3 [-2.2, 2.3] 60% 40% 0.09 
Female Patients 37 1.5 [-2.0, 4.5]  -0.3[-2.2,1.8] 70% 30% 0.5 
ROSC < 15 mins 63 1.0 [-1.6, 3.6]  0.3[-2.2, 2.3] 60% 40% 0.2 
ROSC < 30 mins 89 1.2 [-2.0, 5.0]  0.2[-1.9, 2.1] 60% 40% 0.3 
ROSC > 30 mins 28 1.4 [-2.1, 4.7]  -0.1[-2.7,2.0] 70% 30% 0.5 
 
 
Table 4.15 presents the summary of reductions in the IQR and median SI per patient range of 
hour-to-hour percentage SI change over time during cool and warm as per 12-hour blocks of 
data for all OHCA sub-cohorts. The results and analyses suggest that insulin sensitivity is 
more variable during the cool period and significantly decreases over time for the first 12 
hours of treatment, with consistent trends among all OHCA sub-cohorts. However, the 
overall decrease at block 2-3 (cool-warm transition) and block 3-4 (warming) are not 
significant, even though some results are not consistent across each sub-cohort. 
 
64 
 
Similar SI variability trends are observed between overall OHCA cohort and several sub-
cohorts such as non-diabetes, male, female, survived, non-survived, ROSC<15 and 
ROSC<30. Other sub-cohorts such as diabetes and ROSC > 30 have shown different SI 
variability trends compared to overall OHCA cohort. Thus, these results show that not all 
OHCA patients which are distinguished by sub-cohorts have the same way of SI variability 
even though they have undergone the same treatment protocol from cool to warm period. 
 
Table 4.15:   Summary of reductions in the IQR and median SI per patient range of hour-to-
hour percentage SI change over time during cool and warm as per 12-hour blocks of data for 
all OHCA sub-cohorts. 
 
SI 
variability 
analysis 
 [12-hr 
blocks] 
No of 
Patients 
Block 1-2 (C) 
(0 - 12 vs. 12 - 24 hr) 
Block 2-3 (C-W) 
(12 - 24 vs. 24 - 36 hr) 
Block 3-4 (W) 
(24 - 36 vs. 36 - 48 hr) 
Cohort analysis Per-patient 
analysis 
Cohort analysis Per-patient 
analysis 
Cohort analysis Per-patient 
analysis 
 % 
Reduction 
of IQR 
p-value % 
Decrease 
at median 
p-value  % 
Reduction 
of IQR 
p-value % 
Decrease 
at median 
p-value  % 
Reduction 
of IQR 
p-value % 
Decrease 
at median 
p-value 
All OHCA 
patients 
 
180 31.3 0.3 36.2 0.02 12.4 0.9 17.3 0.2 12.2 0.15 -0.2 0.4 
Survived 
Patients 
 
98 32.1 0.4 33.6 0.01 3.4 0.01 11.2 0.5 19.8 0.03 2.7 0.4 
Non-
Survived 
Patients 
82 30.0 0.04 35.7 0.01 20.8 0.01 30.6 0.2 4.0 0.07 -9.8 0.7 
Diabetes 
Patients 
 
23 35.7 0.3 60.8 0.07 -23.5 0.01 -84.1 0.2 23.0 0.40 21.1 0.3 
Non-
Diabetes 
Patients 
157 30.0 0.3 32.0 0.03 17.2 <0.01 30.1 0.03 10.8 <0.01 9.0 0.7 
Male 
Patients 
 
143 30.0 0.04 35.0 0.04 10.0 <0.01 16.8 0.3 14.0 <0.01 -2.3 0.8 
Female 
Patients 
 
37 39.8 0.4 43.0 0.05 19.3 0.10 17.4 0.4 14.2 0.6 11.3 0.2 
ROSC < 15 
mins 
 
63 34.4 0.7 43.0 0.05 -18.7 <0.01 -4.2 0.03 20.4 0.02 0.7 0.4 
ROSC < 30 
mins 
 
89 31.0 0.03 23.6 0.04 25.1 <0.01 31.0 0.03 11.3 0.05 1.7 0.5 
ROSC > 30 
mins 
 
28 35.1 0.9 47.0 0.02 25.3 <0.01 49.0 0.2 -8.3 0.11 -56.0 0.8 
P-values are calculated using Kolmogorov-Smirnov test   
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4.4   Discussion 
 
4.4.1 Insulin sensitivity level   
 
The insulin sensitivity level results for both per-cohort and per-patient analyses suggest that 
OHCA patients undergoing hypothermic treatment have significantly lower insulin sensitivity 
during the earlier cool period on day 1 than the later warm period on day 2. Both results 
follow the general trend for insulin sensitivity level for critically ill patients over time and are 
consistent with other ICU studies (Langouche et al., 2007, Pretty et al., 2012).  
 
Further analysis shows that the increase in SI level during the first 36 hours are large and 
statistically significant for this cohort. The rapid increases in SI level for the first 36 hours is 
likely due to significant restart of human physiological systems and metabolic activities for 
these patients (Neumar et al., 2008). After 36 hours, the rapid SI increase abates as the 
patients’ metabolism improves and becomes more stable.  
 
Several sub-cohorts have shown consistent SI trend with overall OHCA patients,  This 
suggest that  analysing overall OHCA patients metabolic evolution is sufficient enough for 
developing control scheme. 
 
4.4.2 Insulin sensitivity variability   
 
Both per-cohort and per-patient analysis suggest that OHCA patients undergoing TH 
treatment have high initial variability that decreases over the first 36 hours. However, the 
cool to warm transition at 24 hours shows an increase in variability likely due to the change 
of physiological conditions as body temperature increase from cool to warm between 18 – 36 
hours. The lower decrease in SI variability after 36
th
 hours onwards suggests that the patients’ 
metabolic condition has improved and become more stable. 
 
Further analysis and comparison of SI variability between general ICU patients (Pretty et al., 
2012) and OHCA patients, treated with TH shows that the main difference between them is 
the SI variability increase during the cool-warm transition period for the latter cohort. These 
SI variability results do not follow the same trend with other general ICU studies by Pretty et 
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al. (Pretty et al., 2012), and it is a unique finding for this cohort that could significantly 
impact glycaemic control and safety from hypoglycaemia. 
 
4.4.3 The Impact of SI variability on glycaemic control    
 
Clinically, these results have significant implications for managing glycaemia. Increased SI 
variability leads to increased variability in BG level for a given insulin intervention (Chase et 
al., 2011b). With low and variable insulin sensitivity, glycaemic levels might appear to 
remain unchanged and difficult to control effectively with exogenous insulin. This situation 
may result in increased glycaemic variability as well as an increased risk of hyperglycaemia 
and hypoglycaemia during the first 36 hours of treatment due to greater hour-to-hour SI 
variability with increased insulin resistance (Cueni-Villoz et al., 2011). Thus, since glycaemic 
variability and hypoglycaemia are independent risk factors for the critically ill, it is important 
to understand and manage these patient-specific dynamics, especially those unique to a 
cohort, when implementing glycaemic control. This outcome is particularly important when 
OHCA patients transition from cool to warm. These results may also generalise to other areas 
where glycaemic control is applied to hypothermic patients, such as in the operating theatre. 
 
There are several ways that this low and variable insulin sensitivity could be managed during 
glycaemic control. Reducing exogenous insulin doses, coupled with modulation of the 
glucose content of nutrition would diminish the impact of sudden changes of insulin 
sensitivity on glycaemic outcome. Equally, increased blood glucose measurement frequency 
could improve control and reduce glycaemic variability. Accepting higher glycaemic targets 
during periods of increased variability would trade-off a reduced risk of hypoglycaemia 
against increased hyperglycaemia. Ultimately, the preferred method for any unit may be 
influenced by practical considerations, such as clinical workload. 
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4.5   Summary 
 
This study analyses the metabolic evolution of OHCA patients treated with hypothermia. 
These analyses characterize the metabolic impact of hypothermic treatment on the level and 
variability of insulin sensitivity to inform control. 
 
Two main conclusions are drawn as a result for these cohorts.  
i)   SI level is much lower during hypothermia and consistently increases over time, both 
cool and warm periods. 
 
ii)  Insulin sensitivity is more variable during the cool period and shows contrasting 
behavior during cool-warm transition period between 18 – 30 hours, which indicates that 
there are major changes in physiology and metabolic conditions between cool and warm as 
influenced by human body temperature. Otherwise, it decreases over time. 
 
Finally, this study shows the need for patient-specific glycemic management to ensure good 
control and safety during treatment. These results have significant potential clinical impact on 
the metabolic treatment of these patients, and changes in clinical therapy are required to 
safely treat patients as they transition from cool to warm. 
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Chapter 5: Blood Glucose Level and Variability Analysis                                                                                                                       
 
 
 
This chapter describes a preliminary study of Out-of-Hospital Cardiac Arrest (OHCA) 
patients based on glycaemic characteristics during hypothermia (cool period) and 
normothemia. It analyses the impact of therapeutic hypothermia (TH) on glycaemic outcome, 
including the evolution of blood glucose and its variability, in patients with coma after 
OHCA. Patients’ data were analysed based on cohort as defined in Chapter 3, and results 
were summarized.   
 
5.1   Introduction 
 
One of the adverse events associated with hypothermic therapy is the decrease in insulin 
sensitivity and insulin secretion (Hayashi, 2009). The amount of insulin required to maintain 
glucose levels within normal range (4.4 to 6.1 mmol/L) is thus likely to increase during the 
induction of hypothermia due to both the initial insult and stress, and hypothermia itself. High 
insulin doses can lead to hypoglycaemia if patient condition improves and dosing is not 
adjusted accordingly.  Thus, non-patient-specific approaches can result in highly variable BG, 
which can adversely affect clinical outcomes and mortality (Bagshaw et al., 2009). 
 
This study analyses and compares blood glucose (BG) level and variability, and their 
evolution in OHCA patients undergoing hypothermic treatment. The results provide better 
understanding of the glycaemic condition of these patients which will help in improving 
glycaemic control protocol for use with TH. 
 
5.2   Subjects and Methods 
 
5.2.1 Patients and Data  
 
This analysis was performed on a cohort of 180 OHCA patients (7812 hours) treated with 
hypothermia, shortly after admission in Intensive Care Units (ICUs) of Erasme Hospital, 
Belgium and Lausanne Hospital, Switzerland. These patients were on local AGC protocols. 
Data collections were carried out as per described in sub-chapter 3.1 Additional information 
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for each patient such as mortality, diabetes history, gender and return of spontaneous 
circulation (ROSC) were recorded. These inputs will be taken into consideration for separate 
sub-analysis studies from full cohort. Details of the cohort demography, including sub-
cohorts are presented in Table 3.1.   
 
5.2.2 Analyses and Metrics  
 
BG level during the cool (T<35
o
C) and warm (T>37
o
C) periods were identified hourly. 
Variability  of  BG was  calculated  as  the  hour-to-hour  percentage  change  in  BG 
(%ΔBG), defined:   
   
%∆𝐵𝐺 =  
( 𝐵𝐺𝑛+1 −  𝐵𝐺𝑛)
𝐵𝐺𝑛
 𝑥 100 
 
(5.1) 
 
The use of percentage change, rather than absolute change, normalises the metric so patients 
with differing BG levels can be compared fairly. BG level, variability and gradient were 
analysed during both cool and warm periods on overall cohort and per-patient bases as 
follows; 
i)  Overall cohort patient. 
ii)  Analysis of patient by 12-hour block. 
iii)  Analysis of patient by 6-hour block. 
 
Cohort analysis assess every hours of BG level and variability for the entire cohort and shows 
trend based on the overall group behaviour, whereas per-patient analysis examined the BG 
level by median values within each timeframe. To quantify per-patient variability, the 
interquartile range (IQR) of %ΔBG is calculated and this metric captures the width of the 
hour-to-hour variability distributions for each patient.  
 
The BG analysis of patients using 12-hour and 6-hour time blocks, which includes level and 
variability is described in Table 4.1. This method will examine group behaviour and assess its 
changes for every 12 and 6 hour blocks of the entire treatment from cool to warm periods. 
For cohort analysis, BG and ∆% BG data from all patients was grouped into each appropriate 
time-block. Median values for each time-block were calculated for comparison to the 
previous block, thus capturing overall cohort changes over time in level and hour-to-hour 
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variability. For per-patient analysis, the median value of SI and the interquartile range (IQR) 
of ∆%BG were calculated for each patient, for each time-block. The IQR captures the width 
of degree of variability for a given patient within each hour block. Thus, a reduction in the 
IQR of ∆%BG over time would indicate a reduction in hour-to-hour variability for a given 
patient. 
 
BG level and variability are non-Gaussian and thus were compared using non-parametric 
cumulative distribution functions (CDFs). All distributed data were compared using a 
Wilcoxon rank-sum test (Mann-Whitney U-test), except for BG variability results. BG 
variability was compared using the Kolmogorov-Smirnov test as it has greater power to 
detect differences in the shape of distributions when median values are similar. In all cases, p 
< 0.05 is considered statistically significant.  
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5.3   Results 
 
5.3.1 Results for Complete Cohort 
 
5.3.1.1   BG Level Analysis 
 
Figure 5.1 presents the cumulative distribution functions (CDFs) of hourly BG level and its 
variability for both cool and warm periods by cohort (left panel) and per-patient median BG 
(right panel). Table 5.1 presents summary of BG results for overall OHCA cohort. 
 
Per-Cohort Analysis 
 
Per-Patient Analysis 
 
  
Fig. 5.1:  Blood glucose level and variability distribution by cohort (left) and per-patient median (right) 
during cool and warm after periods for all OHCA patients 
 
 
Table 5.1:  Summary of BG results for overall OHCA cohort.   
 
 
Day 
 
Period Hours Range 
Per-Cohort 
Median BG [IQR  
[mmol/L] 
Per-Patient 
Median BG [IQR] 
[mmol/L] 
1 Cool 
 
0 – 24 hours 9.7 [6.9, 13.1] 7.4 [6.5, 8.5] 
2 Warm 
 
24 – 48 hours 8.5 [6.1, 11.5] 6.5 [5.8, 7.4] 
  p-value 
 
p < 0.05 p < 0.05 
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70% of all OHCA 
patients had higher 
BG during cool  
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The results show that blood glucose levels are initially high during the cool period and 
significantly decrease (p<0.05) over time for the first 2 days of ICU stay, with consistent 
trends between per-cohort and per-patient median values. However, there are around 30% (54 
patients) of all patients that have contrasting results, where BG level is lower during the cool 
period, in contrast to the overall trend. 
 
Figure 5.2 presents the 12-hour block BG level by cohort (left panel) and median BG per-
patient (right panel). Table 5.2 presents the summary of BG results based on 12-hour block, 
and Table 5.3 presents the decrease in median BG between successive blocks.   
  
 Per-Cohort  
 
Per-Patient 
 
Fig. 5.2:  BG level distribution per-cohort (left) and per-patient median (right) for OHCA patients, treated with 
hypothermia using 12 hour blocks of data. Blue colour represent cool period and red colour represent warm   
 
 
Table 5.2:  Summary of BG results for OHCA cohort based on 12-hours block.   
 
 
Day Block Hours Range 
Per-Cohort 
Median BG [IQR]  
[mmol/L] 
Per-Patient 
Median BG [IQR] 
[mmol/L] 
1 1 
0 – 12 hours 9.7 [7.1, 13.2] 7.6 [6.5, 9.3] 
2 12 – 24 hours 8.5 [6.1, 10.2] 6.9 [5.9, 8.2] 
2 3 24 – 36 hours 8.3 [6.1, 11.3] 6.7 [6.0, 7.8] 
4 36 – 48 hours 7.6 [5.8, 9.8] 6.4 [5.7, 7.6] 
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Table 5.3:   Decreasing cohort and per patient median BG during cool and warm (12-hour 
blocks of data) 
 
BG Level 
analysis 
Cohort analysis Per-patient analysis 
 [12-hr blocks] 
% Decrease at 
median 
p-value 
% Decrease at 
median 
p-value 
Block 1-2 (C)            
  (0 - 12 vs. 12 - 24 hr) 
12.4 <0.05 9.2 <0.05 
Block 2-3 (C-W)    
  (12 - 24 vs. 24 - 36 hr) 
2.4 0.1 2.9 0.4 
Block 3-4 (W)        
(24 - 36 vs. 36 - 48 hr) 
8.4 0.1 4.5 0.2 
 P-values calculated using Wilcoxon rank-sum test   
  
The results and analyses from both per-cohort and per-patient analyses suggest that BG levels 
were initially high during the cool period and decrease significantly over time for the first 12 
hours in the ICU (p < 0.05). However, the subsequent blocks show smaller non-statistically 
significant BG decrease at median. 
 
Figure 5.3 presents the 6-hour block BG level by cohort (left panel) and median BG per-
patient (right panel). Table 5.4 presents the summary of BG results based on 6-hour block, 
and Table 5.5 presents the increase in median BG between successive blocks.   
 
Per-Cohort Per-Cohort 
  
Fig. 5.3: BG level distribution per-cohort (left) and per-patient median (right) for OHCA patients, treated with 
hypothermia using 6 hour blocks of data.   
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Table 5.4:  Summary of BG results for overall OHCA cohort based on 6-hour block.   
 
 
Day Block Hours Range 
Per-Cohort 
Median BG [IQR]  
[mmol/L] 
Per-Patient 
Median BG [IQR] 
[mmol/L] 
1 
1 0 – 6 hours 9.9 [7.3, 13.4] 8.3 [7.1, 10.8] 
2 6 – 12 hours 8.3 [6.4, 10.9] 7.5 [6.5, 8.9] 
3 12 – 18 hours 7.9 [6.3, 9.9] 7.3 [6.3, 8.4] 
4 18 – 24 hours 7.7 [5.9, 9.5] 6.9 [5.9, 8.1] 
2 
5 24 – 30 hours 7.6 [5.8, 9.4] 6.8 [5.9, 8.0] 
6 30 – 36 hours 7.9 [6.1, 10.7] 7.0 [6.3, 8.0] 
7 36 – 42 hours 7.4 [5.9, 9.4] 6.9 [6.0, 7.9] 
8 42 – 48 hours 7.3 [5.7, 9.1] 6.8 [5.8, 7.8] 
 
 
Table 5.5:   Decreasing cohort and per patient median BG during cool and warm as per 6-
hour blocks of data 
 
BG Level 
analysis 
Cohort analysis Per-patient analysis 
 [6-hr blocks] 
% Decrease at 
median 
p-value 
% Decrease at 
median 
p-value 
Block 1-2 (C)            
  (0 - 6 vs. 6 - 12 hr) 
16.2 <0.05 9.6 <0.05 
Block 2-3 (C)            
  (6 - 12 vs. 12 - 18 hr) 
4.8 0.06 2.7 0.1 
Block 3-4 (C)            
  (12 - 18 vs. 18 - 24 hr) 
2.5 0.2 5.5 0.4 
Block 4-5 (C-W)    
  (18 - 24 vs. 24 - 30 hr) 
1.3 0.8 1.4 0.4 
Block 5-6 (W)    
  (24 - 30 vs. 30 - 36 hr) 
-3.9 0.06 -2.9 0.1 
Block 6-7 (W)    
  (30 - 36 vs. 36 - 42 hr) 
6.3 0.05 1.4 0.2 
Block 7-8 (W)    
  (36 - 42 vs. 42 - 48 hr) 
1.3 0.4 1.4 0.5 
 P-values calculated using Wilcoxon rank-sum test   
 
The results suggest that BG levels are initially high during the cool period and decrease over 
time, matching the 12-hour block analyses. It is evident that the decrease in BG between each 
time block is significantly larger (p < 0.05) for the first 12 hours of treatment. 
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5.3.1.2   BG Variability Analysis 
  
Figure 5.4 presents the cumulative distribution functions (CDFs) of BG variability for both 
cool and warm after periods by cohort (left panel) and median hourly BG per-patient (right 
panel) for all cohort patients. Table 5.6 presents the summary of BG variability results for 
overall OHCA cohort.     
 
Per-Cohort Analysis 
 
Per-Patient Analysis 
 
  
Fig. 5.4:  Blood glucose level and variability distribution by cohort (left) and per-patient median (right) 
during cool and warm after periods for all ICU patients 
 
Table 5.6:  Summary of BG variability results for overall OHCA cohort.   
 
 
Day 
 
Period Hours Range 
Per-Cohort 
Median DeltaBG  
[IQR] [mmol/L] 
Per-Patient 
Median DeltaBG 
[IQR] [mmol/L] 
1 
Cool 
 
0 – 24 hours -0.6 [-2.3, 1.0] -2.8 [-5.6, -0.9] 
2 
Warm 
 
24 – 48 hours 0.2 [-1.6, 1.9] -1.5[ -3.4, 1.0] 
  
 
p-value 
0.5 0.08 
 
The results show that BG variability trend is similar, both during cool and warm (p=0.5) over 
time for the first 2 days of ICU stay. Besides, there are around 65% (117 patients) of all 
patients that have higher BG variability during the warm period. The results also show that 
85% of %ΔBG are negative bias at cool, compared to 65% at warm periods, indicating more 
rising BG as seen in Figure 5.4. 
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Figure 5.5 presents the cumulative distribution functions of the hour-to-hour percentage 
changes in BG (left panel) and distribution of 50% range of BG variability per-patient (right 
panel) using 12 hour blocks. Table 5.8 presents the summary of BG variability results based 
on 12-hour block, and Table 5.9 presents the percentage reduction in the interquartile range, 
percentage of BG variability decrease at median between successive blocks.   
  
Per-Cohort  
 
Per-Patient 
 
Fig. 5.5:  BG variability per-cohort (left) and 50% range of BG variability per-patient (right) for OHCA 
patients, treated with hypothermia using 12 hour blocks of data. Blue and red lines represent cool warm period 
respectively. 
 
Table 5.7:  Summary of BG variability results for OHCA cohort based on 12-hours block.   
 
 
Day Block Hours Range 
Per-Cohort 
Median DeltaBG 
[IQR] [%] 
Per-Patient 
Median DeltaBG 
[IQR] [%] 
1 1 
0 – 12 hours -0.8 [-2.6, 0.8] 3.9 [2.1, 8.2] 
2 12 – 24 hours -0.4 [-1.8, 1.1] 3.8 [1.8, 6.6] 
2 3 24 – 36 hours 0.3 [-1.5, 2.0] 3.3 [2.2, 6.6] 
4 36 – 48 hours -0.2 [-1.5, 1.4] 3.3 [1.8, 6.1] 
 
The 12-hour block results and analyses from both per-cohort and per-patient suggest that 
blood glucose variability is initially high during the cool period and decreases over time. 
However, small decrease is observed insignificantly (p > 0.05) between these time blocks, 
which suggest that BG variability remains unchanged after 48 hours of treatment. 
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Table 5.8:   Reductions in the IQR and median BG per patient range of hour-to-hour 
percentage BG change over time during cool and warm after as per 12-hour blocks of data 
 
BG Variability 
analysis 
Cohort analysis Per-patient analysis 
 [12-hr blocks] 
%  Reduction 
of IQR 
p-value 
% Decrease at 
median 
p-value 
Block 1-2 (C)            
  (0 - 12 vs. 12 - 24 hr) 
16.5 0.1 2.6 0.2 
Block 2-3 (C-W)    
  (12 - 24 vs. 24 - 36 hr) 
-19.1 0.3 13.2 0.7 
Block 3-4 (W)        
(24 - 36 vs. 36 - 48 hr) 17.6 
0.2 
 
0 
0.2 
 
P-values are calculated using Kolmogorov-Smirnov test   
   
Figure 5.6 presents the cumulative distribution functions of the hour-to-hour percentage 
changes in BG (left panel) and distribution of 50% range of BG variability per-patient (right 
panel) using 6 hour blocks. Table 5.9 presents the summary of BG variability results based on 
6-hour block, and Table 5.10 presents the percentage reduction in the interquartile range, 
percentage of BG variability decrease at median between successive blocks.   
 
Per-Cohort  
 
Per-Patient 
 
Fig. 5.6:  Blood glucose variability per-cohort (left) and 50% range of BG variability CDF per-patient (right) 
for OHCA patients, treated with hypothermia using 6 hour blocks of data.   
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Table 5.9:  Summary of BG variability results for overall OHCA cohort based on 6-hour 
block.   
 
 
Day Block Hours Range 
Per-Cohort 
Median DeltaBG 
[IQR] [%] 
Per-Patient 
Median DeltaBG 
[IQR] [%] 
1 
1 0 – 6 hours -0.9 [-2.9, 0.5] 3.4 [1.7, 6.6] 
2 6 – 12 hours -0.6 [-2.3, 1.0] 2.9 [1.6, 5.3] 
3 12 – 18 hours -0.3 [-1.5, 1.3] 2.8 [1.2, 4.8] 
4 18 – 24 hours -0.4 [-1.8, 0.8] 2.5 [1.1, 4.7] 
2 
5 24 – 30 hours 0.4 [-1.3, 2.0] 2.4 [1.4, 4.2] 
6 30 – 36 hours 0.2 [-1.6, 1.9] 2.6 [1.4, 5.1] 
7 36 – 42 hours -0.2 [-1.6, 1.6] 2.5 [1.2, 4.7] 
8 42 – 48 hours -0.1 [-1.2, 1.1] 2.1 [1.0, 4.1] 
 
 
Table 5.10:   Reductions in the interquartile range and median BG per patient range of hour-
to-hour percentage BG change over time during cool and warm after as per 6-hour blocks of 
data 
 
BG Variability 
analysis 
Cohort analysis Per-patient analysis 
 [6-hr blocks] 
%  Reduction 
of IQR 
p-value 
% Decrease at 
median 
p-value 
Block 1-2 (C)            
  (0 - 6 vs. 6 - 12 hr) 
2.4 0.07 14.7 0.2 
Block 2-3 (C)            
  (6 - 12 vs. 12 - 18 hr) 
15.5 0.09 3.4 0.1 
Block 3-4 (C)            
  (12 - 18 vs. 18 - 24 hr) 
5.5 0.2 10.7 0.5 
Block 4-5 (C-W)    
  (18 - 24 vs. 24 - 30 hr) 
-22.6 0.06 4.0 0.9 
Block 5-6 (W)    
  (24 - 30 vs. 30 - 36 hr) 
-5.1 0.5 -8.3 0.3 
Block 6-7 (W)    
  (30 - 36 vs. 36 - 42 hr) 
9.0 0.06 3.8 0.6 
Block 7-8 (W)    
  (36 - 42 vs. 42 - 48 hr) 
26.5 0.5 16.0 0.1 
P-values calculated using Kolmogorov-Smirnov test   
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These results show that BG variability decreases over time from cool to warm, with 
consistent decrease for the first 24 hours of treatment. However, sudden BGV increases are 
shown between 24 – 36 hours, particularly during cool-warm transition period followed by a 
continuing decrease from 36 hours onwards. These small decreases are observed 
insignificantly (p > 0.05) between these time blocks, which match with previous results and 
analysis based on 12-hour blocks. 
 
5.3.2 Results by Sub-Cohort 
 
5.3.2.1   BG Level Analysis 
 
Table 5.11 presents the summary of BG level results and analysis for OHCA Sub-Cohorts. 
The summary shows that BG levels are high during the cool period and significantly decrease 
(p<0.05) over time for the first 2 days of ICU stay. However, there are approximately around 
30-35% of each sub-cohort patients that have contrasting results against the overall trend. 
Majority of the OHCA sub-cohorts have shown improvement from cool to warm (p<0.05), 
with consistent trends among all OHCA sub-cohorts except for the Diabetes group. 
 
Table 5.11:  Summary of BG level results and analysis for OHCA Sub-Cohorts 
OHCA Sub-Cohort 
No of 
Patients 
 
 
No of 
Samples 
[Hour] 
Median BG 
[IQR] at cool 
period 
[mmol/L] 
Median BG 
[IQR]  at 
warm period 
[mmol/L] 
% patients 
had higher 
BG at cool 
period  
[Diff(Cool-
warm)] 
p-value 
Overall OHCA cohort 180 7812 9.7 [6.9, 13.0] 8.5 [6.1, 11.5] 70% < 0.05 
Survived Patients 98 4337 9.1 [6.8, 11.7] 7.8 [5.8,   9.9] 70% < 0.05 
Non-Survived Patients 82 3475 9.2 [6.6, 12.2] 8.3 [6.0, 10.9] 70% < 0.05 
Diabetes Patients 23 1021 8.8 [7.0, 11.5] 8.1 [6.2, 11.2] 70% 0.3 
Non-Diabetes Patients 157 6791 9.3 [6.7, 12.6] 8.1 [5.9, 10.6] 70% < 0.05 
Male Patients 143 6223 9.4 [6.8, 12.6] 8.4 [6.1, 11.3] 70% < 0.05 
Female Patients 37 1589 8.6 [6.3, 11.2] 7.3 [5.7, 9.1] 70% < 0.05 
ROSC < 15 mins 63 2811 8.7 [6.6, 11.3] 7.7 [5.8, 10.2] 65% < 0.05 
ROSC < 30 mins 89 3797 8.8 [6.4, 11.8] 8.1 [6.0, 10.6] 70% < 0.05 
ROSC > 30 mins 28 1204 8.5 [6.3, 11.8] 7.2 [5.7, 8.9] 65% < 0.05 
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5.3.2.2   BG Variability Analysis 
 
Table 5.12 presents the summary of BG variability results and analysis for OHCA Sub-
Cohorts. The median BG variability results show that BG is more variable during cool than 
warm, and the results are consistent among the sub-cohorts. However, there are around 60% - 
70% patients that have contrasting results, where BG variability is higher during the warm 
period, in contrast to the overall trend.   
 
Table 5.12:   Summary of BG variability results and analysis for OHCA Sub-Cohorts 
OHCA Sub-Cohorts 
No of 
Patients 
 
No of 
Samples 
[Hour] 
Median BG 
variability 
[IQR] at cool 
period 
[%∆SI] 
Median BG 
variability 
[IQR]  at 
warm period 
[%∆SI] 
% patients 
had higher 
BGV during 
cool period 
[Diff(Cool-
warm)] 
p-value 
Overall OHCA cohort 180 7812 -0.6 [-2.3,1.0] 0.2 [-1.6, 1.9] 30% 0.3 
Survived Patients 98 4337 -0.5 [-1.9,0.9] -0.1[-1.5, 1.7] 40% 0.3 
Non-Survived Patients 82 3475 -0.7 [-2.6,1.0] 0.2 [-1.4, 1.7] 30% 0.3 
Diabetes Patients 23 1021 -0.4 [-1.7,0.7] -0.2 [-1.4,1.4] 40% 0.1 
Non-Diabetes Patients 157 6791 -0.6 [-2.4,1.1] 0.2 [-1.6, 1.8] 30% 0.4 
Male Patients 143 6223 -0.5 [-2.3,1.0] -0.1 [-1.6,1.8] 30% 0.3 
Female Patients 37 1589 -0.9 [-2.2,0.9] 0.2 [-1.3, 1.6] 30% 0.2 
ROSC < 15 mins 63 2811 -0.5 [-1.8,0.8] -0.2 [-1.4,1.6] 30% 0.1 
ROSC < 30 mins 89 3797 -0.6 [-2.6,1.3] -0.2 [-1.5,1.6] 35% 0.4 
ROSC > 30 mins 28 1204 -0.9 [-2.6,0.7] 0.3 [1.7,1.9] 25% 0.3 
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5.4   Discussion 
 
Hypothermia leads to lowering of human metabolic rate, including changes in energy 
metabolism (Melhuish, 2009). It also affects metabolism by reducing the production of 
hormones and enzymes from the pancreas and other organs, such as insulin, glucagon and 
adrenaline (Escolar et al., 1987, Escolar et al., 1990, Torlinska et al., 2002), which 
significantly alter metabolic balance and the stress response to insult. Hence, it is expected 
that during hypothermia, internal insulin production, its concentration and insulin sensitivity 
should be lower than normal and the stress response may be modulated to an unknown extent. 
Thus, it is hypothesized that BG may then be higher, as seen clinically in other studies for 
OHCA patients (Cueni-Villoz et al., 2011). Hence, glycaemic control would be more difficult 
given lower insulin sensitivity, requiring more insulin and potentially resulting in greater 
variability and hypoglycaemia. This outcome would typically be exacerbated by the stress of 
the initial insult. 
 
5.4.1       Blood glucose level 
 
BG level results for both per-cohort and per-patient analysis suggest that OHCA 
patients undergoing hypothermic treatment have higher BG levels at cool and decrease over 
time. This results determine general trends for blood glucose levels and are consistent with 
other BG level ICU studies (Neumar et al., 2008). These results are also supported by (Cueni-
Villoz et al., 2011), who have recently showed that mild TH or cool period was associated 
with higher BG levels, increased BG variability, and greater insulin requirements compared 
to the post-rewarming normothermic phase. These researchers were also found that mean BG 
level was higher during hypothermia, but not associated with hospital mortality. 
 
Further studies from both 12-hour and 6-hour blocks analysis show that the decrease in BG 
level during the first 12 hours is large and statistically significant (p<0.05) for this 
cohort. The rapid decreases in BG level are likely due to restart of human physiological 
systems and metabolic activities for these patients (Pretty et al., 2012). After 12 hours, BG 
level shows smaller decrease with no significant different except for block 5-6 (warm) which 
is between (24-30 hrs) and (30-36 hrs). BG is increased by knowing its negative values and 
are likely due to poor neurological outcome (Daviaud et al., 2014). Hence, this results gives 
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an idea of glycemic variability and evolution for this cohort which looks more dynamics and 
responsive during these periods. 
 
Analysis of OHCA sub-cohorts for BG level show that most of the sub-cohorts are recovering 
well based on percentage of BG decrease over time from overall summary. It is evidence that 
diabetic sub-cohort has shown some BG decrease from cool to warm, but with slow progress 
(p=0.3).In fact, this sub-cohort patients experience longer BG level increase during transition 
and warm periods. These findings will lead to a more special control requirement for treating 
OHCA patients with special conditions such as diabetic. 
 
5.4.2       Blood glucose variability 
 
In general, per-cohort and per-patient results suggest that there are no significant BG 
variability differences between cool and warm periods, although variability during the cool 
period is slightly higher than the warm period. Both results determine general trends for 
blood glucose variability and are consistent with similar studies by (Cueni-Villoz et al., 
2011), who have recently showed that mild TH or cool period was associated with increased 
BG variability.   
  
Further studies from both 12-hour and 6-hour blocks analysis show that majority of increased 
BG variability events occur during transition (cool-warm) and warm periods. The BGV 
increase indicates some potential stress across the cool-warm transition with negative 
reductions. These results are likely influenced by local treatment protocol and change of 
physiological conditions due to body temperature increase from cool to warm between 24 – 
36 hours. Recent studies by (Daviaud et al., 2014) concerning BG variability found that for 
low level of BG, high variations were more frequently observed in patients with a poor 
outcome.   Hence, these findings reveal that some sub-cohorts might experience longer poor 
outcome that the others and occurs anytime during treatment (Kauffmann et al., 2011, 
Meynaar et al., 2012) . In fact, high BG variations found during low BG level seems to be 
true since BG level decrease over time from cool to warm. 
 
Analysis of OHCA sub-cohorts for BG level show that most of the sub-cohorts are recovering 
well based on percentage of BG decrease over time from overall summary as well as both 12 
-hour and 6-hour blocks analysis except for diabetic sub-cohort. It is evidence that diabetic 
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sub-cohort has shown some BG decrease from cool to warm, but with slow progress 
(p=0.3).In fact, this sub-cohort patients experience longer BG level increase during transition 
and warm periods. These findings will lead to a more special control requirement for treating 
OHCA patients with special conditions such as diabetic. 
 
5.4.3       Implications for glycaemic control 
  
The demographic patient data by cohort in chapter 3 summarizes the glycaemic management 
inputs and outputs for OHCA patients, treated with hypothermia. In general, patients were 
given the substantial amount of insulin during both periods, but less amount of nutrition at 
cool. As a result, BG levels are recorded high during cool and more likely within the 4 – 7 
mmol/L glycaemic range at warm.     
 
It is recognized that these variations in insulin and nutrition delivery will result in different 
glycaemic outcomes. These results show that the glycaemic control protocols to treat 
hypothermic OHCA patients had different performance. They also indicate the need for 
patient-specific approaches to balance insulin and nutrition in a patient-specific manner (Fisk 
et al., 2012). The evolution and metabolic dynamics among these patients is also similar 
during hypothermia and the first 24 hours of normothermia. 
 
Clinically, these results have significant potential implications for managing glycaemia while 
treating OHCA patients especially during hypothermia, followed by the first 24 hours of 
rewarming. It is important to understand these dynamics, especially those unique to a cohort, 
when implementing glycaemic control, since glycaemic variability and hypoglycaemia are 
independent risk factors for the critically ill (Egi et al., 2006, Bagshaw et al., 2009, Krinsley, 
2009). More specifically, these results suggest that any insulin therapy should not over use 
insulin as per Pretty et.al (Pretty et al., 2012), while treating this cohort patients. Due to high 
level of insulin resistance and the saturation of insulin action (Natali et al., 2000), modulating 
carbohydrate and nutrition inputs might also be explicitly considered (Chase et al., 2008b). In 
particular, early or, excessive nutritional regimes might be avoided in consideration of better 
managing the metabolic dynamics observed in this study. 
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5.5   Summary 
 
This study analyses the glycaemic outcomes of OHCA patients treated with hypothermia. It 
analyses blood glucose (BG) level, its variability and evolution of post-cardiac arrest patients   
who were undergoing hypothermic treatment. It is the first study to fully quantify or 
characterize BG evolution in this cohort including level and variability of both cohort and 
per-patient level.   
 
OHCA Patients treated with hypothermia saw consistently decreasing BG over time, but 
evidenced greater variability, counter to normal trends where both metrics tend to go down 
over the first 48 hours (Pretty et al., 2012). This trend can result in more insulin demand 
during hyperglycemia and a greater risk of hypoglycemia as variability rises, all of which 
indicates the need for patient-specific approaches in each phase. 
 
These results present the first analysis of the hourly evolution of BG level and variability on a 
cohort and per-patient basis. They should lead to better understanding of patient 
physiological conditions based on different perspective such as glycemic outcomes, as well 
as providing the data to implement safer and more accurate glycemic control in this cohort. 
Finally, the outcome of this studies strongly suggest the need to consider both control of BG 
level and minimization of BG variability to improve post-resuscitation care of OHCA 
patients treated with hypothermia. 
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Chapter 6: Exogenous Insulin and Nutrition Analysis                                               
 
 
 
This chapter describes a preliminary study of Out-of-Hospital Cardiac Arrest (OHCA) 
patients based on exogenous insulin and nutrition characteristics during hypothermia (cool 
period) and normothemia (warm period). It analyses the impact of exogenous insulin and 
nutrition modulation during therapeutic hypothermia (TH) on glycaemic outcome. Patient 
data was analysed based on the cohorts, defined in Chapter 3.     
 
6.1   Introduction 
 
Exogenous insulin and nutrition administration play influential role in ICU patient treatment 
progress. The amount of insulin and nutrition is determined based on per-patient physiology 
and metabolic conditions, which were analysed in chapter 4 and 5 previously. Additional 
considerations such as secretion of endogenous insulin and other hormones by pancreas will 
eventually affect the decision as the trend is non-linear (Mitsis et al., 2009) . 
  
This study analyses exogenous insulin and nutrition administration of out of hospital cardiac 
(OHCA) arrest patients from who were undergoing hypothermic treatment. The results 
should provide better understanding of the input elements of these patients for metabolic 
management and their relation with metabolic and glycaemic evolution in the cohort. 
 
6.2   Subjects and Methods 
 
6.2.1 Patients and Data  
 
This analysis was performed on a same ICU cohort of 180 OHCA patients (7812 hours) 
treated with hypothermia from Erasme Hospital, Belgium and Lausanne Hospital, 
Switzerland as per explained in Section 3.1. A summary of the full cohort and sub-cohorts is 
presented in the Table 4.1.   
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6.2.2 Analyses and Metrics  
 
External insulin and nutrition during the cool (T<35
o
C) and warm (T>37
o
C) periods were 
identified from patient data and analysed as follows: 
i)  Overall cohort patient. 
ii)  Analysis of patient by 12-hour block. 
iii)  Analysis of patient by 6-hour block.  
 
Cohort analysis assessed external insulin and nutrition infusions hourly for the entire cohort, 
and shows trends based on the overall group behaviour. Per-patient analysis examined both 
inputs by median values per-patient within each timeframe.   
 
External insulin and nutrition analysis of patients using 12-hour and 6-hour blocks is 
described in the Table 4.1. This method will examine group behaviour and assess its changes 
for every 12 and 6 hour blocks of the entire treatment from cool to warm periods. For cohort 
analysis, external insulin and nutrition data from all patients was grouped into each 
appropriate time-block. Median values for each time-block were calculated for comparison to 
the previous block, thus capturing overall cohort changes over time. For per-patient analysis, 
the median insulin and nutrition inputs were calculated for each patient, for each time-block, 
compared to the previous block. 
 
External insulin and nutrition data are non-Gaussian and were thus compared using non-
parametric cumulative distribution functions (CDFs) and non-parametric statistics. All 
distributed data were compared using a Wilcoxon rank-sum test (Mann-Whitney U-test) 
comparing median values.  In all cases, p < 0.05 is considered statistically significant.  
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6.3   Results on Exogenous Insulin 
 
6.3.1 Results for complete cohort 
 
Figure 6.1 presents the cumulative distribution functions (CDFs) of hourly external insulin 
infusion for both cool and warm periods by cohort (left panel) and median hourly per-patient 
(right panel) for all ICU patients. Table 6.1 summarizes exogenous insulin results and 
analysis for overall OHCA cohort. 
 
Per-Cohort Analysis 
 
Per-Patient Analysis 
 
 
 
Fig. 6.1:  Exogenous insulin distribution by cohort (left) and per-patient median (right) during cool and 
warm after periods for all ICU patients 
 
Table 6.1:  Summary of Exogenous Insulin results for overall OHCA cohort.   
 
 
Day 
 
Period Hours Range 
Per-Cohort 
Median Ex. Insulin 
[IQR] [U/hr] 
Per-Patient 
Median Ex. Insulin 
[IQR] [U/hr] 
1 Cool 
 
0 – 24 hours 2.95 1.80 
2 Warm 
 
24 – 48 hours 2.51 1.65 
  
p-value 
0.5 
 
0.5 
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The results in the Table 6.1 show that exogenous insulin levels are initially higher during the 
cool period and lower during the warm period, but the difference are not significant (p > 
0.05). However, there are around 35% (63 patients) of all patients that have contrasting 
results, where insulin is higher during the warm period, in contrast to the overall trend. 
 
Figure 6.2 presents the 12-hour block exogenous insulin by cohort (left panel) and median 
per-patient (right panel). Table 6.2 presents the summary of insulin infusion results based on 
12-hour blocks and Table 6.3 presents the decrease in median per-patient insulin infusion 
between successive blocks.   
  
 Per-Cohort  
 
Per-Patient 
 
Fig. 6.2:  Exogenous Insulin distribution per-cohort (left) and per-patient median (right) for OHCA patients, 
treated with hypothermia using 12 hour blocks of data. Blue colour represent cool period and red colour 
represent warm   
 
 
Table 6.2:  Summary of exogenous insulin results for OHCA cohort based on 12-hours 
block.   
 
 
Day Block Hours Range 
Per-Cohort 
Median Ex. Insulin 
[IQR] [U/hr] 
Per-Patient 
Median Ex. Insulin 
[IQR] [U/hr] 
1 1 
0 – 12 hours 3.02 1.70 
2 12 – 24 hours 2.45 1.40 
2 3 24 – 36 hours 3.20 1.20 
4 36 – 48 hours 2.70 1.19 
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The results and analyses from the Table 6.3 for both per-cohort and per-patient suggest that 
Ex. insulin infusion are initially high during the cool period and decreases over time for the 
first 2 days in the ICU. However, the decrease is not significant during these period, which 
suggest that the amount of exogenous insulin given to OHCA patients is not much difference 
between cool and warm. 
 
Table 6.3:   Decreasing cohort and per patient median insulin infusion during cool and warm 
(12-hour blocks of data) 
 
Ex. Insulin 
analysis 
Cohort analysis Per-patient analysis 
 [12-hr blocks] 
% Decrease at 
median 
p-value 
% Decrease at 
median 
p-value 
Block 1-2 (C)            
  (0 - 12 vs. 12 - 24 hr) 
18.6 0.07 17.9 0.5 
Block 2-3 (C-W)    
  (12 - 24 vs. 24 - 36 hr) 
-30.4 0.2 14.3 0.7 
Block 3-4 (W)        
(24 - 36 vs. 36 - 48 hr) 
15.9 0.6 0.3 0.7 
 P-values calculated using Wilcoxon rank-sum test   
  
 
Per-Cohort  
 
Per-Patient 
 
Fig. 6.3: Exogenous Insulin distribution per-cohort (left) and per-patient median (right) for OHCA patients, 
treated with hypothermia using 6 hour blocks of data.   
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Table 6.4:  Summary of Exogenous Insulin results for overall OHCA cohort based on 6-hour 
block.   
 
 
Day Block Hours Range 
Per-Cohort 
Median Ex. Insulin 
[IQR] [U/hr] 
Per-Patient 
Median Ex. Insulin 
[IQR] [U/hr] 
1 
1 0 – 6 hours 3.56 3.70 
2 6 – 12 hours 2.50 2.52 
3 12 – 18 hours 2.25 2.31 
4 18 – 24 hours 2.50 2.37 
2 
5 24 – 30 hours 2.55 2.46 
6 30 – 36 hours 2.62 2.70 
7 36 – 42 hours 2.00 2.00 
8 42 – 48 hours 2.00 2.00 
 
 
Table 6.5:   Decreasing cohort and per patient median Exogenous Insulin during cool and 
warm as per 6-hour blocks of data 
 
Ex. Insulin 
analysis 
Cohort analysis Per-patient analysis 
 [6-hr blocks] 
% Decrease at 
median 
p-value 
% Decrease at 
median 
p-value 
Block 1-2 (C)            
  (0 - 6 vs. 6 - 12 hr) 
29.8 0.2 31.2 0.2 
Block 2-3 (C)            
  (6 - 12 vs. 12 - 18 hr) 
10.0 0.4 8.5 0.4 
Block 3-4 (C)            
  (12 - 18 vs. 18 - 24 hr) 
-11.1 0.6 -2.6 0.9 
Block 4-5 (C-W)    
  (18 - 24 vs. 24 - 30 hr) 
-2.0 0.9 -3.8 0.6 
Block 5-6 (W)    
  (24 - 30 vs. 30 - 36 hr) 
-2.7 0.9 -9.8 0.5 
Block 6-7 (W)    
  (30 - 36 vs. 36 - 42 hr) 
23.7 0.8 25.9 0.5 
Block 7-8 (W)    
  (36 - 42 vs. 42 - 48 hr) 
0.0 0.8 0.0 0.9 
 P-values calculated using Wilcoxon rank-sum test   
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Figure 6.3 presents the 6-hour block exogenous insulin by cohort (left panel) and median per-
patient (right panel). Table 6.4 presents the summary of insulin results based on 6-hour block 
and Table 6.5 presents the decrease in median insulin between successive blocks. The results 
and evolution of exogenous insulin, both per-cohort and per-patient reveal that even though 
insulin infusions are initially high during the cool period and decrease over time, there is an 
increased of amount of insulin given between block 4 (18-24 hours) and block 6 (30-36 
hours) before it returns to decreasing over time in subsequent blocks. This increase occurs 
during the   transition from cool to warm and suggest that there is a unique evolution which 
demand for more exogenous insulin infusion during these time periods. Further analysis and 
comparison with other parameters, such as blood glucose and insulin sensitivity will be 
explained in Chapter 8. 
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6.3.2 Results for sub-cohorts 
 
Table 6.6 presents the summary of Ex. Insulin results and analysis for OHCA Sub-Cohorts. 
The summary shows that all OHCA sub-cohorts are consistent with the overall OHCA 
cohort. In general, analyzing the overall OHCA patients is sufficient even though the cohort 
consists of various different backgrounds. Importantly, the clinical outcome of ROSC sub-
cohort showed no difference in exogenous insulin delivered.     
 
Table 6.6:  Summary of Ex. Insulin results and analysis for OHCA Sub-Cohorts 
OHCA Sub-Cohort 
No of 
Patients 
Median Ex. 
Insulin [IQR] 
at cool period 
[U/hr] 
Median Ex. 
Insulin [IQR]  
at warm period 
[U/hr] 
% patients 
had higher 
Ex. Insulin at 
cool period  
[Diff(Cool-
warm)] 
p-value 
Overall OHCA cohort 180 1.8 [1.0, 3.3] 1.6 [0.9, 3.7] 65% 0.5 
Survived Patients 98 1.7 [1.0, 3.0] 1.4 [0.7, 3.1] 65% 0.3 
Non-Survived Patients 82 2.0 [1.0, 3.4] 1.4 [0.8, 2.9] 65% 0.3 
Diabetes Patients 23 1.9 [1.1, 3.2] 1.7 [0.9, 2.9] 40% 0.7 
Non-Diabetes Patients 157 1.7 [1.0, 3.0] 1.5 [0.8, 3.5] 70% 0.4 
Male Patients 143 1.9 [1.1, 3.3] 1.7 [0.9, 3.7] 60% 0.5 
Female Patients 37 1.6 [1.0, 2.7] 1.0 [0.6, 1.9] 70% 0.1 
ROSC < 15 mins 63 1.4 [0.9, 2.5] 1.0 [0.6, 2.6] 70% 0.4 
15 < ROSC < 30 mins 89 2.0 [1.0, 3.9] 1.4 [0.8, 3.3] 70% 0.4 
ROSC > 30 mins 28 2.5 [1.1, 5.0] 1.5 [0.8, 4.1] 70% 0.3 
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6.4   Results on Nutrition/ Dextrose Administration 
 
6.4.1 Results for complete cohort 
 
Figure 6.4 presents the cumulative distribution functions (CDFs) of hourly nutrition/ dextrose 
modulation for both cool and warm periods by cohort (left panel) and median hourly per-
patient (right panel) for all ICU patients.  Table 6.7 presents summary of nutrition results for 
overall OHCA cohort. These results show that the OHCA patients were given lower amounts 
of nutrition/dextrose during the cool period (at initial), and significantly (p < 0.05) increased 
over time during the first 2 days of treatment. However, there are around 35% (63 patients) of 
all patients that have contrasting results, where nutrition is higher during the cool period. 
 
Per-Cohort Analysis Per-Patient Analysis 
 
 
Fig. 6.4:  Nutrition/ dextrose level distribution by cohort (left) and per-patient median (right) during 
cool and warm periods for all ICU patients 
 
Table 6.7:  Summary of nutrition results for overall OHCA cohort.   
 
 
Day 
 
Period Hours Range 
Per-Cohort 
Median Nutrition 
[IQR] [g/hour] 
Per-Patient 
Median Nutrition 
[IQR] [g/hour] 
1 Cool 
 
0 – 24 hours 2.58 2.50 
2 Warm 
 
24 – 48 hours 3.72 3.23 
  p-value 
 
< 0.05 < 0.05 
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Figure 6.5 presents the 12-hour block nutrition/dextrose by cohort (left panel) and median 
per-patient (right panel). Table 6.8 presents the summary of nutrition/dextrose results based 
on 12-hours block and table 6.9 presents the decrease in median nutrition/dextrose between 
successive blocks.  The results and analyses show that nutrition/dextrose during the cool 
period (initially), and increased over time during the first 2 days of treatment. However, the 
increase is significant comparing the cool period to the warm period (Table 6.4). 
 
 
 
 Per-Cohort  
 
Per-Patient 
 
Fig. 6.5:  Nutrition/ dextrose distribution per-cohort (left) and per-patient median (right) for OHCA patients, 
treated with hypothermia using 12 hour blocks of data. Blue colour represent cool period and red colour 
represent warm   
 
 
Table 6.8:  Summary of nutrition results and analysis for overall OHCA cohort based on 12-
hours block.   
 
 
Day Block Hours Range 
Per-Cohort 
Median Nutrition 
[IQR] [g/hour] 
Per-Patient 
Median Nutrition 
[IQR] [g/hour] 
1 1 
0 – 12 hours 2.60 1.48 
2 12 – 24 hours 3.10 2.10 
2 3 24 – 36 hours 4.63 2.50 
4 36 – 48 hours 4.22 2.74 
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Table 6.9:   Decreasing cohort and per patient median nutrition during cool and warm (12-
hour blocks of data) 
 
Nutrition 
analysis 
Cohort analysis Per-patient analysis 
 [12-hr blocks] 
% Decrease at 
median 
p-value 
% Decrease at 
median 
p-value 
Block 1-2 (C)            
  (0 - 12 vs. 12 - 24 hr) 
-19.4 < 0.05 -41.5 < 0.05 
Block 2-3 (C-W)    
  (12 - 24 vs. 24 - 36 hr) 
-49.7 < 0.05 -19.1 < 0.05 
Block 3-4 (W)        
(24 - 36 vs. 36 - 48 hr) 
8.8 0.6 -9.6 0.8 
 P-values calculated using Wilcoxon rank-sum test   
  
Figure 6.6 presents the 6-hour block nutrition/dextrose by cohort (left panel) and median per-
patient (right panel). Table 6.10 presents the summary of nutrition/dextrose results based on 
6-hour block and Table 6.11 presents the decrease in median nutrition/dextrose between 
successive blocks.  The results reveal that even though nutrition/dextrose is initially low 
during the cool period and increases over time, right after the transition from cool to warm 
and specifically between block 5 (24-30 hours) and block 6 (30-36 hours), it decreases. Thus, 
the highest amount of nutrition/ dextrose given occurs during the warm period, right after 
transition from cool to warm and suggests that there is a unique evolution that demands more 
nutrient/dextrose during these time periods compared to a largely decreasing insulin trend in. 
  
Per-Cohort  
 
Per-Patient 
 
Fig. 6.6: Nutrition/ dextrose distribution per-cohort (left) and per-patient median (right) for OHCA patients, 
treated with hypothermia using 6 hour blocks of data.   
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Table 6.10:  Summary of nutrition/dextrose results and analysis for overall OHCA cohort 
based on 6-hours block.   
 
 
Day Block Hours Range 
Per-Cohort 
Median Nutrition 
[IQR] [U/hr] 
Per-Patient 
Median Nutrition 
[IQR] [U/hr] 
1 
1 0 – 6 hours 2.70 3.53 
2 6 – 12 hours 3.34 4.43 
3 12 – 18 hours 4.00 5.60 
4 18 – 24 hours 4.06 6.00 
2 
5 24 – 30 hours 6.00 7.23 
6 30 – 36 hours 6.00 7.09 
7 36 – 42 hours 5.09 6.80 
8 42 – 48 hours 5.00 6.66 
 
Table 6.11:   Decreasing cohort and per patient median nutrition/dextrose during cool and 
warm as per 6-hour blocks of data 
 
Nutrition 
analysis 
Cohort analysis Per-patient analysis 
 [6-hr blocks] 
% Decrease at 
median 
p-value 
% Decrease at 
median 
p-value 
Block 1-2 (C)            
  (0 - 6 vs. 6 - 12 hr) 
-24.0 < 0.05 -25.3 < 0.05 
Block 2-3 (C)            
  (6 - 12 vs. 12 - 18 hr) 
-19.3 < 0.05 -26.4 < 0.05 
Block 3-4 (C)            
  (12 - 18 vs. 18 - 24 hr) 
-1.9 < 0.05 -7.3 < 0.05 
Block 4-5 (C-W)    
  (18 - 24 vs. 24 - 30 hr) 
-47.9 < 0.05 -20.5 < 0.05 
Block 5-6 (W)    
  (24 - 30 vs. 30 - 36 hr) 
0.1 0.5 2.0 0.5 
Block 6-7 (W)    
  (30 - 36 vs. 36 - 42 hr) 
15.2 0.8 4.2 0.9 
Block 7-8 (W)    
  (36 - 42 vs. 42 - 48 hr) 
1.8 0.9 1.9 0.7 
 P-values calculated using Wilcoxon rank-sum test   
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6.4.2 Results for sub-cohorts 
 
Table 6.13 presents the summary of nutrition/dextrose results and analysis for OHCA Sub-
Cohorts. The summary shows that results and analysis among all OHCA sub-cohorts are 
consistent with overall OHCA cohort. Most of the sub-cohorts had significant increase in 
nutrition intake from cool to warm, except sub-cohorts where 15 < ROSC < 30 mins, and 
ROSC > 30 mins.     
 
  
Table 6.12:  Summary of nutrition/dextrose results for OHCA Sub-Cohorts 
OHCA Sub-Cohort 
No of 
Patients 
Median 
Nutrition 
[IQR] in cool 
period 
[g/hour] 
Median 
Nutrition 
[IQR]  in 
warm period 
[g/hour] 
% patients 
had higher 
Nutrition in 
cool period  
[Diff(Cool-
warm)] 
p-value 
Overall OHCA cohort 180 2.5 [0.8, 3.5] 3.2 [1.6, 5.3] 30% < 0.05 
Survived Patients 98 2.6 [0.9, 3.9] 3.2 [1.6, 5.0] 30% < 0.05 
Non-Survived Patients 82 2.1 [0.9, 3.4] 3.0 [2.0, 4.8] 30% < 0.05 
Diabetes Patients 23 2.1 [1.0, 4.2] 4.2 [2.0, 6.2] 15% < 0.05 
Non-Diabetes Patients 157 2.1 [0.8, 3.5] 3.0 [1.6, 5.1] 35% < 0.05 
Male Patients 143 2.5 [1.0, 3.5] 3.1 [1.5, 5.1] 35% < 0.05 
Female Patients 37 2.1 [0.7, 3.2] 3.7 [2.0, 5.7] 25% < 0.05 
ROSC < 15 mins 63 2.5 [0.9, 4.1] 4.2 [2.2, 5.9] 30% < 0.05 
15 < ROSC < 30 mins 89 2.5 [1.1, 3.3] 2.7 [1.4, 4.8] 30% 0.2 
ROSC > 30 mins 28 2.1 [1.3, 3.5] 2.2 [0.5, 4.1] 40% 0.7 
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6.5   Discussion 
 
6.5.1       Exogenous Insulin and Nutrition Modulation during cool and warm 
 
This studies show that upon admission into ICU, OHCA patients treated with hypothermia 
received more exogenous insulin during the cool period and that these infusions decrease 
over time as does hyperglycaemia, as seen in Chapter 5. However, similar cohort were given 
small amount of nutrition / bolus at initial treatment and increased significantly over time 
during hypothermia.  
 
During the warm period, it is obvious that the OHCA patients had received more exogenous 
insulin and nutrient for the first 12 hours of warm period before decreasing the amount at the 
consequent blocks. The increased amount of insulin and nutrient given between block 5 (24 – 
30 hours) and block 6 (30 – 36 hours) is likely due to slight increase in BG level and 
variability during these periods which lead to physiological stress. These results are 
consistent with BG level results as shown in Chapter 5. 
  
6.5.2       The effect of Insulin and Nutrition Control Approach 
  
Previous studies have proved that modulating nutritional rates in addition to insulin can 
achieve very tight control, more successfully than using insulin alone (Chase et al., 2006a). 
For example, van den Berghe et al (van den Berghe et al., 2001) used an average of ~3U/hr 
during trials. Additionally, modulating nutrition also provides a potentially safer method for 
highly critical ill patients (Van den Berghe et al., 2006a). More specifically, as patient 
condition evolves, feed reductions allow less insulin to be used for the same or greater  
glycaemic  reduction,  avoiding  saturation  and/or  sudden  changes  in  glycaemic  level  due  
to excessive insulin. 
  
In  this  study,  dynamic  increases  and  reductions  in  enteral  glucose  administration  rates  
were  used  to assist glycaemic control during cool and warm periods. In fact, the high blood 
glucose level at the beginning of cool period would demand more insulin infusion required at 
initial before decreases over time, thus implies a reasonable decay of glucose appearance in 
the bloodstream. In contrast, the nutritional feed increase from the beginning until cool-warm 
transition period would indicate the patients’ metabolic/ energy demand, following the 
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increase in body temperature from cool to warm. However, as glucose drops are relatively 
slow, but sudden low glycaemic levels can be raised relatively rapidly by increasing the feed 
rate, special care in nutritional feed is required since the patient is still experiencing 
hyperglycaemia and had low metabolic activities during cool period, but needs some glucose 
to rewarm his/ her body. 
  
Overall, this approach of modulating nutrition in addition to exogenous insulin is a significant 
method from other approaches in this field, which use insulin alone. It is supported by recent 
studies that low-calorie (or low dextrose) nutritional inputs reduce hyperglycaemia (Ahrens et 
al., 2005, Dickerson, 2005, McCowen et al., 2000, Patino et al., 1999) and above ~30%  of  
standard  goal  feed  rates  do  not  increase  infectious  complications (Krishnan et al., 2003, 
Rubinson et al., 2004). However, it should be noted that insulin plays multiple roles that are 
both metabolic and non-metabolic. As a result, an insulin plus nutrition approach as presented 
here may have a lesser effect on mortality in a longer randomized trial due to using reduced 
levels of insulin (van den Berghe et al., 2001, Van den Berghe et al., 2006a). 
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6.6   Summary 
 
This study analyses the impact of exogenous insulin and nutrition modulation during 
therapeutic hypothermia (TH) on glycaemia outcome. There are three (3) main results from 
this analysis. 
 
1. Glycemic control during hypothermia and rewarming has achieved by modulating 
dextrose more than exogenous insulin, thus matches results seen in SPRINT control (Chase et 
al., 2008b) . 
  
2.  Some patient sub-cohorts saw major increases in nutrition from cool to warm such as 
diabetes and ROSC < 15 min. Since the significant increase in nutrition occurs while insulin 
modulation is steadily consistent. This shows that patients with diabetes or ROSC < 15 sub-
cohorts are likely to experience major stress hyperglycemia than other sub-cohorts, thus need 
further research. 
 
3. In view of control implications, both exogenous insulin and nutrition show major 
increase at transition (18 – 30 hours) while nutrition delayed or maintain doses for another 6 
hours after transition, thus falls steadily by blocks. 
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Chapter 7: Stochastic Insulin Sensitivity Modelling Analysis 
 
 
 
This chapter presents the adaptation of a stochastic model for SI prediction from adult critical 
care to the unique clinical and physiological case of the OHCA patients, treated with 
hypothermia. Clinically validated, model-based insulin sensitivity (SI) (Chase et al., 2010, 
Evans et al., 2011)  is used to provide a more accurate measure of patient metabolic state and 
its stochastic modelling during cool and warm periods. Modifications to the initial kernel 
density estimation model are made to explore and optimise the relationship between model 
accuracy in predicting ranges of SI variability and the underlying clinical data and dataset. 
Patient data was analysed for the cohort and sub-cohorts defined in Chapter 3, and results 
were summarized.   
 
7.1 Introduction 
 
Model-based glycaemic control methods using both insulin and/or nutrition modulation have 
been employed successfully in the control of hyperglycaemia, as reviewed by Chase et al. 
(Chase et al., 2006b). These methods allow the derivation of patient metabolic state, SI in this 
case, by using serial blood glucose (BG) measurements, and records of nutrition and insulin 
administration (Chase et al., 2007b). Once the current SI has been identified, prediction of 
future SI would allow predictions of outcome BG concentration for an intended insulin and 
nutrition intervention.  
 
Variations in the SI parameter reflect the metabolic response to stress (McCowen et al., 2001) 
and drug therapy (Pretty et al., 2011). Thus, tracking and forecasting this parameter is 
important to provide safe glycaemic control in highly dynamic Out-of-Hospital Cardiac 
Arrest (OHCA) patients, treated with hypothermia. Since stochastic modelling has shown its 
ability to quantify the probability of a future SI  (Lin et al., 2008), the resulting distribution of 
BG concentrations that would result from a given intervention can be determined (Lin et al., 
2008, Le Compte et al., 2010, Evans et al., 2011, Fisk et al., 2012). This information can be 
used to guide both insulin and/or nutrition interventions, which is the key to avoid unintended 
hypoglycaemia, improve overall glycaemic control, and identify periods of potential high 
glucose variability that may be indicative of unusual clinical events (Thomas et al., 2014). 
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7.2 Subjects and Methods 
 
7.2.1  Patients and Data  
 
This analysis was performed on a same ICU cohort of 180 OHCA patients (7812 hours) 
treated with hypothermia from Erasme Hospital, Belgium and Lausanne Hospital, 
Switzerland as per explained in Section 3.1. A summary of the full cohort and sub-cohorts is 
presented in the Table 4.1.   
 
7.2.2  Analyses and Metrics  
 
 Stochastic model of insulin sensitivity will be analysed as follows: 
i)  Overall cohort patient. 
ii)  Analysis of patient by 12-hour block. 
iii)  Analysis of patient by 6-hour block.  
 
Overall cohort analysis assessed the stochastic model behaviour of insulin sensitivity during 
both cool and warm, which includes percentage of SI and BG within prediction interval and 
analysis of modifying kernel density estimation. 
 
The stochastic model of SI using 12-hour and 6-hour blocks is described in the Table 4.1. 
This method will examine stochastic model group behaviour and assess its changes for every 
12 and 6 hour blocks of the entire treatment from cool to warm periods. The analysis includes 
percentage of SI and BG within prediction interval and analysis of modifying kernel density 
estimation.  
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7.2.3 The Stochastic Model 
 
A 2-D kernel density estimation method is used to construct the stochastic model that 
describes the hourly transition of SI. The kernel density method combines probability 
distribution functions for each point of data to generate an overall density function for the 
dataset. This method has the advantage of producing a smooth, physiologically likely, 
continuous function across the parameter range to provide continuity when interpolating SI 
forecasts to account for each particular patient state. It also automatically accounts for any 
possible multimodality where the density of data may show several distinct peaks 
corresponding to patterns of changes in SI. The overall result is a bivariate probability density 
function for the potential parameter values.  
 
The goal of this statistical model is to quantify the range of SI one or more hours ahead in 
time (SI,n+1) based on available data (SI, n , SI ,n − 1 , SI ,n − 2 , . . ., SI ,0) to guide real-time clinical 
control (Evans et al., 2011, Lin et al., 2011, Thomas et al., 2014). Thus, it is important that 
the model is also cohort-specific as possible for greatest accuracy.  
 
A 2-D kernel density method is chosen because the distribution of SI, n+1 varies with SI, n, and 
cannot be simply described with a single standard statistical distribution (Lin et al., 2008). 
Thus, variations in SI can be treated as a Markov process. A Markov process has the property 
that the conditional probability density function of future states of the process, given the 
current state, depends only upon the current state. Therefore, using the Markov property of 
the stochastic behaviour of SI, the conditional probability density of SI ,n+1 taking on a value y 
can be calculated by knowing SI ,n = x. Model equations and its derivations were defined in 
(Lin et al., 2006, Lin et al., 2008). 
 
𝑃(𝑆𝐼,𝑛+1 = 𝑦|𝑆𝐼,𝑛 = 𝑥) =
𝑃(𝑆𝐼,𝑛 = 𝑥, 𝑆𝐼,𝑛+1𝑦)
𝑃(𝑆𝐼,𝑛 = 𝑥)
 
(7.1) 
 
Considering the fitted SI in a 2-D space. (𝑆𝐼,𝑛 𝑆𝐼,𝑛+1 ), the joint probability density function 
across the x–y (SI, n – SI, n+1) plane is defined by the fitted values shown by the dots, whose 
coordinates are denoted by xi and yi : 
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P(x, y) =    
1
𝑛
 ∑
𝜑 (𝑥;  𝑥𝑖, 𝜎𝑥𝑖 
2 )
𝑃𝑥𝑖
𝑛
𝑖=1
 
𝜑(𝑦; 𝑦𝑖, 𝜎𝑦𝑖
2    )
𝑃𝑦𝑖
 
 
(7.2) 
where: 
 
𝑃𝑥𝑖  =   ∫ 𝜑(𝑥; 𝑥𝑖, 𝜎𝑥𝑖
2
𝑆𝐼,𝑢𝑝𝑝𝑒𝑟
𝑆𝐼,𝑙𝑜𝑤𝑒𝑟
 ) 𝑑𝑥     
 
 
 
(7.3) 
 
𝑃𝑦𝑖  =   ∫ 𝜑(𝑦; 𝑦𝑖, 𝜎𝑦𝑖
2
𝑆𝐼,𝑢𝑝𝑝𝑒𝑟
𝑆𝐼,𝑙𝑜𝑤𝑒𝑟
 ) 𝑑𝑦    
 
 
(7.4) 
 
Effectively, the joint 2-D probability density function is the normalized summation of normal 
probability density functions 𝜑(𝑥; 𝑥𝑖 , 𝜎𝑥𝑖
2  )  centered at each individual data point. It thus 
turns discrete data into a smooth analytically defined function. 
 
In Equations (7.2)–(7.4), the variance 𝜎 at each data point is a function of the local data 
density in a centred and orthonormalised space of x and y. Putting Equations (7.3) and (7.4) 
into Equation (7.2) normalises each 𝜑(𝑥; 𝑥𝑖 , 𝜎𝑥𝑖
2  ) and 𝜑(𝑥; 𝑥𝑖 , 𝜎𝑥𝑖
2  ) in the positive domain, 
effectively putting boundaries along 𝑥 = 𝑆𝐼,𝑙𝑜𝑤𝑒𝑟 and 𝑦 = 𝑆𝐼,𝑢𝑝𝑝𝑒𝑟, and enforcing the 
physiological validity of the SI values.  
 
In Equation (7.1), the right hand side denominator can be calculated by integrating Equation 
(7.2) with respect to y. Hence, Equation (7.1) can be calculated: 
 
P(𝑆𝐼,𝑛+1  =  y | 𝑆𝐼,𝑛 =  x)  =  ∑ 𝜔𝑖(𝑥)
𝑛
𝑖=1
𝜑(𝑦; 𝑦𝑖, 𝜎𝑦𝑖
2  )
𝑃𝑦𝑖
 
 
 
 
(7.5) 
where: 
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𝜔𝑖(𝑥) =  
𝜑 (𝑥;  𝑥𝑖, 𝜎𝑥𝑖 
2 )
𝑃𝑥𝑖
⁄
 ∑
𝜑 (𝑥;  𝑥𝑗, 𝜎𝑥𝑗 
2 )
𝑃𝑥𝑗
⁄𝑛𝑗=1
 
 
(7.6) 
Thus, knowing SI, n = x at hour n, the probability of SI, n+1 = y at hour (n+1) can be calculated 
using Equations (7.5) and (7.6) across the x–y plane. Where there is a higher density of data, 
more certainty can be drawn on the “true” behavioural pattern. 
 
In conclusion, Equations (7.5) and (7.6) define the 2-dimensional kernel density estimation in 
conditional SI variability. Note that SIn+1 variability is “conditional” because it depends on the 
prior state SIn. More specifically, knowing SI at any hour n, SIn = x, the probability of SI at 
hour n + 1, SIn+1 = y, can be calculated from Equation (7.5). 
 
In summary, the 2-dimensional kernel density estimation method creates a smooth, 
continuous model surface that reflects the sample data pattern. Note that the example shown 
is the “conditional” 2-dimensional kernel density estimate function as defined in Equation 
(7.5). Every slice of the surface in panel C along the y axis is the probability distribution in y 
(SIn+1) given x (SIn), and therefore its area under the curve along the y axis sums to 1.0. In 
comparison, the kernel density estimation joint probability function defined in Equation (7.2) 
has the volume under the 3-D surface equal to 1.0. The final 3-D SI stochastic model is thus 
developed and shown in Figure 7.2 for the data set used for this study. 
 
Based on results from in-sample tests, where the stochastic model is generated from the entire 
retrospective dataset and tested on the same data, and out-of-sample tests, where different 
subsets of data are used for model generation and testing, the kernel density estimator was 
modified by multiplying the variance estimators by a constant c (i.e., cσx and cσy) to explore 
the model probability bound determination for this data. This adjustment to the variance 
estimator effectively adjusts the kernel bandwidth and the degree of smoothing over the data. 
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7.3 Stochastic Analysis by Overall Cohort 
 
7.3.1    Hourly Insulin Sensitivity Variation in OHCA Patients 
  
Figure 7.1 presents the distribution of hourly variation in SI for the 180 OHCA patients 
during cool (4987 hours) and warm (5001 hours) periods. Approximately 85% of the values 
during cool period, and 70% during warm period are below 1.0 x 10
-3
 L/(mU.min). The 
results show that the hourly variation of SI is wider during cool period, but there are higher SI 
values in the warm period. 
 
Cool  Warm 
  
Fig. 7.1:   Distribution of hourly variation in SI for OHCA patients, treated with hypothermia during cool (left) 
and warm (right) periods as presented in 2-D kernel density method. 
 
 
7.3.2 Conditional Probability Density Function 
 
Figure 7.2 presents the conditional probability density plot for the stochastic model described 
in Section 7.2.3. These 3-D plots indicate the overall cohort variations in SI at the x-y plane 
and the conditional probability density of SI,n+1 at the z-plane. The results show that the 
conditional probability density p[SI(n+1)|SI(n)] at the value SI < 1.0 x 10
-3
 during the cool period 
is wider than during the warm period.   
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Cool  Warm 
 
 
Fig. 7.2:   Conditional probability density function SI, n+1 knowing SI, n  for OHCA patients, treated with 
hypothermia during cool (left) and warm (right) periods. The structure of the plot is unimodal in the region S I, n 
< 1.0 x 10
-3
 and SI, n+1 < 1.0 x 10
-3
, corresponding to the region of dataset density. 
 
Figure 7.3 presents the 5
th
, 25
th
, 50
th
, 75
th
, and 95
th
 percentile probability bounds calculated 
for both cool and warm periods by integrating the conditional probability density function in 
Figure 7.2, including the distributing points. In return, the forecasted BG values are 
calculated based on an equal-tailed 0.9 probability interval of SI (i.e. BGn+1 = [f(SI95), f(SI5)]) 
(Lin et al., 2006). 
 
Cool  Warm 
  
Fig. 7.3:   Probability interval and distribution of hourly variation in SI for OHCA patients, treated with 
hypothermia during cool (left) and warm (right) periods.   
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7.3.3 Stochastic Model Prediction Width 
 
Table 7.1 shows the in-sample results of stochastic model prediction widths for both cool 
(ncool = 4622 predictions) and warm (nwarm = 4832 predictions) periods at c=1. The number of 
predictions is less than the total hours of SI as the patient data records are not always evenly 
divisible by 1h, and predictions can only be computed after the second hour of patient data.  
 
Table 7.1: Sample results for stochastic model prediction widths at c= 1 
Variable 
Prediction width / 
Range 
Value 
Cool Warm 
% SI within prediction 
interval 
[25
th
 – 75th ] 60.7 % 62.8 % 
[5
th
 – 95th ] 90.2 % 92.1 % 
% BG within prediction 
interval 
[25
th
 – 75th ] 59.4 % 62.1 % 
[5
th
 – 95th ] 92.6 % 92.8 % 
BG prediction interval width 
[25
th
 – 75th ] 2.8  mmol/L 1.9 mmol/L 
[5
th
 – 95th ] 8.0 mmol/L 5.4 mmol/L 
Median absolute percent BG point prediction error 5.5 % 5.0 % 
Median absolute BG point prediction error 0.4 mmol/L 0.35 mmol/L 
Data are presented as cohort median (ncool = 4622 predictions and nwarm = 4832 predictions) 
 
For the cool period, SI predictions (60.7%) were within the (25th–75th) probability intervals, 
corresponding to 59.4% of BG predictions. Similarly, 90.2% of SI predictions were within the 
(5th–95th) probability intervals, corresponding to 92.6% of BG predictions. Thus, the 
proportion of fitted SI and predicted BG values that fell within the (25th–75th) probability 
intervals were measurably higher than the expected 50%, but approximately closer to 90% for 
the (5th–95th) probability intervals. The overall median absolute prediction error comparing 
predicted BG based on the 50th percentile of predicted SI to the interpolated value from 
retrospective data is 5.5%, corresponding to an average BG error of 0.4 mmol/L. The width 
of the (25th–75th) BG probability interval is 2.8 mmol/L. Similarly, the (5th–95th) BG 
probability interval width is 8.0 mmol/L. 
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For the warm period, the median absolute percentage BG point prediction error comparing 
predicted BG based on the 50th percentile of predicted SI to the interpolated value from 
retrospective data is 5.0%, corresponding to an average BG error of 0.35 mmol/L. The width 
of the (25th–75th) BG probability interval is 1.9 mmol/L and the (5th–95th) BG probability 
interval width is 5.4 mmol/L. SI predictions of 62.8% were within the (25th–75th) probability 
intervals, corresponding to 62.1% of BG predictions. Similarly, 92.1% of SI predictions were 
within the (5th–95th) probability intervals, corresponding to 92.8% of BG predictions.  Thus, 
the proportion of fitted SI and predicted BG values that fell within the (25th–75th) were 
measurably higher than expected 50% but closer to the expected 90% within (5th–95th) 
probability intervals. 
 
7.3.4 Cross-Validation Comparison Studies 
 
Table 7.2 and 7.3 shows the results of the cross validation comparison study for 180 patients’ 
cohort during cool and warm respectively. Generally, these results are consistent between 
groups, suggesting that the overall model contains sufficient data to account for the range of 
dynamics observed in this cohort.    
 
Table 7.2: Cross-validation comparison study for 180 patient cohort (Cool period) 
Group 
[Cool] 
Groups 
used to 
create 
model 
% SI within interval % BG within 
interval 
BG interval width 
(mmol/L) 
BG point 
prediction 
error (%) 
BG point 
prediction 
error 
(mmol/L) 
[25th -75th] [5th- 95th] [25th-75th] [5th- 95th] [25th-75th] [5th- 95th] 
1 [-,2,3,4,5] 60.1 90.5 48.4 87.6 2.5 7.4 15.0 1.1 
2 [1,-,3,4,5] 61.2 90.0 49.5 89.7 2.5 7.6 9.5 0.65 
3 [1,2,-,4,5] 61.9 90.8 57.8 94.1 2.8 8.0 4.0 0.3 
4 [1,2,3,-,5] 61.9 90.8 59.6 95.6 2.9 8.5 4.0 0.3 
5 [1,2,3,4,-] 62.6 90.7 58.8 94.5 3.1 8.7 3.5 0.3 
Overall [1,2,3,4,5] 60.7 90.2 59.4 92.6 2.8 8.0 5.5 0.4 
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Table 7.3: Cross-validation comparison study for 180 patient cohort (Warm period) 
Group 
[Warm] 
Groups 
used to 
create 
model 
% SI within interval % BG within 
interval 
BG interval width 
(mmol/L) 
BG point 
prediction 
error (%) 
BG point 
prediction 
error 
(mmol/L) 
[25th -75th] [5th- 95th] [25th-75th] [5th- 95th] [25th-75th] [5th- 95th] 
1 [-,2,3,4,5] 64.1 92.3 62.5 93.1 1.7 5.2 12.5 1.0 
2 [1,-,3,4,5] 64.0 92.6 62.7 92.9 1.7 4.6 7.0 0.5 
3 [1,2,-,4,5] 61.7 91.8 61.7 92.9 1.9 5.7 4.5 0.3 
4 [1,2,3,-,5] 63.1 92.7 61.9 92.9 1.9 5.5 4.5 0.3 
5 [1,2,3,4,-] 63.8 92.8 64.0 93.4 2.0 5.7 4.0 0.3 
Overall [1,2,3,4,5] 62.8 92.1 62.1 92.8 1.9 5.4 5.0 0.35 
 
7.3.5 Probability Bound-Determination 
 
Table 7.4 shows the effect of modifying the kernel density estimation for several values of c, 
ranging from 0.1 to 3.0 for the stochastic model derived from OHCA retrospective data. For 
this cohort, the increase of c values higher than 1.0, yield better coverage widths that contain 
numbers closer to the approximately expected proportion of original sample data values. 
Thus for cool period, the value c=1.0 enables SI probability values to provide equivalent BG 
optimal coverage in the (25th–75th) intervals with 60.7% and 59.4% and in the (5th–95th) 
intervals with 90.2% and 92.6% respectively. Similarly, for warm period, the value c=3.0 will 
ensure SI probability values to provide equivalent BG optimal coverage in the (25th–75th) 
intervals with 64.9% and 59.8% and in the (5th–95th) intervals with 91.5% and 91.1% 
respectively.   
 
Table 7.4: Comparison of probability bounds for modifications of kernel density estimator 
(σ`x = cσx AND σ`y = cσy) during both cool and warm periods.  
 
 
C 
  
 Cool Period Warm Period 
% of SI within 
probability bounds 
% of BG within 
prediction bounds 
% of SI within 
probability bounds 
% of BG within 
prediction bounds 
[25th-75th] [5th-95th] [25th-75th] [5th-95th] [25th-75th] [5th-95th] [25th-75th] [5th-95th] 
0.1 49.3 87.8 49.4 89.3 45.5 83.7 40.7 80.5 
0.2 50.2 88.4 50.3 87.7 48.2 84.4 42.4 80.8 
0.3 51.1 88.5 51.2 90.3 50.4 85.2 44.0 80.8 
0.5 53.5 88.6 53.4 91.1 52.2 85.9 47.7 81.1 
1.0 60.7 90.2 59.4 92.6 55.8 87.1 49.1 82.8 
1.5 66.2 91.3 65.3 94.5 58.0 88.9 51.2 84.5 
2.0 69.6 92.1 70.1 96.4 60.4 90.1 53.2 87.1 
2.5 72.2 92.7 74.3 97.5 62.8 91.2 57.3 89.3 
3.0 74.0 93.4 77.6 98.3 64.9 91.5 59.8 91.1 
Ideal 50% 90% 50% 90% 50% 90% 50% 90% 
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 Results in Table 7.4 at c=1.0 during cool period and c=3.0 during warm period are further 
reflected in Figure 7.4 which shows the probability-bound determination for raw SI data and 
its corresponding BG forecasted values based on an equal-tailed 0.90 SI probability interval. 
 
 COOL PERIOD 
Given kernel density estimator c = 1.0 
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Fig. 7.4:    Probability-bound determination for raw SI data and corresponding BG forecasted values based on an 
equal-tailed 0.90 probability interval of SI between 5
th
 -95
th
 at local variance estimator, both cool ( c=1.0) and 
warm (c=3.0) period. The solid lines represent the 5%, 25%, 50%, 75% and 95% probability bounds.    
 
The difference of optimal c values between cool and warm suggests that the variation and 
stochastic modelling for both periods are different, leading to different control requirements 
to ensure safe glycaemic control in the highly dynamic conditions. In particular, c=1.0 could 
be suitable during cool period since the SI data is more dense at lower percentiles, but at high 
115 
 
variation. However, at warm conditions, the stochastic model shows higher probability 
distribution coverage of SI variations, which usually occur when SI data distribution is wider, 
less variable and closer to ideal percentage within bounds. Thus, c=3.0 would be a better 
level of stochastic control for this cohort during warm period. 
 
 
 
Fig. 7.5:  Simulated trial using model-based control with stochastic model forecasts. The top plot shows the 
comparison between blood glucose concentration under simulated control (blue line) and retrospective control 
(red line). The middle plot shows model-fitted SI (green line) and the bottom plot shows administration of 
insulin during simulated control (pink line) compared to retrospective control (blue line). The yellow shaded 
areas in the top and middle plots show the 5
th
-95
th
 percentile of forecasted BG and SI respectively. 
 
Figure 7.5 shows a simulated trial results for individual OHCA patient, demonstrating the 
combination of Intensive Control Insulin-Nutrition Glucose (ICING) system model and the 
stochastic model, specifically the model forecasts for the 5
th
 and 95
th
 percentiles of future SI. 
These values are substituted into equation (2.32), and systems of equations are solved over 
the forecast interval to generate the series of future BG based on variability in SI. The result 
of forecasted BG is compared to the interpolated value from retrospective or clinical data to 
determine model forecast performance. 
 Cool period  Warm period  Idle period between cool and warm 
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7.4 Stochastic Analysis by 12-hours Block 
 
7.4.1 Stochastic Model Prediction Width 
 
Table 7.5 shows the in-sample results of stochastic model prediction widths based on 12 
block hours analysis at c=1. 
 
Table 7.5: Stochastic model prediction widths at c= 1 based on 12-block analysis 
Variable 
Prediction 
width / 
Range 
Cool Warm 
Block 1     
[0-12 hrs] 
Block 2        
[12-24 hrs] 
Block 3     
[24-36 hrs] 
Block 4     
[36-48 hrs] 
% SI within prediction 
interval 
[25
th
 – 75th ] 58.7 55.1 52.7 50.7 
[5
th
 – 95th ] 90.4 88.1 87.7 86.7 
% BG within prediction 
interval 
[25
th
 – 75th ] 51.5 50.7 48.1 46.6 
[5
th
 – 95th ] 91.2 88.2 85.1 84.7 
BG prediction interval 
width (mmol/L) 
[25
th
 – 75th ] 3.5 2.1 2.0 1.8 
[5
th
 – 95th ] 9.8 5.9 5.7 4.9 
Median absolute percent BG point 
prediction error (%) 
4.5 6.5 4.5 6.0 
Median absolute BG point prediction 
error (mmol/L) 
0.35 0.4 0.3 0.4 
  
Generally, SI and BG prediction interval coverage meets the prediction expectation despite 
exceeding its ideal values of 50% and 90% for both (25
th
 – 75th) and (5th-95th) interval width 
respectively. To improve the percentage optimization of prediction internal coverage, it is 
suggested that the stochastic model uses smaller values of local variance estimator for each 
time block. BG probability interval width for both (25
th
 – 75th) and (5th-95th) is wider at block 
1, and subsequently decreased for the remaining blocks. The median 1-h absolute BG 
prediction error, comparing predicted BG based on the median of predicted SI to the 
interpolated value from retrospective data is ranged between 4.5 – 6.5 %, corresponding to an 
average BG errors of 0.3 – 0.4 mmol/L. Thus, the proportion of fitted SI and predicted BG 
values that fell within the (25
th
 – 75th) and (5th – 95th) probability intervals for 12-hour block 
analysis were measured higher than the expected 50% and 90%. 
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7.4.2 Probability Bound-Determination 
 
Table 7.6 shows the effect of modifying the kernel density estimation for several values of c, 
ranging from 0.1 to 3.0 based on 12-hour block analysis. For this cohort, the increase of c 
values higher than 1.0, yield better coverage widths to the approximately expected proportion 
of original sample with highly variable data values. In contrast, lower values of c provides 
better coverage widths for original sample with less variable data values, especially at higher 
values of SI where data are less dense. Besides, the modification of the kernel bandwidth will 
also affect the subsequent degree of smoothing, where the probability distribution becomes 
less smooth due to smaller c (c < 1.0). 
 
To improve the percentage optimization of prediction internal coverage, this analysis 
suggested that the stochastic model uses bigger values of local variance estimator (c > 1.0), 
for each time block. The results has shown that for block 1, c=1.0 and followed by block 2 
(c=1.5), and block 3 and 4 (c=2.0 and 2.5). The trend shows the value of estimator, c is 
increasing as SI increases from cool to warm. The difference of optimal c values between 12-
hour blocks suggests that the variation and stochastic modelling for each time block is 
different, leading to different control requirements to ensure safe glycaemic control in the 
highly dynamic conditions. 
 
Table 7.6: Comparison of probability bounds for modifications of kernel density estimator 
(σ`x = cσx AND σ`y = cσy) based on 12-hour block analysis 
 
 
c 
  
 Cool Period Warm Period 
% of SI within  
probability bounds 
at Block 1  
[0 – 12] hours 
% of SI within 
probability bounds 
at Block 2  
[12 – 24] hours 
% of SI within  
probability bounds 
at Block 3  
[24 – 36] hours 
% of SI within  
probability bounds 
at Block 4  
[36 – 48] hours 
[25th-75th] [5th-95th] [25th-75th] [5th-95th] [25th-75th] [5th-95th] [25th-75th] [5th-95th] 
0.1 51.6 88.9 47.5 85.8 45.4 83.8 44.4 81.9 
0.2 51.4 89.3 47.7 86.2 47.1 84.1 45.3 83.2 
0.3 51.7 89.5 49.1 86.8 49.9  84.4 47.0 84.6 
0.5 53.1 89.7 52.1 87.3 51.1 86.2 48.6 85.3 
1.0 58.7 90.4 55.1 88.1 52.7 87.7 50.7 86.7 
1.5 62.7 91.0 58.4 90.0 54.9 89.2 51.5 87.4 
2.0 65.6 91.5 62.7 90.5 56.0 90.4 53.1                              89.0
2.5 67.3 92.3 64.3 91.4 59.2 92.2 54.7 90.4 
3.0 68.0 92.8 66.2 91.9 63.1 93.3 57.5 92.7 
Ideal 50% 90% 50% 90% 50% 90% 50% 90% 
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7.5 Stochastic Analysis by 6-hour Block 
 
7.5.1 Stochastic Model Prediction Width 
 
In addition to 12-hour block analysis, further stochastic analysis by 6-hour block is carried 
out in similar method to analyse SI variation and forecasting evolution for this cohort in more 
details. Table 7.7 presents the in-sample results of stochastic model prediction widths based 
on 6 hour block analysis at c=1. 
 
Table 7.7: Stochastic model prediction widths at c= 1 based on 6-hour block analysis 
Variable 
Predicti
on width 
/ Range 
Cool Warm 
Block 1     
[0-6 hrs] 
Block 2        
[6-12 
hrs] 
Block 3     
[12-18 
hrs] 
Block 4     
[18-24 
hrs] 
Block 5     
[24-30 
hrs] 
Block 6     
[30-36 
hrs] 
Block 7     
[36-42 
hrs] 
Block 8    
[42-48 
hrs] 
% SI within 
prediction 
interval 
[25
th
 – 
75
th
 ] 
58.7 57.2 56.9 55.5 51.9 52.1 52.6 52.6 
[5
th
 –  
95
th
 ] 
90.4 89.5 89.0 87.3 87.2 88.2 88.3 87.7 
% BG within 
prediction 
interval 
[25
th
 – 
75
th
 ] 
52.4 51.5 50.3 49.2 47.2 46.8 47.1 47.3 
[5
th
 –  
95
th
 ] 
91.1 89.0 88.2 86.5 84.7 83.2 83.5 83.3 
BG prediction 
interval width 
[25
th
 – 
75
th
 ] 
4.2 2.7 2.2 2.1 2.0 1.9 1.9 1.7 
[5
th
 –  
95
th
 ] 
10.9 7.3 6.1 5.9 5.2 6.4 5.4 4.5 
Median absolute percent 
BG point prediction error 
2.5 6.5 4.5 7.0 4.0 5.5 4.5 5.5 
Median absolute BG point 
prediction error (mmol/L) 
0.2 0.4 0.3 0.45 0.25 0.4 0.35 0.35 
  
The results show that SI and BG prediction interval coverage meets the prediction expectation 
despite exceeding its ideal values of 50% and 90% for both (25
th
 – 75th) and (5th-95th) interval 
width respectively. BG probability interval width for both (25
th
 – 75th) and (5th-95th) is wider 
at block 1, and subsequently decreased for the remaining blocks, except block 6. This is due 
to higher BG variation as a results of TGC for this cohort. 
 
The median 1-h absolute BG prediction error, comparing predicted BG based on the median 
of predicted SI to the interpolated value from retrospective data is ranged between 2.5 – 7.0 
%, corresponding to an average BG errors of 0.2 – 0.5 mmol/L. It is also observed that the 
proportion of fitted SI and predicted BG values that fell within the (25
th
 – 75th) and (5th – 95th) 
probability intervals for 6-hour block analysis were measured higher than the expected 50% 
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and 90%. Thus, majority of the 6-hour block stochastic model analysis results match with the   
12-hour block stochastic model analysis which suggest that further stochastic control will be 
sufficient with 12-hour block stochastic models. 
 
7.5.2 Probability Bound-Determination 
 
Table 7.8 shows the effect of modifying the kernel density estimation for several values of c, 
ranging from 0.1 to 3.0 based on 6 hour block analysis. For this cohort, the results has shown 
that for block 1, c=1.0 and followed by block 2 to block 3 (c=1.5), and block 4 to block 5 
(c=2.0). The trend shows that the value of estimator, c is increasing as SI increases from cool 
to warm, and match with 12-hour block stochastic model analysis as shown in the Table 7.6. 
 
 
 
 
 
 
 
.   
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Table 7.8: Comparison of probability bounds for modifications of kernel density estimator (σ`x = cσx AND σ`y = cσy) based on 6-hour block 
analysis 
 
 
 
C 
  
 Cool Period Warm Period 
% of SI within  
probability bounds 
at Block 1  
[0 – 6] hours 
% of SI within 
probability bounds 
at Block 2  
[6– 12] hours 
% of SI within  
probability bounds 
at Block 3  
[12 – 18] hours 
% of SI within  
probability bounds 
at Block 4  
[18 – 24] hours 
% of SI within  
probability bounds 
at Block 5  
[24 –  ] hours 
% of SI within  
probability bounds 
at Block 6  
[36 – 48] hours 
% of SI within  
probability bounds 
at Block 7  
[36 – 48] hours 
% of SI within  
probability bounds 
at Block 8  
[36 – 48] hours 
[25th-
75th] 
[5th- 
95th] 
[25th-
75th] 
[5th- 
95th] 
[25th-
75th] 
[5th- 
95th] 
[25th-
75th] 
[5th- 
95th] 
[25th-
75th] 
[5th- 
95th] 
[25th-
75th] 
[5th- 
95th] 
[25th-
75th] 
[5th- 
95th] 
[25th-
75th] 
[5th- 
95th] 
0.1 51.6 88.9 52.7 85.3 53.5 85.8 51.7 86.0 44.9 84.2 45.0 85.3 45.5 85.5 46.2 85.6 
0.2 51.4 89.3 53.5 86.2 54.3 86.6 52.1 86.2 45.3 84.5 45.4 85.8 46.2 85.8 46.7 85.9 
0.3 51.7 89.5 54.0 86.9 54.7 86.9 53.5 86.6 46.3 85.8 46.7 86.6 47.4 86.6 48.0 86.7 
0.5 53.1 89.7 55.6 88.8 55.1 87.8 54.3 87.4 48.4 86.5 48.6 87.0 49.2 87.1 49.3 87.3 
1.0 58.7 90.4 57.2 89.5 56.9 89.0 55.5 87.3 51.9 87.2 52.1 88.2 52.6 88.3 52.6 87.7 
1.5 62.7 91.0 58.9 90.7 58.0 90.6 57.2 88.2 54.9 87.8 55.2 88.6 55.5 88.8 55.7 88.3 
2.0 65.6 91.5 61.0 93.5 60.2 92.1 59.2 90.7 55.6 90.3 56.1 89.3 56.2 89.5 57.2 88.9 
2.5 67.3 92.3 63.4 94.2 62.7 92.5 60.8 92.4 56.2 91.9 55.8 90.9 57.3 90.1 58.5 89.5 
3.0 68.0 92.8 65.7 94.9 63.9 92.6 62.1 92.9 56.7 92.8 57.5 91.2 57.9 91.3 59.0 90.7 
Ideal 50% 90% 50% 90% 50% 90% 50% 90% 50% 90% 50% 90% 50% 90% 50% 90% 
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7.6 Stochastic Analysis by Sub-Cohort 
 
7.6.1 Stochastic Model Prediction Width 
 
Tables 7.9 and 7.10 show summary of cross-validation comparison study for OHCA sub-
cohorts at both cool and warm respectively with c=1. Looking at these tables, it must be 
noted that SI and BG results for all sub-cohorts are not much different compared to the 
overall OHCA cohort, even though the percentage of SI and BG values within interval during 
warm are slightly higher than cool for each respective sub-cohorts. This outcome suggests 
that stochastic models derived from the overall cohort are different between cool and warm, 
but applicable for sub-cohorts, regardless of patient background and any other status. 
 
Predicting BG values based on an equal-tailed 0.90 SI probability interval is a more practical 
forecasting approach (Lin et al., 2008, Evans et al., 2011, Fisk et al., 2012) . Ideally, the 
probability-bound determination for raw SI data and its corresponding BG forecasted values 
based on an equal-tailed 0.90 SI probability interval must be about the same. In general, the 
sub-cohort analysis shows that the SI percentage coverage in the (25th–75th) and the (5th–
95th) intervals and BG percentage coverage in the (25th–75th) and the (5th–95th) intervals 
are not much different within a tolerance of ± 3.0%. 
 
However, there are two sub-cohorts that show differences greater than ± 3.0% which are 
Diabetes and ROSC > 30 mins. For example, the SI and BG percentage coverage in the (5th–
95th) interval for diabetic sub-cohort during cool period is 87.8 % and 95.1 % respectively 
and the difference is 7.3%. Since the error and bounds are larger for diabetes and ROSC > 30 
mins, predicting BG values based on an equal-tailed 0.90 SI probability interval is most likely 
inaccurate for both cool and warm periods in these cases. Thus, if making a stochastic model 
for these sub-cohorts, values of c >1.0 would be required. 
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 Table 7.9: Cross-validation comparison study for OHCA sub-cohorts (Cool period) at c=1. 
  
OHCA  
Sub-Cohort  
 
 No of 
Patient 
% SI within interval % BG within interval 
BG interval width 
(mmol/L) 
BG point 
prediction 
error (%) 
BG point 
prediction 
error 
(mmol/L) 
[25th -75th] [5th- 95th] [25th-75th] [5th- 95th] [25th-75th] [5th- 95th] 
Overall OHCA cohort 180 
60.7 90.2 59.4 92.6 2.8 8.0 5.5 0.4 
Survived Patients 98 64.6 91.5 64.4 93.8 2.5 7.5 4.0 0.3 
Non-Survived Patients 82 60.0 89.7 61.5 94.2 3.1 8.9 7.0 0.5 
Diabetes Patients 23 68.6 83.4 65.0 87.2 3.8 8.7 12.5 1.2 
Non-Diabetes Patients 157 60.9 90.0 58.4 92.5 2.6 7.7 6.5 0.45 
Male Patients 143 61.8 90.8 59.8 92.8 2.7 8.0 5.0 0.35 
Female Patients 37 64.8 89.6 61.7 94.7 3.1 8.4 7.0 0.45 
ROSC < 15 mins 63 69.3 92.7 66.4 93.7 2.7 7.9 2.5 0.2 
ROSC < 30 mins 89 61.1 90.5 63.3 94.4 2.8 7.7 8.0 0.55 
ROSC > 30 mins 28 63.5 87.8 66.8 95.1 2.6 11.2 15.5 1.5 
 
 
Table 7.10: Cross-validation comparison study for OHCA sub-cohorts (Warm period) at c=1. 
  
OHCA  
Sub-Cohort  
 
 No of 
Patient 
% SI within interval % BG within interval 
BG interval width 
(mmol/L) 
BG point 
prediction 
error (%) 
BG point 
prediction 
error 
(mmol/L) 
[25th -75th] [5th- 95th] [25th-75th] [5th- 95th] [25th-75th] [5th- 95th] 
Overall OHCA cohort 180 
62.8 92.1 62.1 92.8 1.9 5.4 5.1 0.35 
Survived Patients 98 66.3 93.1 63.2 93.0 1.8 4.6 5.2 0.35 
Non-Survived Patients 82 63.0 92.6 56.1 93.9 2.0 6.4 4.5 0.35 
Diabetes Patients 23 68.1 94.9 63.8 96.3 2.8 7.9 8.0 0.5 
Non-Diabetes Patients 157 63.4 92.4 61.7 92.7 1.7 4.7 5.5 0.4 
Male Patients 143 63.2 92.2 61.8 92.9 1.9 5.3 5.0 0.35 
Female Patients 37 61.4 95.5 61.6 95.3 1.7 5.5 5.5 0.35 
ROSC < 15 mins 63 65.6 92.5 63.8 93.5 2.1 5.7 4.0 0.3 
ROSC < 30 mins 89 69.6 95.0 65.4 93.8 1.8 5.4 5.5 0.4 
ROSC > 30 mins 28 61.4 95.3 56.8 93.9 1.5 4.5 7.0 0.5 
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7.6.2 Probability Bound-Determination 
 
Table 7.11 shows the summary analysis of the effect of modifying kernel density estimation, 
c ranging from 0.1 to 4.0 for OHCA sub-cohorts. In general, the increased values of c yield 
wider coverage width whereas the decreased value of c yields narrow coverage width. 
  
Table 7.11: Cross-validation comparison study for 180 patient cohort (Warm period) 
  
OHCA  
Sub-Cohort  
 
 No of 
Patient 
 c, Kernel Density Estimator 
[Range: 0.1 – 4.0] 
 Cool Period
 
 Warm Period 
Overall OHCA cohort 180 1.0 3.0 
Survived Patients 98 1.0 2.0 
Non-Survived Patients 82 1.5 3.5 
Diabetes Patients 23 1.5 4.0 
Non-Diabetes Patients 157 1.0 3.0 
Male Patients 143 1.0 3.0 
Female Patients 37 1.0 3.0 
ROSC < 15 mins 63 1.0 2.0 
ROSC < 30 mins 89 1.0 2.5 
ROSC > 30 mins 28 1.5 4.5 
 
Looking at the above table, it must be noted that kernel density estimator for all sub-cohorts 
are not much different compared to the overall OHCA cohort for both cool and warm. 
However, there are two sub-cohorts that show unique kernel density estimator results which 
are diabetes (1.5, 4.0) and ROSC > 30 mins (1.5, 4.5). These results shown in the bracket are 
out of range compared to overall OHCA cohort and other sub-cohorts. Since kernel density 
estimator difference is highest for both diabetes and ROSC > 30 mins, the system need more 
powerful controller and may require further specific module in order to process the data and 
match with the variation difficulties from these two sub-cohorts. 
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7.7 Discussion 
 
The stochastic model presented in this paper is constructed by the distribution of insulin 
sensitivity variation using a 2-D kernel density method. This model has been employed 
previously on a cohort of adult intensive care (Lin et al., 2008) and neonatal intensive care 
patients (Le Compte et al., 2010). The percentage SI within prediction interval results by Lin 
et al. of 54.0% within the (25th–75th) probability bound shows that normal adult ICU 
patients with normal body temperature produce far closer to the ideal 50%, followed by 
neonates’ results by Le Compte et al. which record 62.6% at the same interval. However, the 
stochastic model results of 60.7% at cool and 62.8% at warm on the same probability bound 
for the OHCA patients, treated with hypothermia as shown in Table 7.1 appear to be unique 
and surprisingly more similar to neonates (Le Compte et al., 2010) .  Additionally, the model-
based SI parameter used in this study is also model-specific, and thus may also account for 
different physiological effects in cardiac arrest patients compared to normal adult ICU 
patients both during cool and the first 24 hours of warm period after induced hypothermia.  
 
The kernel density estimator (c) method employed in this stochastic model provides a layer of 
safety as wider probability bounds would be more likely to capture dynamics and any 
changes not observed in the cohort. The choice of kernel density estimator depends on the SI 
data variations, and its corresponding BG forecasted values based on an equal-tailed 0.90 SI 
probability interval between 5
th
 – 95th at local variance estimator. Lower values of c means 
the distribution of SI is narrower, and vice versa. The correct choice of c will ensure the 
prediction accuracy is maintained at 90% of total distribution. 
 
As the (5
th 
- 95
th
) band is what has been used for control previously (Le Compte et al., 2010), 
these cohort shows that they are closer to ideal 90%. However, wider coverage bands may 
also have impact on glycaemic control performance. As the wider probability band might be 
useful to avoid potential hypoglycaemia, it may also force a controller to maintain a mildly 
hyperglycaemic state. This is very true for OHCA patients, treated with hypothermia as the 
overall BG interval width of the (5th–95th) percentile probability band for c = 1.0 were 8.0 
mmol/L and 5.4 mmol/L during cool and warm respectively, which is relatively very wide 
and would likely to have a significant impact on performance for a controller targeting a 
typical range between 4–7 mmol/L or 3 mmol/L BG interval width.    
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The cross validation comparison study for the 180 patient cohort showed consistent results, 
suggesting that the cohort dataset is large enough to reasonably reflect the vast majority of 
target patients presented. However, the contrasting trend has shown for patients group during 
warm period, where the percentage of SI within this interval is higher than the percentage of 
forecasted BG. In fact, this trend matches results for adult intensive care (Lin et al., 2008) and 
neonatal intensive care patients (Le Compte et al., 2010). Thus, this is also appear to be 
another unique findings for this cohort suggesting different control scheme should be defined 
for cool and warm periods. 
 
Modifying local data density variance estimator c to the value greater than 1.0 will result in 
more accurately distributions that better reflect the observed data prediction coverage (Le 
Compte et al., 2010). However,  60% of SI and BG distributions for the OHCA patients’ 
cohort are within the (25th–75th) prediction interval and around 5% -12% are out of bound 
for both cool and warm periods. Thus, a more robust modelling is required for highly variable 
patient.  Hence, value of c = 1.0 and 3.0 provides the best tradeoff of bias and variance during 
cool and warm periods respectively. These chosen probability bound values have shown 
smooth probability bounds containing an appropriate proportion of prediction to obtain the 
desired prediction and glycaemia control performance at different physiology conditions. 
 
7.8 Summary 
 
Overall, this stochastic method and analysis in this study provides predictions based on a 
cohort dataset. The prediction bounds for more dynamic patients are difficult to decide since 
the SI variability distribution for this cohort is unique, particularly during cool period.  This 
observation is far differing than for the less dynamic patients who are typically more 
conservative. Thus, the probability bounds are optimized in a cohort sense, but not 
necessarily applicable on a per-patient basis.   
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Chapter 8: Summary of OHCA Patient Analysis   
 
 
 
This chapter presents the analysis summary of OHCA patients based on metabolic, 
glycaemic, and exogenous insulin and nutrition characteristics and evolution during 
hypothermia (cool period) and normothemia (warm period). Patients were analysed based on 
overall cohort, sub-cohorts, and 6 and 12 hour time block. Results from each patient 
characteristics were combined and summarized. Finally, the summary of main findings from 
this study determines control design consideration for this cohort. 
  
8.1   Overview of OHCA Patient Analysis 
 
The overview of OHCA patient analysis is shown in Figure 8.1. In general, OHCA patients 
were undergone preliminary analysis during cool and warm before proceeding with new 
glycaemic controller design and development. The analysis is equally important as the 
controller development since it provides scientific evidence and understanding of patients’ 
physiology and metabolic evolution especially during cool and warm. Besides, this analysis 
will embark further discussion and predictions on why these unique phenomena occur at 
specific time range. Hence, the outcome will benefit glycaemic controller development with 
proposed clinical settings.  
 
 The analyses are divided into 3 main parts: 
 
i)  Input 
Exogenous insulin and nutrition are regarded as ‘inputs’ in the system since OHCA 
patient will receive these materials during treatment. Thus, the analysis of inputs will 
give an idea of how determine the best insulin and nutrition modulation strategy to 
deal with highly resistive and variable patient, particularly at critical situation and 
time. This idea in turn will be adopted and implemented in control design.   
 
 
 
 
128 
 
ii)  System 
Model-based insulin sensitivity (SI), generated from the ICING model will be able to 
describe metabolic system behaviour of OHCA patient. Thus, the analysis will 
provide scientific information about patient metabolic level and evolution over time, 
from cool to warm conditions. The understanding of SI evolution is vital for design 
and implementation glycaemic control. In addition to that, model-based SI can be 
exploited to create its stochastic model, which describes the metabolic variability 
conditions of the patient. Analysis of SI stochastic model is important for improving 
stochastic control, particularly in reducing metabolic and glycaemic variability. 
  
iii)  Output 
Blood glycose (BG) is regarded as ‘output’ in the system since this metric will be 
measured and monitored during treatment. Thus, the analysis of glycaemic output will 
give an idea of how OHCA patient physiological and metabolic conditions response 
to insulin and nutrition administration as well as other inputs. This idea in turn will be 
adopted and implemented in control design.   
 
 
These parameters will undergo the same analysis method and format since it is easier to 
gather results, analyse and summarize, which lead to better interpretation of unique 
phenomena at certain conditions and time. The overall analysis will allow interpretation and 
comparison of OHCA patients during cool and warm, while the time-block analysis will 
allow the same interpretation at specific time range. Thus, this will provide better reference 
and guidance in the effort to develop and implement safer metabolic management. 
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Fig. 8.1:   Overview of OHCA patient analysis 
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8.2    Analysis Summary by Overall Cohort 
 
8.2.1 Statistical Analysis Summary 
 
A statistical analysis which summarize OHCA patient assessment results per-cohort based on 
metabolic, glycaemic, and exogenous insulin and nutrition characteristics and evolution 
during hypothermia (cool period) and normothemia (warm period) is presented in the Table 
8.1. Stochastic model of SI during cool and warm will use Kernel Density Estimator, c in this 
analysis. 
Patient conditions and problem identifications is added in the list to explain about physiology 
and metabolic conditions during cool and warm. Any problems identified or unique 
phenomena observed from the analysis shall be included. Treatment observation will describe 
about how treatment was done based on insulin and nutrition analysis. 
  
 Referring to the Table 8.1, it shows that OHCA patient had very low metabolic activity 
during cool period but significantly increased over time. This shows that generally OHCA 
patients have improved physiologically and metabolically during treatment in ICU. 
Additionally, these patient would have higher metabolic variability during cool and decreases 
at warm. However, the metabolic variability decrease is not significant, implying that not 
much different in this aspect between cool and warm for the first 48 hours of treatment. 
Hence, implementing conventional glycaemic control on these patients is difficult, suggesting 
that model-based patient specific approach should be the way during this duration. 
 
The physiology and metabolic conditions during cool and warm is also influencing the 
glycaemic outcome of the patient. The summary results in the Table 8.1 show that BG during 
cool is significantly higher than warm. This shows that these patients were undergo 
glycaemic control successfully during treatment in ICU, resulted in BG level decrease from 
cool to warm. However, glycaemic variability decrease is not significant, implying that not 
much different between cool and warm for the first 48 hours of treatment. Thus, this shows 
that implementing glycaemic control can only improve BG level, but difficult to reduce BG 
variability using these method due to high metabolic variability. 
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Insulin and nutrition administration presents how the treatment was done on OHCA patients. 
In this summary, it shows that more exogenous insulin is given during cool than warm. This 
trend match with the fact that BG is higher during cool period and decreases over time. 
However, the feeding decrease is not significant, implying that not much different or less 
modulation of insulin during cool and warm for the first 48 hours of treatment.  
 
Unlike insulin, less nutrition is given during cool and significantly increases over time. This 
is because when the patient was initially admitted and hypotenized, blood glucose level is 
very high and demand more insulin to decrease. However, metabolic activity is low but 
highly variable. As metabolic activity increased and glycaemic level decreased, it is predicted 
that the body needs more energy. The situation is exaberated by the temperature rise from 
cool to warm. Hence, nutrition modulation plays significant role during treatment which 
support patients glucose needs while insulin amount is maintained to support metabolic 
activities.  
 
With these insulin and nutrition modulation strategy, it resulted in improving glycaemic level 
but difficult to reduce BG variability using this method due to high metabolic variability. 
However, these findings is important to enable current glycaemic control method for OHCA 
patients is studied carefully, understand its background and problems and finally model the 
suitable controller to overcome the problems. 
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Table 8.1:  Summary of SI results for overall OHCA cohort.   
 
 
Variable 
 
Metrics 
Period (2 days in ICU)  
p-value Cool Warm 
Insulin 
Sensitivity (SI) 
[L/mU/min]1.0 
 
Median SI [IQR] 
[L/mU/min] 
2.4 x 10
-4
                 
[1.1, 3.5] x 10
-4
 
5.2 x 10
-4
               
[2.8, 8.3] x 10
-4
 
p < 0.05 
Median %∆SI 
[IQR][%] 
2.3  
[-0.8, 8.9] 
 0.4  
[-2.5, 3.4] 
0.08 
Blood Glucose 
(BG) [mmol/L] 
Median BG [IQR] 
[L/mU/min] 
7.4  
[6.5, 8.5] 
 6.5  
[5.8, 7.4] 
p < 0.05 
Median %∆BG 
[IQR][%] 
-2.8  
[-5.6, -0.9] 
-1.5 
[ -3.4, 1.0] 
0.08 
Insulin Infusion 
(U) [U/hour] 
Median U [IQR] 
[U/hour] 
1.80 
[1.0, 3.3] 
1.65 
[0.9, 3.7] 
0.5 
Dex / Nutrition 
(P) [g/hour] 
Median P [IQR] 
[g/hour] 
2.50 
[0.8, 3.5] 
3.23 
[1.6, 5.3] 
p < 0.05 
Stochastic 
Model of SI 
Kernel Density 
Estimator, c 
1.0 3.0  
Patient conditions and problem 
identifications 
Lower metabolic 
activities due to low 
body temperature.        
T < 35
o
 
-------------------------- 
Low SI but highly SI 
resistance and variable. 
-------------------------- 
Higher BG level and 
variability. 
  
Metabolic activities 
increased at optimum 
working temperature. 
36.5
o
 < T < 37.5
o
 
------------------------- 
SI increases, lower SI 
resistance and less 
variable. 
------------------------- 
BG level decreases 
and variability 
reduced but not 
significant. 
 
Treatment observations 
 
Patients were given 
higher doses of 
exogenous insulin. 
--------------------------- 
Received average 
amount of nutrition. 
 
Patients were given 
slightly lower doses of 
exogenous insulin   
------------------------- 
Received significant 
increase amount of 
nutrition. 
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8.2.2 Analysis Summary by 6-hour and 12-hour blocks 
 
Table 8.2 and Table 8.3 illustrate statistical analyses which summarize OHCA patients’ 
metabolic, glycaemic, and exogenous insulin and nutrition characteristics and evolution based 
on 12-hour and 6-hour blocks respectively.   
  
Analysis summary by 12-hour blocks shows that OHCA patients had low metabolic activity 
during block 1 (0 -12 hours) but significantly increased over time. However, these patients 
would have higher metabolic variability during cool and significantly decreases for the first 
24 hours of treatment. After 24 hours, the metabolic variability decrease is not significant. 
This results match with overall analysis summary (Table 8.1) and analysis by 6-hour block 
(Table 8.3), which indicate that implementing glycaemic control is difficult with different 
characteristics and evolution for each time block, suggesting that developing control based on 
per time block should be another alternative apart from per cohort. 
 
The summary results in the Table 8.2 and Table 8.3 show that these patients were undergo 
glycaemic control successfully during treatment in ICU, resulted in BG level decrease 
significantly from block 1 (0 -12 hours) over time. However, glycaemic variability decrease 
is not significant, implying that not much different between these time blocks for the first 48 
hours of treatment. This results match with overall analysis summary (Table 8.1) and analysis 
by 6-hour block (Table 8.3), which indicate that that implementing glycaemic control can 
only improve BG level, but difficult to reduce BG variability due to variations of  metabolic 
variability between each time blocks. 
 
Insulin and nutrition administration presents how the treatment was done on OHCA patients 
per each time block. In this summary, it shows that more exogenous insulin is given during 
block 1 (0 -12 hours) but decreased over time insignificantly. In contrast, less nutrition is 
given during when the patient is initially admitted to ICU, and significantly increases over 
time. This results match with overall analysis summary and analysis by 6-hour block. With 
these insulin and nutrition modulation strategy, it resulted in improving glycaemic level but 
difficult to reduce BG variability due to high metabolic variability. However, this finding is 
important to study current glycaemic control method for OHCA patients based on per time 
block. 
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Table 8.2:  Summary of results for overall OHCA cohort based on 12-hour block analysis 
 
 
Variable 
 
Metrics 
Cool Period [0-24 hours] Warm Period [24-48 hours] 
Block 1 
[0-12] hours 
Block 2 
[12-24] hours 
Block 3 
[24-36] hours 
Block 4 
[36-48] hours 
Insulin 
Sensitivity (SI) 
[L/mU/min] 
 
Median SI [IQR] 
[L/mU/min] 
1.9 x 10
-4
                     
[1.0, 3.0] x 10
-4
 
2.7 x10
-4   
[1.2, 4.5] x 10
-4
 
4.8 x10
-4   
[2.5, 8.3] x 10
-4
 
5.2 x10
-4   
[3.0, 8.5] x 10
-4
 
Median %∆SI 
[IQR][%] 
9.0  
[5.1, 17.0] 
5.8  
[2.8, 10.3] 
4.8  
[2.8, 9.5] 
4.8  
[2.7, 9.2] 
Blood Glucose 
(BG)[mmol/L] 
Median BG [IQR] 
[L/mU/min] 
7.6  
[6.5, 9.3] 
6.9  
[5.9, 8.2] 
6.7  
[6.0, 7.8] 
6.4  
[5.7, 7.6] 
Median %∆BG 
[%][IQR] 
3.9  
[2.1, 8.2] 
3.8  
[1.8, 6.6] 
3.3  
[2.2, 6.6] 
3.3  
[1.8, 6.1] 
Insulin Infusion 
(U) [U/hour] 
Median U [IQR] 
[U/hour] 
2.7 2.4 2.2 2.2 
Dex / Nutrition 
(P) [g/hour] 
Median P [IQR] 
[g/hour] 
2.5 4.1 4.5 3.8 
Stochastic 
Model of SI 
Kernel Density 
Estimator, c 
1.0 0.5 0.3 0.3 
Patient conditions and problem 
identifications 
Maintenance phase   
---------------------------- 
 Low SI, but highly 
resistance and variable 
----------------------------- 
High BG and variability 
 
Rewarming phase 
-------------------------- 
Low SI, but start 
rising, and variable 
-------------------------- 
Reduced BG and 
variability 
Rewarming phase 
---------------------------- 
 SI start rising, and 
variable 
----------------------------- 
Reduced BG and 
variability 
Maintenance phase  
--------------------------- 
 SI rising, and variable 
--------------------------- 
Reduced BG and 
variability 
Treatment observations 
 
High insulin, low 
nutrition 
Average insulin and 
nutrition 
High insulin and 
nutrition 
Average insulin and 
nutrition 
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Table 8.3:  Summary of results for overall OHCA cohort based on 6-hour block analysis 
  
 
Variable 
 
Metrics 
Cool Period [0-24 hours] Warm Period [24-48 hours] 
Block 1 
[0-6] hours 
Block 2 
[6-12] hours 
Block 3 
[12-18] hours 
Block 4 
[18-24] hours 
Block 5 
[24-30] hours 
Block 6 
[30-36] hours 
Block 7 
[36-42] hours 
Block 8 
[42-48] hours 
Insulin Sensitivity 
(SI) 
[L/mU/min] 
 
Median SI [IQR] 
[L/mU/min] 
1.5 x10-4   
[0.6, 2.6] x10-4 
1.9 x10-4   
[0.9, 3.2] x 10-4 
2.1 x10-4   
[1.0, 4.0] x 10-4 
3.0 x10-4   
[1.2, 5.1] x 10-4 
4.5 x10-4   
[2.2, 8.3] x 10-4 
4.4 x10-4   
[1.7, 8.7] x 10-4 
4.8 x10-4   
[2.6, 7.7] x 10-4 
5.0 x10-4   
[2.7, 8.5] x 10-4 
Median %∆SI 
[IQR][%] 
10.7  
[4.7, 25.6] 
6.8  
[3.4, 14.4] 
5.8  
[2.9, 10.9] 
4.3  
[2.0, 8.6] 
4.0  
[2.4, 8.8] 
4.5  
[2.1, 9.0] 
4.3  
[2.1, 7.1] 
4.2  
[1.5, 6.3] 
Blood Glucose 
(BG)[mmol/L] 
Median BG[IQR] 
[L/mU/min] 
8.3  
[7.1, 10.8] 
7.5  
[6.5, 8.9] 
7.3  
[6.3, 8.4] 
6.9  
[5.9, 8.1] 
6.8  
[5.9, 8.0] 
7.0  
[6.3, 8.0] 
6.9  
[6.0, 7.9] 
6.8  
[5.8, 7.8] 
Median %∆BG 
[IQR][%] 
3.4  
[1.7, 6.6] 
2.9  
[1.6, 5.3] 
2.8  
[1.2, 4.8] 
2.5  
[1.1, 4.7] 
2.4  
[1.4, 4.2] 
2.6  
[1.4, 5.1] 
2.5  
[1.2, 4.7] 
2.1  
[1.0, 4.1] 
Insulin Infusion  
(U) [U/hour] 
Median U [IQR] 
[U/hour] 
3.70 2.52 2.31 2.07 2.16 2.70 2.00 2.00 
Dex / Nutrition (P) 
[g/hour] 
Median P [IQR] 
[g/hour] 
3.53 4.43 5.60 6.00 7.23 7.09 6.80 6.66 
Stochastic Model 
of SI 
Kernel Density 
Estimator, c 
1.0 0.5 0.5 0.5 0.5 0.3 0.3 0.3 
Patient conditions and problem 
identifications 
Maintenance phase   
---------------------------- 
 Low SI, but highly 
resistance and variable 
----------------------------- 
High BG and variability 
 
Rewarming phase 
-------------------------- 
Low SI, but start rising, 
and variable 
-------------------------- 
Reduced BG and 
variability 
Rewarming phase 
---------------------------- 
 SI start rising, and 
variable 
----------------------------- 
Reduced BG and 
variability 
Maintenance phase  
--------------------------- 
 SI rising, and variable 
--------------------------- 
Reduced BG and 
variability 
Treatment observations 
 
High insulin, low 
nutrition 
Average insulin and 
nutrition 
High insulin and 
nutrition 
Average insulin and 
nutrition 
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8.3   Analysis by Sub-Cohort 
 
Table 8.4 presents statistical analyses which summarize OHCA patients’ metabolic, 
glycaemic, and exogenous insulin and nutrition characteristics and evolution by sub-cohorts. 
  
Generally, majority of results from sub-cohorts match with overall OHCA patients which 
suggest that analysis of overall OHCA patients is sufficient to represent each sub-cohort. 
However, it is observed that diabetes sub-cohort has shown difficulties to decrease BG level 
even though the treatment received are the same as the other sub-cohorts. 
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Table 8.4:  Analysis summary for OHCA patients by sub-cohort 
 
Analysis Summary 
by Sub- Cohort 
No 
 
Insulin Sensitivity 
(SI) [L/mU/min] 
 
SI Variability 
(%∆SI) [%] 
Blood Glucose 
(BG)[mmol/L] 
 
 BG Variability 
(%∆BG) [%] 
Insulin Infusion 
(U) [U/hour] 
Dex / Nutrition  
(P) [g/hour] 
Cool Warm 
p-
value 
Cool Warm 
p-
value 
Cool Warm 
p-
value 
Cool Warm 
p-
value 
Cool Warm 
p-
value 
Cool Warm 
p-
value 
All OHCA patients 180 
2.5 
x10-4  
 5.4 
x10-4  
< 
0.05 
 1.2   0.2  0.08 9.7   8.5   
< 
0.05 
-0.6  0.2 0.3 1.8  1.6   0.5 2.5   3.2   
< 
0.05 
Survived Patients 98 
2.5 
x10-4 
 5.8 
x10-4 
< 
0.05 
1.0   0.3  0.1 9.1   7.8   
< 
0.05 
-0.5  -0.1 0.3 1.7   1.4   0.3 2.6   3.2   
< 
0.05 
Non-Survived 
Patients 
82 
2.2 
x10-4 
 5.1 
x10-4 
< 
0.05 
1.4  0.07 0.2 9.2   8.3   
< 
0.05 
-0.7  0.2  0.3 2.0   1.4   0.3 2.1   3.0   
< 
0.05 
Diabetes Patients 23 
2.3 
x10-4 
 4.1 
x10-4 
< 
0.05 
1.0 0.04 0.3 8.8   8.1   0.3 -0.4 -0.2 0.1 1.9   1.7   0.7 2.1   4.2   
< 
0.05 
Non-Diabetes 
Patients 
157 
2.4 
x10-4 
 5.7 
x10-4 
< 
0.05 
1.2   0.3 0.06 9.3   8.1   
< 
0.05 
-0.6 0.2 0.4 1.7   1.5   0.4 2.1   3.0   
< 
0.05 
Male Patients 
 
143 
2.5 
x10-4 
 5.6 
x10-4 
< 
0.05 
1.0  0.3 0.09 9.4   8.4   
< 
0.05 
-0.5 -0.1 0.3 1.9   1.7   0.5 2.5   3.1   
< 
0.05 
Female Patients 
 
37 
2.0 
x10-4 
 4.8 
x10-4 
< 
0.05 
1.5  -0.3 0.5 8.6   7.3   
< 
0.05 
-0.9 0.2 0.2 1.6   1.0   0.1 2.1   3.7   
< 
0.05 
ROSC < 15 mins 
 
63 
2.7 
x10-4 
 5.7 
x10-4 
< 
0.05 
1.0  0.3 0.2 8.7   7.7   
< 
0.05 
-0.5 -0.2 0.1 1.4   1.0   0.4 2.5   4.2   
< 
0.05 
ROSC < 30 mins 
 
89 
2.3 
x10-4 
 5.3 
x10-4 
< 
0.05 
1.2  0.2 0.3 8.8   8.1   
< 
0.05 
-0.6 -0.2 0.4 2.0   1.4   0.4 2.5   2.7   0.2 
ROSC > 30 mins 
 
28 
2.0 
x10-4 
 5.3 
x10-4 
< 
0.05 
1.4  -0.1 0.5 8.5   7.2   
< 
0.05 
-0.9 0.3 0.3 2.5   1.5   0.3 2.1   2.2   0.7 
* Results comparison based on per-cohort 
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8.4   Control Design Considerations 
 
 
Hyperglycaemia or high blood sugar (glucose) is prevalent in critical care (Capes et al., 2000, 
McCowen et al., 2001, Mizock, 2001, van den Berghe et al., 2001) which increases the risks 
of further complications and mortality (Capes et al., 2000, van den Berghe et al., 2001, 
Krinsley, 2003) . An analysis summary of OHCA patient, treated with hypothermia shown in 
this chapter suggests that the main intention of glycaemic control on these cohort during cool 
and warm is solely to maintain blood glucose level within normal range (4.4 to 6.1 mmol/L) 
(Plank et al., 2006b), even though the metabolic and physiological conditions are still 
unstable. This is obvious since consistent insulin dosage is given to the patients throughout 
the first 2 days of treatment, while modulating nutrient ensures patients glucose needs to 
support metabolic activities. As a results, majority of blood glucose levels (Table 8.3) are 
recorded at moderate level (6.1 to 8.0 mmol/L), except for block 1 (0-6 hours). 
 
The success in maintaining blood glucose level within 6.1 to 8.0 mmol/L at this stage is 
important since the patients had highly insulin resistant and variable during the first 2 days of 
cool and warm. The difficulties in dealing with these metabolic and physiological 
backgrounds paid off by maintaining blood glucose at these levels before further decrease to 
within normal range. Hence, exogenous insulin and nutrition administration approach for this 
cohort is the key for successful glycemic control. However, the ability of insulin and nutrition 
modulation method to reduce BG level for this cohort does not reflect the mortality statistics 
as shown in the Table 3.4. There are about 45.6% OHCA patient who were not survived after 
undergo the same therapies as mention above. This fact is supported by a study of survival 
rates from OHCA found that 14.6% of those who had received resuscitation by ambulance 
staff survived as far as admission to hospital. Of these, 54% died during admission, half of 
these within the first 24 hours, while 46% survived until discharge from hospital. Of those 
who were discharged from hospital, 70% were still alive 4 years (Cobbe et al., 1996). This 
shows that mortality rate is still high even though glycaemia control is implemented and 
successfully maintaining blood glucose level within 6.1 to 8.0 mmol/L at this stage. The 
question is, besides hyperglycemia what else causing a cardiac arrest patient to increase its 
mortality rate? 
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Referring to the summary results in the Table 8.1-8.3, it shows that glycaemic variability 
(%∆BG) decrease is not significant, implying that there is not much different in glycaemic 
variability between cool or warm for the first 48 hours of treatment (p > 0.05). Since there are 
about 45.6% OHCA patient who were not survived after undergo the same therapies, the 
inability of glycemic control to reduce glycemic variability significantly from cool to warm 
might be the possible cause of cardiac arrest patient’s high mortality rate. This fact is 
consistent with similar studies by Krinsley (Krinsley, 2009), who have showed that increased 
glycaemic variability is associated with mortality in critically ill patients. Additionally, the 
event of hypoglycaemia (BG < 2.22 mmol/L) is potentially increased during rewarming (Lee 
et al., 2013), which is also contributed to higher risk of death (Finfer et al., 2012). 
 
Thus, even though the glycaemic control scheme implemented on these cohort has shown 
successful in maintaining blood glucose level within 6.1 to 8.0 mmol/L throughout the 
treatment from cool to warm, but the fact that only 54.4% survive from this method has 
ruined its reputation. This method is unable to decrease glycemic variability significantly as 
mentioned above. Hence, different glycemic control approach and settings should be 
proposed in order to overcome the problems posed by this cohort.   
 
In order to develop suitable glycaemic controller for OHCA patients, treated with 
hypothermia, the design should consider several problems identified from the above analysis: 
 
i) Very low metabolic activities, but high glycaemic level at initial (cool period), 
which demand too much insulin given during cool period 
 It is not surprised that an OHCA patient, treated with hypothermia will have a very 
high blood glucose level at the initial of cool period. Hyperglycaemia is dangerous 
and demand more insulin externally. However, an overdose insulin infusion might 
increase metabolic variability, which will influence higher glycaemic variability, 
which may cause hypoglycaemia and associated with mortality. Thus, controller 
design should consider higher BG target (Moghissi et al., 2009), and gradually BG 
decrease from cool to warm rather than drastic change. This consideration will affect 
insulin and nutrition administration to ensure safe and reliable glycaemic control. 
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ii) High glycaemic variability due to metabolic variability, which may cause 
hypoglycaemia episode and associated with mortality. 
The event of hypothermia and the first 24 hours of rewarming is critical for an OHCA 
patient since metabolic conditions is unstable and highly variable especially at 
transition period between cool and warm. This may cause hypoglycemia, which is 
associated with mortality (Egi et al., 2006, Bagshaw et al., 2009, Krinsley, 2009). It 
was notable that modulating both insulin and nutrition inputs may achieve good 
control with lesser insulin and reduces hypoglycemic risk. Thus, controllers with the 
ability to adapt patient-specific metabolic conditions and forecast possible future 
parameter values such as blood glucose should be able to provide better modulation of 
insulin and nutrition inputs.  
 
However, the unique metabolic evolution and variability found in OHCA cohort during the 
cool-warm transition period between 18 – 30 hours (Sah Pri et al., 2014)  suggested that 
either higher BG targets (Moghissi et al., 2009) , and/or adding nutritional intake (Suhaimi et 
al., 2010) must be considered, in addition to patient-specific adaptive glycaemia control. 
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8.5   Control Performance Measures 
 
Understanding the difficulties and defining desired controller performance is the first step to 
controller design. A variety of performance metrics have been used in different critical care 
glycaemic studies, with their differences often confounding direct comparisons between 
studies.  These metrics can be summarised as five basic goals: 
 
i) Mean blood glucose level   
 
Mean blood glucose level is calculated over all measurements (Krinsley, 2004) or over 
limited measurements, such as first morning measurement (van den Berghe et al., 2001, Van 
den Berghe et al., 2003). The average is the simplest performance measure and the one used 
in both landmark clinical studies.  However, it provides no further information on glucose 
excursions or tightness of control. In addition, an average value should utilise all blood 
glucose measurements and not just a morning average (van den Berghe et al., 2001), which 
can hide variability and poor control. 
 
ii) Distribution of blood glucose level:   
 
Most studies report an average glycaemic level and standard deviation, assuming blood 
glucose measurements are normally distributed. As a negative blood glucose concentration is 
physically impossible, a log-normal distribution provides a more accurate representation of 
the underlying spread of measurements. Finally, empirical cumulative distribution functions 
provide a framework to display all measurements and allow interpretation of results for any 
desired glycaemic band. 
 
iii) Time in a glycaemic band:   
 
Time in a glycaemic band is calculated as the time or percentage of measurements in a 
specific band, such as 4–6.1 mmol/L (Wong et al., 2006a, Wong et al., 2006b) or 4.5–6.1 
mmol/L (Plank et al., 2006b). Maximising this metric is essentially equivalent to minimising 
the Hyperglycaemic Index (HGI) or area under the blood glucose level curve (Van den 
Berghe, 2004, Vogelzang et al., 2004). This metric provides a surrogate measure of the 
average value, as well as an indication of the tightness of the glycaemic control result.  Using 
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multiple overlapping or contiguous bands provides a good definition of the total glucose 
distribution under control. 
 
iv) Glucose variability:   
 
Glucose variability measured as the standard deviation or 90% interval over the data. This 
metric has only been employed recently (McDonnell et al., 2005) and measures the tightness 
of blood glucose control around the average or target value. However, it provides no 
indication of the absolute glycaemic levels obtained and some methods assume normal or 
other statistical distributions that may not match the data. Hence, confidence intervals 
determined from the data may prove more useful.    
 
v) Hypoglycaemic episodes:   
 
Hypoglycaemic episodes measured as the number or percentage of measurements that are 
below a defined hypoglycaemic threshold. The typical definition is 2.2 mmol/L, although 
some studies use higher thresholds (Lonergan et al., 2006b, Plank et al., 2006b). Variability 
also captures some of this information when associated with the average or median glucose 
values. More importantly, this measure is a critical indicator of the safety of the control 
methods used. 
 
Finally, clinical end-points such as mortality are a patient-specific outcome and tied to the 
control of glucose on a per-patient basis.  Whole cohort results allow analysis of the full 
glycaemic control data set to assess outcomes such as hypoglycaemia, which has a typically 
low incidence rate but great clinical implications.  Thus, each categorisation method provides 
a different insight into the data, and both are required to clearly describe the performance of a 
particular protocol (Goldberg et al., 2006). 
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Chapter 9: STAR Control Performance Analysis and Virtual 
Trials   
 
 
This chapter presents a comparative study of STAR controller performance over Out-of-
Hospital Cardiac Arrest (OHCA) patients based on general and OHCA-specific stochastic 
models. It analyses the improvement in glycaemic control that can be achieved by these 
stochastic models during treatment, including the evolution of blood glucose and its 
variability. 
   
9.1 Introduction 
 
Cardiac arrest patients in particular have benefited from TGC (van den Berghe et al., 2001), 
but can be highly insulin resistant and variable, especially during the first 24 hours of stay 
(Pretty et al., 2012). Hypothermia or lowering body temperature below 35 degree Celsius is 
increasingly used to treat out of hospital cardiac arrest (OHCA) (Hayashi, 2009, Turk, 2010) 
and these patients often simultaneously receive insulin. During hypothermia, physiological 
and metabolic conditions can be highly variable, unstable and beyond patient-specific 
prediction. The result leads to ad-hoc treatment protocols based primarily on local clinical 
experience.  
  
The development and implementation of glycaemic control for the OHCA cohort is not 
straightforward, as the cohort is known to be highly resistant and metabolically variable, 
particularly during hypothermia and the first 24 hours after rewarming (Sah Pri et al., 2014) . 
However, the OHCA patient analysis summary from Chapter 8 should lead to better 
understanding of patient physiological conditions and its evolution from various perspectives, 
such as metabolic and glycaemic outcomes. Thus, input from that analysis could prove very 
important to develop safer and more accurate glycaemic control in this cohort. 
 
Several design parameters must be considered in designing this glycaemic control algorithm. 
Virtual trial offers the opportunity to explore control strategies in simulation before pilot 
clinical trials (Lonergan et al., 2006a, Chase et al., 2007b) . In particular, the proposed control 
algorithm needs to reduce elevated blood glucose levels in a controlled, predictable manner 
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while directly accounting for external nutrition. The controller must also account for inter and 
intra- patient variability and varying physiological condition. Hence, it must be adaptive 
and/or able to identify changes in patient dynamics, particularly with respect to insulin 
sensitivity. The protocol should also require relatively infrequent (1-3 hours) sensor 
measurements to minimise labour and comply with existing protocols to ensure the method 
developed could be readily implemented in a clinical environment (Chase et al., 2008a, 
Mackenzie et al., 2005). 
 
STAR (Stochastic TARgeting) is a stochastic targeted, model based glycaemic control 
framework (Evans et al., 2012, Evans et al., 2011, Fisk et al., 2012, Le Compte et al., 2009, 
Le Compte et al., 2012) that uses a time varying insulin sensitivity (SI [L/mU/min]) (Chase et 
al., 2010) to provide an adaptive patient-specific response that accounts for both inter-patient 
variability and future intra-patient variability over time. This insulin sensitivity characterizes 
a patient’s current metabolic state, and likely future changes in that state are forecast using 
population based stochastic modelling (Lin et al., 2008). This approach creates a range of 
possible future insulin sensitivity outcomes based on a patient’s current insulin sensitivity. It 
enables a treatment to be selected that best overlaps the range of possible BG outcomes with 
a clinically defined target band, and a prescribed, typically 5
th
 percentile, level of 
hypoglycaemic risk. Detailed descriptions of stochastic model methods and the STAR 
protocol can be found in Section 2.5.2. 
 
The performance and safety of STAR is highly dependent on the effectiveness of the 
stochastic modelling. Poor stochastic forecasting results in poor glycaemic control (Dickson 
et al., 2013). High variability in insulin sensitivity over time and between patients has been 
shown to limit possible performance of glycaemic control in simulation (Chase et al., 2011b, 
Dickson et al., 2012). Conservatively, high variability results in overly conservative 
stochastic models for some critical care patients. The resulting stochastic forecasting bands 
are wide, which may not be representative of the overall OHCA cohort, resulting in lower 
doses of insulin and higher BG levels. To enable better and equally safe control for this 
cohort of patients, the stochastic model used needs to be improved.  
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More specifically, the current STAR controller employs a stochastic model derived from 
adult ICU clinical data from patients treated using the SPRINT protocol. It include all 
diagnoses and all days of stay (Lin et al., 2008, Fisk et al., 2012). Thus, a new stochastic 
model will be developed, specifically for the OHCA cohort, and cool-warm periods. The 
analysis includes blood glucose (BG) level and variability, and control performance in 
treating OHCA patients.   
 
9.2  Subjects and Methods 
 
9.2.1   Patients and Data  
 
This analysis was performed on a cohort of 180 OHCA patients (7812 hours) treated with 
hypothermia, shortly after admission in the Intensive Care Units (ICUs) of Erasme Hospital, 
Belgium and Lausanne Hospital, Switzerland. Patients were on local AGC protocols. BG and 
temperature readings were taken 1-2 hourly. Data were divided into three periods: 1) cool 
(T<35
o
C); 2) an idle period of 2 hours as hypothermia was removed; and 3) warm (T>37
o
C). 
A maximum of 24 and a minimum of 15 contiguous hours for each period were considered, 
ensuring a balance of contiguous data between periods. A summary of the full cohort with 
sub-analysis studies are presented in Chapter 3. 
 
9.2.2 Controller Development and Implementation  
 
The model-based insulin sensitivity parameter SI, drives the dynamics of the blood glucose 
model and has been shown to be independent of the exogenous insulin and nutrition 
administration inputs from which it is identified (Chase et al., 2010). As a results, once a 
patient-specific profile of time-varying insulin sensitivity is identified from clinical data, it 
can be used to simulate and predict blood glucose concentration based on different insulin 
and nutrition control schemes. Such analyses have been used extensively in protocol design 
for adult critical care using the model  (Chase et al., 2007b, Lonergan et al., 2006b)  and 
others (Wilinska et al., 2008). 
 
The clinical implementation procedure for a virtual trial of a model-based controller is shown 
in Figure 10.1. A BG measurement and subsequent controller intervention represents one 
cycle of the loop. The virtual trial procedure replaces the ‘Patient’ with a forward solution of 
147 
 
the model using an insulin sensitivity profile previously generated from retrospective clinical 
data. Sensor noise and other variations can be included as required (Lonergan et al., 2006b, 
Chase et al., 2007b) .  
 
 
 
 
Fig. 9.1:   Virtual trial procedure 
 
To create a virtual trial patient, their blood glucose history, along with the administered 
insulin and nutrition history, are used to fit the patient-specific insulin sensitivity profile. This 
 START 
Input fitted insulin 
sensitivity profile 
Take a ‘virtual’ BG 
measurement 
Use a Controller to 
determine new insulin 
& dextrose rates 
Generate a model BG 
curve to use for next 
‘virtual’ BG measurement. 
Save output data 
Produce a figure 
comparing input data 
& simulated trial 
END 
Simulated trial 
complete? 
NO 
YES 
Loop through the 
entire length of fitted 
insulin sensitivity 
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SI profile is then used by the controller to solve Equations 2.16 - 2.22 (Chapter 2) to predict 
blood glucose concentration based on controller specified insulin and nutrition rates. Several 
combinations of infusion rates can be simulated to select the dosage that will most likely 
meet target BG concentration or other criteria. Thus, the model-based controller adapts to the 
current metabolic state of the cardiac arrest patients in real-time.   
 
In this research, virtual trials were carried out over all OHCA cohort by using a clinically 
validated model (Chase et al., 2007b, Chase et al., 2008b, Le Compte et al., 2009) .  Insulin 
sensitivity (SI) generated from each patient is used as the critical marker of a patient’s 
metabolic state, and is assumed independent of the insulin and nutrition inputs. There are 
strong reasons why virtual trials simulation is used extensively throughout these studies: 
i) Virtual trials enable the rapid testing of new TGC intervention protocols, as well as 
 analysis with respect to glycaemic control protocol performance, safety from 
 hypoglycaemic, clinical burden, and the ability to handle dynamic changes in patient 
 metabolic state (Lin et al., 2006, Chase et al., 2008b).  
ii) Virtual patients trial methods presented are validated in their ability to accurately 
 simulate in advance the clinical results of an independent TGC protocol, and directly 
 enabling rapid design and optimization of safe and effective TGC protocols (Chase et 
 al., 2010). 
 
The STAR controller has already fulfilled the control requirements defined in Chapter 8 and 
has already shown its capability to perform tight glycaemic control over general ICU patients 
(Fisk et al., 2012). The controller is patient-specific, effectively manages BG level within 4 – 
7 mmol/L and has an element of prediction. The stochastic features in the controller provide 
the ability to adapt to future patient-specific variations. The algorithm for STAR controller is 
shown in the Figure 2.10. 
 
The new stochastic model for a specific STAR-OHCA controller is developed using this 
retrospective OHCA cohort data. The model is generated from changes in insulin sensitivity 
over this cohort. Hence, it is more specialized for OHCA patients, compared to the current 
stochastic model used by STAR. The stochastic model for this controller uses the best kernel 
density estimation values [c] during cool (c=1) and warm (c = 3), as determined in Chapter 7. 
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Fig 9.2: The STAR-OHCA Controller Algorithm 
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The model-based STAR-OHCA controller is implemented using the same clinically validated 
metabolic system model and stochastic models. The algorithm for STAR-OHCA controller is 
shown in the Figure 9.2. Controller assessment was carried for the following cases: 
 
i)  STAR controller with insulin input only, maintain original dextrose. The controller is 
denoted as STAR 1 throughout the assessment. 
ii) STAR controller with modulating insulin and nutrition/ dextrose over 30% goal feed 
if such patients exist, else insulin input only. The controller is denoted as STAR 2 
throughout the assessment. 
iii)  STAR-OHCA controller with insulin input only, maintain original dextrose. The 
controller is denoted as STAR-OHCA 1 controller throughout the assessment. 
iv)  STAR-OHCA controller with modulating insulin and nutrition/ dextrose over 30% 
goal feed if such patients exist, else insulin input only. The controller is denoted as 
STAR-OHCA 2 controller throughout the assessment. 
 
Results and performance are compared with the retrospective clinical data. 
 
 
9.2.3 Analyses and Metrics  
 
Control performance outcomes are compared and analysed statistically by percentage time in 
the 4-8 mmol/L band and percentage BG > 10 mmol/L. Safety is evaluated in the percentage 
BG < 4.0 mmol/L and number of patients with severe hypoglycaemia (BG < 2.22 mmol/L). 
As the STAR framework is the same in all cases, controller effort is not assessed. These data 
are non-Gaussian and were thus compared using non-parametric cumulative distribution 
functions (CDFs) and non-parametric statistics. All distributed data were compared using a 
Wilcoxon rank-sum test (Mann-Whitney U-test) comparing median values.  In all cases, p < 
0.05 is considered statistically significant.  
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9.3 Virtual Trial Analysis and Discussion 
 
9.3.1 Comparative Analysis with the Retrospective Data 
 
Figure 9.3 shows the cumulative distribution functions (CDFs) of hourly BG level for the 
retrospective data, and the STAR and STAR-OHCA controller combination for the cool (left 
panel) and warm (right panel) periods. Table 9.1 summarizes the BG level results. Table 9.2 
presents a comparative analysis of these controllers. The results show that four controllers 
had significantly lower BG in the warm period (p < 0.05) than the retrospective data. The 
cool periods were similar. 
 
  
Cool   Warm 
  
Fig. 9.3:  Cumulative distribution functions (CDFs) of hourly BG level for the retrospective 
data and the STAR and STAR-OHCA controller combination, both cool (left panel) and 
warm (right panel) periods. 
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Table 9.1: Summary of BG level results for retrospective data, and STAR and STAR-OHCA 
controller combination   
 
Controllers 
Median BG 
[IQR] at cool 
period 
[mmol/L] 
Median BG 
[IQR]  at warm 
period 
[mmol/L] 
% patients had 
higher BG at cool   
[Diff(Cool-
warm)] 
p-value 
STAR Controller 1 
 
7.2 [5.9, 8.5] 5.9 [5.1, 6.9] 75%  
< 0.05 
STAR Controller 2 
 
7.5 [6.1, 9.1] 6.1 [5.2, 7.5] 70% 
< 0.05 
STAR-OHCA Controller 1 
 
6.7 [5.7, 8.1] 5.6 [5.0, 6.7] 70% < 0.05 
STAR-OHCA Controller 2 
 
7.1 [5.7, 8.6] 5.9 [5.1, 7.0] 70% < 0.05 
Retrospective Data 
 
7.4 [6.5, 8.5] 6.5 [5.8, 7.4] 70 % 
< 0.05 
P-values calculated using Wilcoxon rank-sum test   
 
 
Table 9.2: BG level comparative analysis of stochastic based controllers with the 
retrospective data. 
 
BG Level 
Analysis 
 Cool Period  Warm Period 
 [Controllers] 
% Decrease at 
median 
p-value 
% Decrease at 
median 
p-value 
Retrospective vs 
STAR Controller 1            
6.5 
0.22 
13.0 
< 0.05 
Retrospective vs 
STAR Controller 2            
1.7 
0.12 
9.3 
0.05 
Retrospective vs 
STAR-OHCA 
Controller 1            
32.1 0.18 25.2 < 0.05 
Retrospective vs 
STAR-OHCA 
Controller 2            
19.8 0.08 23.2 < 0.05 
 P-values calculated using Wilcoxon rank-sum test   
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Figure 9.4 shows the cumulative distribution functions (CDFs) of hourly BG variability for 
the retrospective data and stochastic based controllers. Table 9.3 summarizes the results. 
Table 9.4 presents the BG variability comparative analysis. While BG variability is slightly 
higher for the stochastic based controllers, the changes are not statistically or clinically 
significant. This variability is likely a result of lowering BG levels further in the warm period 
than the retrospective control was able to accomplish. 
  
 
Cool  Warm 
  
Fig. 9.4: Cumulative distribution functions (CDFs) of hourly BG variability for retrospective 
data and stochastic based controllers, both cool (left panel) and warm (right panel) periods.   
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Table 9.3:  Summary of BG variability results for retrospective data and stochastic based 
patient-specific controllers 
 
Controllers 
Median BG 
variability 
[IQR] at cool 
period 
[%∆BG] 
Median BG 
variability 
[IQR]  at warm 
period 
[%∆BG] 
% patients had 
higher BGV 
during cool 
period 
[Diff(Cool-
warm)] 
p-value 
STAR Controller 1 
[With insulin only] 
-3.9 [-7.5, -1.7] -1.9 [-5.3, 1.5] 35 0.24 
STAR Controller 2 
[With insulin and dextrose] 
-3.9 [-6.6, -1.5] -1.7 [-3.1, 1.5] 30 0.15 
STAR-OHCA Controller 1 
[With insulin only] 
-2.9 [-5.4, -1.7] -1.8 [-3.4, 1.1] 30 0.21 
STAR-OHCA Controller 2 
[With insulin and dextrose] 
-2.9 [-5.2, -1.6] -1.8 [-2.9, 1.1] 30 0.11 
Retrospective Data 
 
-2.8 [-5.7, -0.9] -1.5 [-3.3, 1.0] 30 0.30 
P-values calculated using Wilcoxon rank-sum test   
 
 
Table 9.4:  BG variability comparative analysis of patient-specific controllers with the 
retrospective data. 
 
BG Variability 
Analysis 
 Cool Period  Warm Period 
 [Controllers] 
%  Reduction 
of IQR 
p-value 
%  Reduction  
of IQR 
p-value 
Retrospective vs 
STAR Controller 1            
-36.8 0.34 -43.9 0.51 
Retrospective vs 
STAR Controller 2            
-35.8 0.28 -46.1 0.4 
Retrospective vs 
STAR-OHCA 
Controller 1            
-25.7 0.22 -37.6 0.06 
Retrospective vs 
STAR-OHCA 
Controller 2            
-30.1 0.15 -36.2 0.12 
 P-values calculated using Wilcoxon rank-sum test   
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9.3.2 Control Performance Analysis   
 
Table 9.5 and Table 9.6 presents the summary of STAR, STAR-OHCA and retrospective 
controller performance analysis during cool and warm respectively. This summary compares 
the performance of STAR and STAR-OHCA controller with retrospective or clinical data. 
 
During the cool period, stochastic-based controllers have shown better performance in 
managing glycaemia than retrospective control. These stochastic-based controllers delivered 
a higher percentage of BG within desired glycemic bands and a lower percentage of BG 
within the hyperglycemic band. In contrast, the retrospective control had performed much 
better in ensuring safety and minimizing hypoglycemic events among the cardiac arrest 
patients than other stochastic-based controllers. This outcome is illustrated by lower 
percentages of BG < 4 mmol/L. 
 
During warm period, all controllers have shown some improvement compared to the cool 
period. However, the trend remain the same where STAR controllers have shown better 
performance in managing glycaemia than the retrospective data. This time, they have 
delivered higher percentage of BG within desired glycemic band and lower percentage of BG 
within the hyperglycemic band as compared to the non-stochastic-based controllers.  
 
In terms of glycemic safety, all controllers have shown some increase in percentage of BG < 
4 mmol/L during the warm period compared to the cool period. The increase have also 
increased the number of hypoglycemic events among the OHCA patients for model-based 
controllers, except for retrospective data. Stochastic-based controllers have shown poor 
performance in ensuring safety during warm where percentage of BG < 4 mmol/L has 
increased to 5% and around 4 patients experienced hypoglycemic episode during treatment. 
This has revealed that for OHCA cohort, glycemic variability is increased during rewarming 
or at transition period between cool and warm which is also matched with metabolic 
evolution studies (Sah Pri et al., 2014).  
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Table 9.5:  Summary of STAR, STAR-OHCA and retrospective controller performance analysis during cool period 
 
 
Table 9.6:  Summary of STAR, STAR-OHCA and retrospective controller performance analysis during warm period 
 
Summary of STAR, STAR-OHCA and 
retrospective controller performance analysis 
during  cool period 
 
Retrospective 
Data 
 
STAR   
Controller 1 
  
STAR   
Controller 2 
  
STAR-OHCA 
Controller 1 
  
STAR-OHCA 
Controller 2 
  
Whole cohort statistics:      
Total patients, number (n) 180 180 180 180 180 
Total treatment, hours (h) 3693 3693 3693 3693 3693 
BG Median [IQR],  (mmol/L) 7.6 [6.3, 9.7] 7.1 [5.6,8.9] 7.7 [6.0 , 9.7] 6.1 [5.2, 7.8] 6.3 [5.2, 8.5] 
Hyperglycaemic bands:      
% BG > 10.0 mmol/L  22.8 17.2 22.8 12.0 15.0 
% BG within 8.0 – 10.0 mmol/L  20.8 18.8 22.7 12.0 15.4 
Desired glycaemic bands:      
% BG within 4.0 – 8.0 mmol/L 55.8 61.0 51.6 74.3 68.2 
% BG within 4.0 – 7.0 mmol/L 37.5 44.3 36.4 61.8 56.7 
Safety glycaemic bands:      
% BG < 4.4 mmol/L 1.4 5.5 5.7 4.0 3.6 
% BG < 4.0 mmol/L 0.6 3.1 2.9 1.8 1.4 
% BG < 2.22 mmol/L 0.0 0.04 0.0 0.03 0.0 
No of patients < 2.22 mmol/L 0 1 0 1 0 
Interventions:      
Median insulin rate [IQR] (U/hr) 2.0 3.5 4.0 4.5 6.0 
Median glucose rate [IQR] (g/hr) 4.0 3.9 4.2 2.2 3.3 
Med. glucose rate [IQR] (% goal) 61.2 60.0 64.2 34.2 50.0 
during warm period 
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Whole cohort statistics:      
Total patients, number (n) 180 180 180 180 180 
Total treatment, hours (h) 3760 3760 3760 3760 3760 
BG Median [IQR],  (mmol/L) 6.8 [5.9, 8.0] 6.0 [5.2, 7.1] 6.2 [5.4, 7.5] 5.4 [5.0, 6.3] 5.5 [5.0, 6.6] 
Hyperglycaemic bands:      
% BG > 10.0 mmol/L  8.1 4.4 7.0 2.7 4.4 
% BG within 8.0 – 10.0 mmol/L  17.1 10.6 13.2 6.5 8.7 
Desired glycaemic bands:      
% BG within 4.0 – 8.0 mmol/L 74.0 80.0 74.9 87.5 84.6 
% BG within 4.0 – 7.0 mmol/L 53.5 67.3 61.5 79.7 76.1 
Safety glycaemic bands:      
% BG < 4.4 mmol/L 2.4 8.7 8.0 6.2 4.7 
% BG < 4.0 mmol/L 0.8 5.0 4.9 3.3 2.3 
% BG < 2.22 mmol/L 0.0 0.5 0.3 0.3 0.2 
No of patients < 2.22 mmol/L 0 4 4 4 3 
Interventions:      
Median insulin rate [IQR] (U/hr) 1.0 1.5 2.0 2.0 2.0 
Median glucose rate [IQR] (g/hr) 6.4 4.6 6.1 5.2 6.5 
Med. glucose rate [IQR] (% goal) 97.4 70.6 93.2 80.0 99.4 
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9.3.3 Dealing with Hypoglycaemic Episodes   
 
Figure 9.5 and 9.6 present patient plots who had experienced hypoglycemia after simulation 
with STAR1-OHCA and STAR2-OHCA controller respectively, during warm period.   
 
 
Erasme 128 Lausanne 43 
 
 
Lausanne 57 Lausanne 135 
  
 
Fig. 9.5:  BG control during virtual trial for OHCA patients. These patients had experienced 
hypoglycemia after simulation with STAR1-OHCA controller during warm period.   
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Fig. 9.6:  BG control during virtual trial for OHCA patients. These patients had experienced 
hypoglycemia after simulation with STAR2-OHCA controller during warm period.   
 
In general, these results have suggested that hypoglycemia have occurred for the first 12 
hours of warm period. This indicates that the sudden drop of insulin sensitivity (SI) before or 
in the first few hours of warm period, followed by continued rise which cause hypoglycemia. 
This result match with the metabolic evolution and variability uniqueness of the OHCA 
cohort, particularly at transition period between cool and warm (Sah Pri et al., 2014). Thus, it 
is suggested that these controller should consider adding nutritional intake (Suhaimi et al., 
2010) and limit the insulin infusion during this period, in addition to patient-specific adaptive 
glycaemia control. In specific, for the first 12 hours of rewarming, set the controller to limit 
maximum insulin dose at 2U or 3U, while adding more dextrose to 20% or 40%. 
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9.4   Summary 
 
Knowing that this cohort has high metabolic variation, the additional element of stochastic 
provides better control. With its capability to predict future BG ranges based on current BG 
level and insulin sensitivity, it allows the controller to select the best possible intervention for 
performance and safety. Thus, results from virtual trials have shown that a STAR controller, 
with cohort-specific stochastic models can significantly improve performance. 
 
The performance of STAR-OHCA controller during cool and warm, with both insulin and 
nutrition inputs is slightly better than the controller with insulin only. By adding nutrition / 
dextrose input, it will elevate higher BG level, which resulted in more BG percentage within 
hyperglycaemic band. Even though the percentage of BG within the desired bands would be 
slightly less, but this approach will improve safety and minimize hypoglycaemic episodes. 
 
STAR-OHCA controller with modulating insulin and nutrition/ dextrose over 30% goal feed 
appears to be the best controller for OHCA patients based on virtual trial simulation. The 
controller has performed well in glycaemic management, while minimizing the number of 
patients who have BG < 2.22 mmol/L to 3 patients only. These patients represent 1.7% of 
OHCA cohort, which is relatively very low for the controller, compared to any published 
protocol, which normally average of 8-15% hypoglycaemic episodes. 
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Chapter 10: Conclusion  
 
 
The work in this thesis presents the development of a complete system for model-based 
glycaemic control in cardiac arrest patients. It covers the analysis of cohort data to proof-of-
concept virtual trials. A valid physiological system model (ICING-2 model) was employed to 
determine patient-specific metabolic state. Prediction and control were assisted by a 
stochastic model of insulin sensitivity variation as part of a STAR framework approach. A 
clinical simulation framework built around trials on ‘virtual patients’ provided an 
environment to optimise protocol development. The finalized system is thus ready for clinical 
validation and eventual use. 
 
10.1     Introduction 
 
Out-of-Hospital Cardiac Arrest (OHCA) patients often experience hyperglycaemia (Neumar 
et al., 2008, Taylor et al., 1994). These patients belong to one group who can be highly 
insulin resistant and variable, particularly on the first two days of stay (Pretty et al., 2012), as 
well as those who may particularly benefit from glycaemic control (van den Berghe et al., 
2001). Therapeutic hypothermia (TH) is often used with OHCA patients to protect against 
brain injury (Eisenburger et al., 2001, Lee and Asare, 2010), which leads to a lowering of 
metabolic rate, reduce plasma insulin, induce insulin resistance and alter blood glucose 
homeostasis (Cueni-Villoz et al., 2011). One of the adverse events associated with 
hypothermic therapy is a decrease in insulin sensitivity and endogenous insulin secretion 
(Hayashi, 2009). Recent studies in adults have shown that a 17% - 45% reduction in mortality 
can be gained if tight glucose regulation is achieved to average levels from 6.0 mmol/L - 7.75 
mmol/L (Chase et al., 2008b, Krinsley, 2004, van den Berghe et al., 2001) . However, such a 
level of tight control is difficult to achieve for the cardiac arrest patients who are already 
highly insulin resistant and variable (Pretty et al., 2012). The goals for this research is to 
develop effective and safe tight glycaemic control for OHCA patient, treated with 
hypothermia. 
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10.2 OHCA Patient Analysis   
 
The OHCA patient analysis in this research studied the physiology and patient background 
per-cohort and per-patient, which involve inputs (external insulin and nutrition), output 
(blood glucose) and metabolic behaviour (insulin sensitivity) during the cool and warm 
periods. A validated ICING-2 model of the glucose regulatory system from adult critical care 
was employed for the case of OHCA patients treated with hypothermia, to create virtual 
patients and analyse metabolic response. Model performance and its accuracy was within 
variations that would also account for dynamic patient evolution. The model thus provided a 
first in-silico result for capturing the metabolic dynamics of OHCA patients treated with 
hypothermia. Its validity and accuracy are equally important, as the results would be used to 
lead to good glycaemic control for this specific cohort. 
 
Analyses of metabolic evolution assessed the metabolic impact of cardiac arrest and 
subsequent hypothermic treatment. In particular, the level and variability of insulin sensitivity 
(SI) over time are presented for the first time and display unique characteristics, specific to 
this cohort. Generally, SI level is much lower during hypothermia and consistently increases 
over time, during both the cool and warm periods. Insulin sensitivity is more variable during 
the cool period and shows contrasting behavior during the cool-warm transition period 
between 18 – 30 hours, which indicates that there are major changes in physiology and 
metabolic conditions at the transition between cool and warm. This is a unique outcome 
never observed in other critically ill cohorts (Sah Pri et al., 2014).   
 
Analyses of glycemic evolution and outcomes of OHCA patients treated with hypothermia 
saw consistently decreasing BG over time, but evidenced greater variability, counter to 
typical trends in the critically ill, where both metrics tend to go down over the first 48 hours 
(Pretty et al., 2012). This trend can result in more insulin demand during hyperglycemia and a 
greater risk of hypoglycemia as variability rises, all of which indicates the need for patient-
specific approaches in each phase. Thus, the outcome of this studies strongly suggest the need 
to consider both control of BG level and minimization of BG variability to improve post-
resuscitation care of OHCA patients treated with hypothermia. 
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The impact of exogenous insulin and nutrition modulation during therapeutic hypothermia 
(TH) on glycaemia outcome has also been studied in this research apart from insulin 
sensitivity and glycemic analysis. Glycemic control during hypothermia and rewarming has 
achieved by modulating dextrose more than exogenous insulin. In view of control 
implications, both exogenous insulin and nutrition show major increases at the transition (18 
– 30 hours), while nutrition is delayed or maintained for another 6 hours after transition, and 
afterward falls steadily by blocks. These trends lead to more difficult control and increased 
risk in these periods. 
 
A stochastic model to provide insulin sensitivity predictions was developed from a set of 
insulin sensitivity data for the OHCA cohort. The model provided conservative prediction 
estimators that resulted in greater coverage than expected from the probability bounds. 
Modifying the data density estimator by introducing a constant scaling factor showed 
appropriate coverage was obtained at approximately 10-50% of the original value. Desired 
prediction performance can be obtained by choosing suitable value of scaling factor for the 
probability bound. Importantly, cool and warm periods showed very different stochastic 
behaviour, further reinforcing the need for cohort specific models in this case. 
 
Finally, these studies all show the need for patient-specific glycemic management to ensure 
good control and safety during treatment. These results could have significant potential 
clinical impact on the metabolic treatment of these patients. As a result, changes in clinical 
therapy are suggested to safely treat these patients, particularly as they transition from cool to 
warm. 
 
10.3 Control Design Requirements and Specifications 
 
The OHCA patient analysis was summarized, where results and analysis from the inputs 
(external insulin and nutrition), output (blood glucose) and metabolic behaviour (insulin 
sensitivity) were gathered to observe the overall situation from cool to warm as well as based 
on time block, 12-hour / 6-hour blocks. This information was used to come up with control 
design requirement and specifications. 
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The main objective of glycaemic control design requirements and specifications is to 
minimize glycaemic variability and hypoglycaemia, while maintaining BG level at desired 
target levels. This new control definitions and clinical settings have led to a new glycaemic 
controller development specifically for OHCA patients, treated with hypothermia. The 
development of a stochastic-based STAR-OHCA controller inherits some methods from the 
STAR framework used previously, but with modifications to the stochastic models, based on 
this retrospective OHCA data. The overall approach is thus a new control method for this 
specific and unique cohort. 
  
10.4 Virtual Trials Validation 
    
Results from virtual trials simulation have shown that stochastic based control such as STAR 
and STAR-OHCA can provide better glycemic management performance for OHCA patients, 
in both the cool and warm periods, compared to retrospective data. In contrast, stochastic-
based controllers may be less able to ensure safety and minimizing hypoglycemic events 
during the cool-warm transition period. However, limiting insulin dosing at this time solves 
this issue. 
 
All controllers are also struggled to minimize hypoglycemic events. These last results show 
that the performance of stochastic based control have limits, but can provide safe and 
effective control of this highly unique metabolic situation.  
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Chapter 11: Future Work  
 
 
The patient analysis, models development and control methods presented in this thesis 
provide a framework for glucose control in OHCA patients, treated with hypothermia. These 
developments open the doors for wider use of tight glucose control as a treatment in highly 
critical care such as cardiac arrest patients with physiological conditions in cool and warm, as 
well as in further research opportunities. 
 
11.1 Reviewing Endogenous Insulin Secretion (Uen) Parameters for the ICING-2 
Model during Cool and Warm 
 
The endogenous insulin secretion model based as a function of BG (Equation 2.45) in the 
ICING-2 model was successfully developed by Pretty (Chase et al., 2007b). Its upper and  
lower  bounds  on  pre-hepatic  insulin  secretion  rates  of Umin  (1000 mU/hr ) and Umax 
(16000 mU/hr) were defined  by (Chase et al., 2010) and (Chase et al., 2008a). The parameter 
k1 and k2 of this model were determined based on distribution of c-peptide and BG samples 
obtained from clinical trials studying sepsis in Christchurch Hospital ICU. However, these 
clinical trials did not consider change of human body temperature will affect the accuracy of 
Uen as well as the ICING-2 model in calculating model-based insulin sensitivity. In particular, 
there was no separation of samples taken between cool and warm body temperature during 
the trials. 
 
Thus, it is recommended that a comprehensive study on endogenous insulin secretion should 
be conducted to validate the endogenous insulin secretion model based as a function of BG 
(Equation 2.45) in the ICING-2 model particularly during cool and warm. It would be best if 
these samples are obtained from cardiac arrest patient treated with hypothermia. The outcome 
results should lead to the ICING-2 model parameter review. 
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11.2 Clinical Trials for Performance Validation 
 
Controller performance is assessed based on virtual trials. The selection STAR-OHCA 
controller for tight glycaemic control refers to virtual trial results. However, these results 
were not validated clinically. Thus, there is a need for validating its control performance 
against real patients by conducting clinical trials against OHCA patients. While do trial, 
additional data from patient could be recorded such as blood pressure, and heart bit, as well 
as sample c-peptide for endogenous insulin secretion analysis during cool and warm. 
 
Additionally, these clinical trials can also validate the accuracy of the ICING-2 model in 
generating model-based insulin sensitivity during cool and warm. The model performance 
can be compared between virtual trial and clinical trial results. Thus, the outcome should be 
able to determine model errors and explore ways of improving these errors separately 
between cool and warm.  
. 
11.3 Investigation of Stochastic Control based on Sub-Cohort Models 
 
The stochastic models presented in this thesis are created using 180 OHCA patients’ 
intensive care data, which include overall cohort and sub-cohorts. Further observations of 
metabolic behaviour between patients sub-cohort were analysed in the sub-chapter 4.3.2 and 
the results showed unique insulin sensitivity variation across each sub-cohort. A summary of 
sub-cohort results based 6 hour block analysis can also be referred to Appendix 1 and 2. 
These studies have helped better understanding of metabolic dynamics for each sub-cohort. 
Thus, advance study on stochastic model and control between sub-cohorts should create the 
opportunity to improve the stochastic based controller problems in reducing BG variability 
and minimizing hypoglycaemic event.  It is recommended that virtual and clinical trials 
should be conducted based on sub-cohorts stochastic model in search for better tight 
glycaemic control (TGC). In addition to that, the outcome of this study should lead to 
identifying better potential illness biomarker for future OHCA treatment and control such as 
ROSCs and diabetes. 
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11.4  Further Improvement of STAR-OHCA Controller 
 
The outcome of research studies have shown that the performance of stochastic based control 
such as STAR and STAR-OHCA have a limit. Even though these controllers were the best 
for effective TGC, but it is too risky to implement on highly variable patients, in particular 
during transition period at warm (Sah Pri et al., 2014). In order to improve the controller, it is 
suggested that: 
  
i)  Combine patient-specific stochastic-based control with targeted control approach, 
particularly in setting the upper and lower glycaemic limit. 
It is noted that for STAR controller, upper and lower limits are set by the stochastic 
model whereas for Targeted controller (Chase et al., 2005, Magee, 2007), both limits 
are set by the end user. With these features, STAR controller is more patient-specific 
and suitable for optimization control. Targeted controller is suitable for robust control 
since the controller is good in enforcing BG values within the desired target range. 
Thus, by combining both features, the controller can behave as patient-specific 
stochastic-based with targeted glycaemic range control. 
 
ii) Applying separate stochastic model method (Thomas et al., 2014), particularly at the 
transition period (rewarming phase) during warm conditions. 
 The 12-hour block approach can be applied during warm period, where a stochastic 
model can be developed solely for the first 12 hours of warm period, followed by 
another stochastic model for the subsequent hours after rewarming. 
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Appendix 1 
Summary of increasing cohort and per patient median SI during cool and warm as per 6-hour blocks for all OHCA sub-cohorts 
SI Level 
analysis 
 [6-hr 
blocks] 
No of 
Patients 
Block 1-2 (C) 
(0 - 6 vs. 6 - 12 hr) 
Block 2-3 (C) 
(6 - 12 vs. 12 - 18 hr) 
Block 3-4 (C) 
(12 - 18 vs. 18 - 24 hr) 
Block 4-5 (C-W) 
(18 - 24 vs. 24 - 30 hr) 
Block 5-6 (W) 
(24 - 30 vs. 30 - 36 hr) 
Block 6-7 (W) 
(30 - 36 vs. 36 - 42 hr) 
Block 7-8 (W) 
(36 - 42 vs. 42 - 48 hr) 
Cohort 
analysis 
Per-patient 
analysis 
Cohort 
analysis 
Per-patient 
analysis 
Cohort 
analysis 
Per-patient 
analysis 
Cohort 
analysis 
Per-patient 
analysis 
Cohort 
analysis 
Per-patient 
analysis 
Cohort 
analysis 
Per-patient 
analysis 
Cohort 
analysis 
Per-patient 
analysis 
% 
Increase 
at 
median 
p-
value 
% 
Increase 
at 
median 
p-
value 
% 
Increase 
at 
median 
p-
value 
% 
Increase 
at 
median 
p-
value 
% 
Increase 
at 
median 
p-
value 
% 
Increase 
at 
median 
p-
value 
% 
Increase 
at 
median 
p-
value 
% 
Increase 
at 
median 
p-
value 
% 
Increase 
at 
median 
p-
value 
% 
Increase 
at 
median 
p-
value 
% 
Increase 
at 
median 
p-
value 
% 
Increase 
at 
median 
p-
value 
% 
Increase 
at 
median 
p-
value 
% 
Increase 
at 
median 
p-
value 
All 
OHCA 
patients 
 
180 30.6 <0.01 30.4 <0.01 8.9 0.1 8.8 0.2 31.3 <0.01 42.6 0.01 57.4 <0.01 52.1 <0.01 -1.5 0.16 -2.2 0.6 2.8 0.22 9.3 0.4 5.0 0.3 5.3 0.6 
Survived 
Patients 
 
98 33.0 <0.01 26.4 0.05 15.5 0.01 26.6 0.3 28.1 <0.01 31.1 0.03 51.2 <0.01 46.5 <0.01 -1.8 0.4 0.2 0.8 7.4 0.5 4.2 0.6 0.6 0.3 9.1 0.6 
Non-
Survived 
Patients 
82 31.3 <0.01 18.6 0.05 8.2 0.3 18.0 0.4 26.7 <0.01 31.0 0.02 76.3 <0.01 64.3 <0.01 -2.7 0.2 4.1 0.5 -3.4 0.4 0.5 0.4 10.6 0.6 4.6 0.9 
Diabetes 
Patients 
 
23 28.2 0.04 45.3 0.02 4.4 0.3 4.0 0.8 53.0 0.05 50.7 0.3 29.0 <0.01  22.2 <0.01 -25.3 0.1 -6.0 0.7 17.2 0.3 22.4 0.6 10.0 0.3 8.6 0.8 
Non-
Diabetes 
Patients 
157 31.2 <0.01 30.3 0.02 10.3 0.02 7.0 0.2 27.3 <0.01 44.1 0.03 64.7 <0.01 63.9 <0.01 -0.4 0.4 -4.2 0.7 5.3 0.3 9.6 0.5 2.6 0.4 8.4 0.7 
Male 
Patients 
 
143 36.6 <0.01 45.6 <0.01 6.3 0.1 -0.5 0.4 25.2 <0.01 32.0 0.05 61.5 <0.01 55.8 <0.01 -3.2 0.2 -4.0 0.6 7.0 0.2 8.3 0.4 3.2 0.1 11.3 0.5 
Female 
Patients 
 
37 1.0 0.6 7.6 0.5 46.0 0.03 13.6 0.4 47.0 <0.01 79.0 0.1 45.0 <0.01 55.6 0.07 3.6 0.8 -0.4 0.9 -1.3 0.7 10.3 0.8 -9.6 0.4 -5.5 0.9 
ROSC < 
15 mins 
 
63 36.0 <0.01 52.0 0.06 10.7 0.02 18.6 0.2 43.8 <0.01 26.9 0.08 43.6 <0.01 40.1 <0.01 -5.9 0.06 -6.0 0.6 -1.7 0.8 -0.4 0.9 4.0 0.3 12.8 0.5 
ROSC < 
30 mins 
 
89 30.0 <0.01 28.2 0.02 9.7 0.2 24.4 0.5 13.0 0.1 17.0 0.1 72.0 <0.01 78.5 <0.01  0.9 1.0 3.7 0/9 4.4 0.2 16.8 0.3 7.2 0.4 -0.1 0.9 
ROSC > 
30 mins 
 
28 4.2 0.6 25.0 0.2 14.8 0.3 30.0 0.6 22.4 0.1 -14.0 0.3 57.5 <0.01 39.0 <0.01 -6.6 0.4 24.0 0.7 26.0 0.2 -39.0 0.6 3.0 0.7 -2.5 1.0 
P-values are calculated using Wilcoxon rank-sum test   
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Appendix 2 
 
Summary of reductions in the interquartile range and median SI per patient range of hour-to-hour percentage SI change over time during cool and 
warm after as per 6-hour blocks of data for all OHCA sub-cohorts 
 
SI 
variability 
analysis 
 [6-hr 
blocks] 
No of 
Patients 
Block 1-2 (C) 
(0 - 6 vs. 6 - 12 hr) 
Block 2-3 (C) 
(6 - 12 vs. 12 - 18 hr) 
Block 3-4 (C) 
(12 - 18 vs. 18 - 24 hr) 
Block 4-5 (C-W) 
(18 - 24 vs. 24 - 30 hr) 
Block 5-6 (W) 
(24 - 30 vs. 30 - 36 hr) 
Block 6-7 (W) 
(30 - 36 vs. 36 - 42 hr) 
Block 7-8 (W) 
(36 - 42 vs. 42 - 48 hr) 
Cohort 
analysis 
Per-patient 
analysis 
Cohort 
analysis 
Per-patient 
analysis 
Cohort 
analysis 
Per-patient 
analysis 
Cohort analysis Per-patient 
analysis 
Cohort analysis Per-patient 
analysis 
Cohort 
analysis 
Per-patient 
analysis 
Cohort 
analysis 
Per-patient 
analysis 
% 
Reduction 
of IQR 
p-
value 
% 
Decrease 
at 
median 
p-
value 
% 
Reduction 
of IQR 
p-
value 
% 
Decrease 
at 
median 
p-
value 
% 
Reduction 
of IQR 
p-
value 
% 
Decrease 
at 
median 
p-
value 
% 
Reduction 
of IQR 
p-
value 
% 
Decrease 
at 
median 
p-
value 
% 
Reduction 
of IQR 
p-
value 
% 
Decrease 
at 
median 
p-
value 
% 
Reduction 
of IQR 
p-
value 
% 
Decrease 
at 
median 
p-
value 
% 
Reduction 
of IQR 
p-
value 
% 
Decrease 
at 
median 
p-
value 
All 
OHCA 
patients 
180 23.4 0.02 36.3 <0.01 15.8 0.9 13.5 0.1 11.7 0.63 26.8 0.03 9.4 0.6 7.8 0.8 -8.5 0.5 -13.5 0.8 13.7 0.4 4.1 0.7 10.7 0.04 19.1 0.03 
Survived 
Patients 
 
98 21.6 0.05 26.5 0.03 13.3 0.03 14.5 0.3 22.4 0.15 28.0 0.05 9.4 <0.01 8.9 0.06 -6.4 <0.01 -12.8 0.08 15.1 0.6 16.4 0.43 17.2 0.9 9.4 0.2 
Non-
Survived 
Patients 
82 28.0 0.9 45.2 0.06 21.5 0.01 16.4 0.2 13.6 0.4 21.6 0.2 25.0 <0.01 24.2 0.03 -15.7 <0.01 -17.8 0.09 15.5 0.6 10.1 0.7 2.8 0.02 24.6 0.06 
Diabetes 
Patients 
 
23 8.0 0.5 -11.4 0.7 35.0 0.5 35.7 0.4 8.0 0.04 35.6 0.2 -28.3 0.1 -125.0 0.08 -13.5 0.3 22.2 0.5 0.7 0.9 20.7 0.5 44.6 0.3 38.1 0.05 
Non-
Diabetes 
Patients 
157 25.0 0.02 42.6 <0.01 14.5 0.7 8.8 0.1 9.6 0.9 28.0 0.06 14.3 <0.01 9.9 0.03 -7.0 <0.01 -7.4 0.08 13.4 0.5 -2.6 0.8 5.5 
0.07 
 
16.3 0.1 
Male 
Patients 
 
143 21.3 0.04 40.0 <0.01 14.2 0.7 17.0 0.08 15.3 0.6 24.0 0.04 4.7 <0.01 3.6 0.06 -8.8 <0.01 -20.0 0.8 14.7 0.6 4.0 0.9 8.5 0.08 21.7 0.03 
Female 
Patients 
 
37 28.7 0.5 15.2 0.8 27.5 0.6 15.0 0.7 -1.3 0.9 22.4 0.4 19.0 <0.01 20.0 0.03 -7.0 0.5 10.5 0.7 14.0 0.5 20.7 0.3 14.1 0.2 5.5 0.8 
ROSC < 
15 mins 
 
63 17.4 0.7 33.8 0.04 16.0 0.8 18.2 0.6 26.3 0.8 27.8 0.1 -48.1 <0.01 -20.8 0.05 13.5 0.2 5.7 0.2 -4.7 0.6 -11.9 0.7 30.0 0.6 26.4 0.08 
ROSC < 
30 mins 
 
89 7.0 <0.01 29.2 0.02 23.5 0.9 15.0 0.1 16.0 0.4 28.6 0.1 24.1 <0.01 10.6 0.02 -20.8 <0.01 -20.0 0.07 20.0 0.7 15.4 0.6 10.0 0.01 15.9 0.2 
ROSC > 
30 mins 
 
28 56.4 0.5 45.0 0.04 5.5 0.5 43.7 0.4 -17.5 0.6 14.1 0.5 40.2 <0.01 24.6 0.04 -30.7 <0.01 -18.5 0.07 14.3 0.7 16.3 0.6 -34.4 0.08 -7.2 0.8 
P-values are calculated using Kolmogorov-Smirnov test   
 
